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Cancer remains one of the leading causes of death worldwide with high 
morbidity and mortality. Though significant advances have been made in the 
fundamental understanding of cancer biology, the treatment of some cancer forms 
remains elusive, and in general cancer treatments suffer from severe side effects. 
Cancer cells share many common features with the normal host cells from which 
they derive. As a consequence, traditional anticancer agents do not achieve the 
specific toxicity shown by bacterial and viral chemotherapeutics due to their lack 
of selectivity, and ultimately they lead to significant off-target effects.  
Interestingly, cancer cells show different composition of cell membrane 
compared to healthy cells, with an enhanced expression of specific proteins (i.e. 
cell-surface markers) required to increase the provision of nutrients and to enhance 
cell-cell signaling and communication. Thus, a valid strategy to improve the 
selectivity of the treatments relies on the development of molecules able to 
discriminate between diseased and healthy cells by interacting with these cell-
surface markers. Over the past decades an exciting trend in life sciences and 
biotechnology has been the rapid development of highly specific structures 
recognizing these cell-surface markers. Nanomedicine aims at exploiting these 
ligands to generate nanoscale platforms for targeted cancer therapy and diagnosis. 
In this way, non-selective therapeutics are localized and concentrated at the 
targeted site via ligands that recognize tumor-associated markers, thus leading to 
negligible off-target effect. 
Aptamers are short single-chained DNA or RNA molecules able to recognize 
molecular targets with high affinity and specificity owing to their exclusive spatial 
conformation that are emerging as a class of biocompatible ligands with huge 
potential in diagnostics and therapeutics. Despite the rapid development of a wide 
variety of targeted delivery platforms exploiting aptamers as nanocarriers against 
cell-surface receptors, these strategies show some limitations that could hamper 
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the transition to clinical application, including elaborated design, difficult scale-
up, and complex aptamer-payload conjugate preparation. Furthermore, aptamers 
as targeting moieties have been used mainly to deliver small drugs and small 
interfering RNAs. However, a modular aptamer-based platform to deliver large 
therapeutic payloads, such as therapeutic aptamers recognizing cancer-associated 
protein, was not developed yet, likely due to limitations in designing suitable 
assemblies in which the oligonucleotide modules retain their proper activity. 
Therefore, the work reported in this thesis addresses these restrictions in aptamer 
technology for targeted delivery applications.  
In this thesis, I shall describe novel designs and molecular engineering strategies 
that lead to aptamer-based nanoassemblies with enhanced and innovative features 
as tools for targeted cancer therapy. These assemblies exploit known RNA and 
DNA aptamers recognizing a cell-surface protein, the transferrin receptor (TfR). 
Particularly, TfR was chosen as biomolecular target owing to (i) its upregulation 
in many solid tumors (e.g. breast, prostate, pancreatic, ovarian, lung) and (ii) its 
constitutive endocytic pathway. Thus, aptamers binding TfR may discriminate 
between tumor and healthy cells and aptamer-based platforms may selectively 
deliver into target cells therapeutic payloads upon binding to TfR via receptor-
mediated endocytosis. To achieve these goals, this thesis work exploits the 
synergy among different studies of aptamer properties, in terms of folding 
stability, recognition of target cell population and efficiency of internalization into 
target cells.  
The outline of the thesis is the following:  
- Chapter 1 provides a review of aptamers an emerging class of targeting 
ligands for cancer therapy. Emphasis on the advantages of aptamers compared to 
antibodies will be reported together with their drawbacks and the innovative 
solutions to overcome these limitations. The in vitro evolutionary selection 
process used for the aptamer generation will be described. Then, I shall introduce 
the main approaches and the most representative applications of cell-specific 
aptamers. Particularly, I shall focus on the conjugation designs used to deliver 
traditional anticancer drugs and functional therapeutic oligonucleotides.  
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- In Chapter 2 I shall describe a molecular-engineering strategy to develop a 
drug-delivery system that is able to (i) target human tumor cells via an anti-
transferrin receptor RNA aptamer and (ii) perform selective co-delivery of a 
chemotherapeutic drug (doxorubicin) and of an inhibitor of a cell-survival factor, 
the NF-κB decoy oligonucleotide. I shall demonstrate that this platform shows 
selective cytotoxicity activity towards tumor cells, owing to the targeting 
properties of the aptamer. Upon internalization, the NF-κB decoy does inhibit NF-
κB activity, reducing tumor chemoresistance towards doxorubicin and enhancing 
its therapeutic efficacy specifically in target cells.  
- In Chapter 3 a biophysical study to unveil the conformation-dependent activity 
of an anti-mouse TfR DNA aptamer will be reported. I shall demonstrate the 
presence of competing folding pathways, which sensibly affected the aptamer 
activity. Indeed, two main aptamer conformers were identified and their activities 
investigated both in vitro and in living cells. Actually, only one conformer was 
able to bind mouse TfR. Starting from these observations I rationally designed 
variations of the parent sequence aimed at stabilizing the active conformation. 
This strategy led to an enhanced aptamer sequence with higher affinity and 
improved biological activity, which emerges as a valid targeting ligand both for in 
vitro and in vivo applications. 
- In Chapter 4, I shall report on the design and synthesis of a modular platform 
for aptamer-mediated cellular delivery of increasingly large RNA payloads (~50-
60 kDa). In order to demonstrate the versatility of this platform, anti-TfR RNA 
and DNA aptamers, previously investigated in Chapter 2 and 3, will be exploited 
as targeting and delivery tools, and fluorescent RNA aptamers (known as RNAs 
mimic of GFP) as large functional RNA payloads. These aptamers were chosen as 
RNA sensors to monitor both their intracellular localization and to evaluate 
folding alterations within the oligonucleotide platform because their fluorescence 
depends on the retaining of the proper fold. Taking inspiration from the design of 
the delivery system described in Chapter 2, the assembly is generated through 
straightforward self-assembly by means of a short oligonucleotide bridge that 
contains regions complementary to both aptamers. In this chapter, I shall 
demonstrate the possibility to selectively deliver to living cells large functional 
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RNAs using different combinations of targeting and payload aptamers. This 
“proof of concept” is the first evidence of an aptamer-mediated aptamer delivery.  
- In Chapter 5 I shall summarize the main findings of this research activity and 






1   
Nucleic acid aptamers: new tools for targeted 
drug delivery applications 
1.1 Brief overview on targeted therapy: passive and targeting 
drug delivery  
One hundred years ago, Paul Ehrlich popularized the “magic bullet” concept as an 
ideal strategy for targeted therapy against virtually any disease. Theoretically, a 
magic bullet is a therapeutic agent able to overcome biological barriers, 
distinguish between diseased and healthy tissues and selectively kill only target 
cells, avoiding off-target effect1. Despite extensive research carried out in this 
field, safe and efficient drug delivery for the treatment of most disorders (e.g. 
cancer and infectious diseases) remains a major challenge both for clinical 
translation and the development of new therapies2. Conventional therapeutic 
agents are administered systemically and are unable to target the site of the 
disease, ultimately leading to unwanted side effects and to a reduction of the 
therapeutic index (i.e. the ratio between the dosage of a drug that causes a lethal 
effect and the dosage that causes a therapeutic effect). Nanomedicine aims at 
overcoming these drawbacks, allowing the construction of nanosized molecular 
devices (10-200 nm) for targeted delivery of therapeutic and/or diagnostic agents3. 
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During the last decade, the rapid expansion of new nanotechnologies tailored to 
cancer treatment has been an exciting trend in nanomedicine. Compared with 
conventional therapy, nanomedicine offers significant advantages and new 
perspectives in which novel drug-delivery platforms exploit passive and active 
targeting to improve their therapeutic index4. Passive targeting takes advantage of 
the unique physiology and structure of the tumor microenvironment (e.g. highly 
permeable vasculature, and poorly-defined lymphatic system), which results in 
drug accumulation through the enhanced permeability retention (EPR) effect 
(Fig.1). This strategy can be achieved by modulating the size, shape, and surface 
properties of the drug delivery platform. To date, dozens of nanosized devices, 
named first-generation nanomedicines, were approved by the Food and Drug 
Administration (FDA) and proved to be well tolerated in patients5,6. However, 
several factors mainly dependent on patient and/or stage of disease (such as blood 
pressure, structure of neo-vasculature, and disease type and location) can 
adversely affect passive transport, often leading to inadequate drug concentration 
into target districts and lower therapeutic efficacy3,7 (Fig.1). 
 
 
Fig 1 Physiological properties of tumor tissue and vasculatures that influence cancer 
drug delivery. Reprinted from Kobayashi et al.8; Copyright © Ivyspring International 
Publisher (2013). 
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Ultimately, passive targeting strategy does not discriminate satisfactorily 
between normal and cancerous cells; this in turn leads to modest improvements 
compared to conventional therapeutic strategies9. 
A common strategy to enhance selectivity relies on targeting specific 
biomolecules overexpressed on the surface of tumor cells. To this end, many 
ligands were developed and exploited to deliver potent nonspecific cytotoxic 
agents selectively to malignant cells. The general structure of these ligand-payload 
platforms involves a targeting moiety linked to a therapeutic payload via a spacer 
that often contains a cleavable bond10. Alternatively, specific targeting ligands can 
be conjugated and displayed on the surface of nanosized devices (or nanocarriers) 
designed for passive targeting drug delivery. When the suitable recognition motif 
is included in these nanocarriers, it endows the entire system with selectivity 
towards target cells, leading to more efficient “actively targeted” nanostructures, 
also called second-generation nanodevices11 (Fig. 2).  
 
 
Fig. 2 Schematic representation of several mechanisms by which nanocarriers can 
deliver drugs to tumors. Nanocarriers are shown as blue circular structures. Passive 
tissue targeting is achieved by extravasation of nanoparticles through increased 
permeability of the tumor vasculature and ineffective lymphatic drainage (EPR 
effect). Active cellular targeting (inset) can be achieved by functionalizing the surface 
of nanoparticles with ligands that promote cell-specific recognition and binding. The 
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nanoparticles can (i) release their contents in close proximity to the target cells; (ii) 
adhere to cell membrane and act as an extracellular sustained-release drug depot; or 
(iii) internalize into the cell. Adapted from Peer et al.12 Reprinted by permission from 
Macmillan Publishers Ltd: Nature Nanotechnology (Ref. 12), Copyright © 2007 
1.2 Cell-surface markers: the gate at the entrance of diseased 
cells 
Several genetic mutations lead to the deregulation of specific signaling 
pathways involved into cell proliferation, survival, or differentiation, causing 
uncontrolled cell growth and acquisition of neoplastic phenotype13. As a 
consequence of this mutated signal transduction, specific cell-surface and 
intracellular receptors show high expression levels in diseased tissue compared 
with other tissues (for example tumors versus healthy cells)13,14. An ideal target 
molecule is overexpressed on the surface of cancer cells rather than within its 
intracellular compartment (e.g cytoplasm or nucleus). Although several 
intracellular receptors (such as steroid receptors and retinoic acid receptors) are 
upregulated in cancer, a drug-delivery platform must be cell permeable to target 
and interact with them at an intracellular level. This would likely cause unwanted 
side effects due to nonspecific internalization10. In contrast, ligands that target 
cell-surface receptors can be engineered to be membrane-impermeable, reducing 
their nonspecific cell uptake10. Therefore cell-surface markers represent ideal 
targets for the specific delivery of therapeutics to malignant cells avoiding off-
target effects. The two main features of the targeted cell-surface receptor that must 
be considered while designing a targeted drug delivery device are (i) the extent of 
its overexpression in cancer cells relative to normal cells and (ii) its ability to 
perform a receptor-mediated endocytosis of the drug delivery platform, allowing 
intracellular accumulation of therapeutic quantities. This latter property is tightly 
dependent on the type of targeted therapy. Internalization might be essential for 
optimal results in therapies such as antibody-drug conjugates or 
immunoliposomes15,16. In other cases, such as antibody-directed-enzyme-prodrug 
therapy (ADEPT)17, no internalization is required for the targeted drug delivery 
tool used in this approach: i.e. an antibody-enzyme conjugate. Indeed, after 
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antibody recognition of a non-internalizing receptor, the antibody-enzyme 
conjugate must be located on the cell-surface to convert non-active prodrugs into 
active cell-permeable cytotoxic molecules through the enzyme portion18. In this 
strategy, however, the activated drugs that are released in the tumor interstitial 
space might diffuse and non-selectively internalize into the nearby normal cells 
that do not express the cell-surface marker, causing off-target effects17. Thus, 
internalization of the targeted receptor appears to be the preferential way to 
achieve a desired therapeutic effect with negligible side effects. 
With regard to the high level of expression of the targeted receptor in tumor 
cells, a threefold upregulation is commonly considered sufficient to perform 
efficient targeted drug delivery, although higher expression enhancement is 
obviously preferred10. Note that many healthy tissues are quiescent (or non-
mitotic): they do not show cell proliferation and are thus less sensitive to 
antimitotic chemotherapeutic drugs. In this context, even a threefold 
overexpression leads to a significant improvement of the selectivity compared 
with the corresponding non-targeted therapy. Notably, several targeted receptors 
currently under clinical investigation are expressed in two- to five-fold excess in 
malignant tissues10. 
Some tumor processes lead to cleavage of extracellular domains of cell-surface 
markers, shedding them into circulation18. These circulating domains may 
compete with the intact cell-surface markers for the binding of the ligand-payload 
platform, leading to accumulation in a body district away from the tumor tissue 
and reducing the therapeutic efficacy. The choice of candidate receptors should 
therefore avoid proteins undergoing this processing. 
It is worth mentioning that in receptor-mediated drug delivery, the ligand-
payload platform internalizes into target cells upon binding with its target 
molecule by a receptor-mediated endocytosis and then traffics through different 
intracellular vesicular compartments, depending on the receptor is exploited for 
the internalization. Some of the most common endocytic compartments 
encountered during intracellular trafficking include: endosomes (early, late and 
recycling) and lysosomes (Fig. 3).  
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 Fig. 3 Internalization pathway of a ligand-targeted therapeutic agent. The ligand-
payload conjugate includes within its structure: a targeting ligand; a spacer; a 
cleavable bridge that is stable in circulation but that permits drug release following 
endocytosis into a target cell; and a therapeutic ‘warhead’. Upon binding with the 
targeted receptor, the ligand–drug conjugate is internalized into the cells. During the 
intracellular trafficking of the ligand-payload conjugate several compartments are 
encountered including early endosome, compartments for uncoupling of receptor and 
ligand (CURLs), recycling endosome, and lysosomes. Adapted from Srinivasarao et al.10 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery 
(Ref. 10), Copyright © 2015. 
Particularly, during the endocytosis pathway the intravesicular environment of 
the endosome undergoes alterations of pH, ion composition, and redox potential. 
According to these different features it is possible to distinguish early and late 
endosomes19. Overall, these environmental variations may lead to the dissociation 
of the ligand-payload platform from the receptor. Note that the compartment 
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where the dissociation occurs is termed compartment for uncoupling of receptor 
and ligand (CURL) and usually corresponds to the early endosome20. After that, 
the unbound receptor and the free ligand-payload can be sorted into separate 
vesicular compartments, allowing the receptor to be either degraded in the 
lysosomes or recycled on the plasma membrane for another round of 
endocytosis21. 
Importantly, the delivery platform can be engineered to release the therapeutic 
payload at the endolysosomal stage, where conventional chemotherapeutic drugs 
can freely diffuse to the cytoplasm and perform their anticancer activity22,23.  
A critical aspect in the receptor-mediated targeted delivery is the availability of 
receptors on the surface of cancer cells that can interact with the excess of ligand-
payload platforms present on the extracellular side, in order to allow continuous 
drug uptake. In this context, an ideal targeted receptor will be one that either 
recycles frequently or is resynthesized rapidly following degradation10. 
Importantly, most cell-surface markers show enhanced receptor-recycling rate or 
resynthesis rate in malignant cells compared with healthy cells, thus allowing 
increased receptor-mediated delivery of therapeutics in cancer cells10,24. 
Here, I shall discuss the properties of three cell-surface receptors that were 
extensively investigated in the last decade. One of these proteins, the transferrin 
receptor, is also the target receptor exploited in this thesis for our drug delivery 
studies.  
 
PSMA. Prostate-specific membrane antigen (PSMA) is a 100 kDa type II 
membrane glycoprotein expressed in all types of prostatic tissues, including 
normal epithelial cells25, benign prostatic hyperplasia26, prostatic intraepithelial 
neoplasia27, and cancerous tissue28. Furthermore, very low levels of PSMA were 
detected in kidney, proximal small intestine, salivary gland, and brain29. In 
addition to full-length PSMA, several splice variants exist in prostatic tissue, 
namely PSM’, PSM-C, PSM-D, and PSM-E. Notably, the N-terminally truncated 
PSMA variant, termed PSM', is the most frequently described alternatively spliced 
variant of PSMA and is the most prevalent form in healthy prostatic cells where it 
is located cytosolically30. During malignant progression, prostatic epithelial cells 
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express the transmembrane/extracellular form of the protein, PSMA. Therefore, 
the ratio of PSMA/PSM' mRNA was shown to correlate with cancer progression31. 
Note that, almost 95% of prostate cancers express PSMA, with the highest level of 
expression found in the most aggressive cancers32. 
Interestingly, besides being expressed in prostatic tissues, PSMA is also 
expressed in tumor-associated neovasculature of many solid cancers including 
prostate, lung, breast and colon33. Thus, targeting neoangiogenesis through PSMA 
may represent a valid diagnostic and therapeutic option in several solid tumors. 
Although a PSMA-endogenous ligand was not discovered yet, PSMA can 
constitutively internalize into cells by receptor-mediated endocytosis via clathrin-
coated pits34. In the last decade, several PSMA targeted ligands such as 
antibodies35, aptamers36 and peptides37 were developed and exploited to perform 
targeted delivery of chemotherapeutics and imaging agents into PSMA-positive 
tumor cells both in vitro and in vivo38. Particularly, these ligands were internalized 
upon binding with PSMA on the cell membrane even without possessing agonist-
like function.  
 
HER2. The human epidermal growth factor receptor-2 (EGFR2 or HER2) is a 
member of the human epidermal growth factor receptor (EGFR) family, a class of 
Receptor Tyrosine Kinase (RTK). In fact, HER2 is a 185 kDa transmembrane 
receptor with an extracellular binding domain and an intracellular tyrosine kinase 
domain. Upon binding with specific extracellular ligands, receptor dimerization 
occurs with the formation of homodimers or heterodimers with HER3 or HER4 
that triggers intracellular signaling cascades. The most activated downstream 
signaling pathways lead to increased proliferation and invasiveness. Notably, 
overexpression of HER2 is associated with subsets of multiple cancer types such 
as breast, ovarian, cervical, uterine, and gastric39. Particularly, overexpression in 
25-30% of all breast cancers coincides with an aggressive phenotype and poor 
prognosis. This HER2-upregulation is due to a remarkable gene amplification (e.g. 
25-50 copies of HER2 gene) that may lead up to a 40-to 100-fold enhanced 
protein expression40,41. 
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Unlike other RTKs of this family whose extracellular domains shuttle between a 
closed inactive state and a ligand activated open state, HER2 exhibited a 
constitutively active open state. Additionally, HER2 has the strongest catalytic 
kinase activity and heterodimers containing HER2 exhibit the most effective 
downstream signaling activation. This feature suggests to target HER2 both for 
inhibiting this receptor and carrying therapeutic or diagnostic agents. 
Interestingly, HER2 targeted agents were extensively used to treat HER2-
positive breast cancer41 Particularly, Trastuzumab (Herceptin®), a human 
monoclonal anti-HER2 antibody with inhibitory property, recently received FDA 
approval for the treatment of HER2 overexpressing breast cancer42. Trastuzumab 
can be used alone or in combination with chemotherapy drugs such as 
doxorubicin, cisplatin, cyclophosphamide, and either paclitaxel or docetaxel43. 
Although Trastuzumab is the first treatment for HER2 positive-breast cancer, 
several intracellular resistance mechanisms against this antibody were recently 
discovered that lead to a reduced therapeutic efficacy or insensitivity to 
Trastuzumab44,45. To date, novel targeted therapies and new systems to overcome 
Trastuzumab resistance are under investigation46. 
Finally, recent findings showed that HER2-targeted therapeutic agents also 
inhibited the growth of breast cancer stem cells found in HER2-negative patients 
suggesting the importance of HER2 as target for multiple types of breast cancer47.  
 
TfR. Transferrin receptor (also known as CD71) is a type II transmembrane 
homodimer glycoprotein (180 kDa) involved in the cellular uptake of iron and in 
the regulation of cell growth. The TfR monomer contains three domains: a large 
extracellular C-terminal domain, a single-pass transmembrane domain, and a short 
intracellular N-terminal domain. Iron uptake occurs via the internalization of iron-
loaded transferrin (Tf) mediated by the interaction with the TfR (Fig. 4). Tf is a 
monomeric glycoprotein (called apo-Tf) that can transport one (monoferric Tf) or 
two (diferric Tf) iron atoms. Diferric Tf (also known as holo-Tf) has the highest 
affinity for the TfR; being 10- to 100-fold more affine to TfR compared with apo-
Tf at physiological pH48. Upon binding TfR, the Tf/TfR complex is internalized in 
clathrin-coated pits through receptor-mediated endocytosis48. Particularly in the 
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endosomal compartment, the transferrin structure undergoes a conformational 
change due to pH decrease and iron is released from the protein. Tf still remains 
bound to its receptor at this pH and the apo-Tf/TfR complex is recycled back to 
the cell surface where apo-Tf is released ready to bind iron atoms in the 
extracellular milieu. Interestingly, TfR undergoes recycling constitutively, with or 
without binding to its ligand, transferrin49. 
 
 
Fig. 4 Schematic representation of transferrin receptor-mediated endocytosis. The 
TfR is constiuitively internalized via receptor-mediated endocytosis. Upon binding of 
iron-loaded transferrin to TfR, internalization of the tripartite complex occurs. This 
complex is delivered into endosomes where the decrease in pH triggers the release of 
iron from the Tf/TfR complex. The bipartite complex is sorted to either its 
corresponding degradation or recycling pathways in the early endosome. The 
restoration of neutral pH following recycling to the cell surface induces the 
dissociation of the Tf/TfR complex Adapted from Hsu et al.49 Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology (Ref. 49), 
Copyright © 2012. 
Iron is a co-factor involved in many enzymatic reactions including metabolism, 
respiration, and DNA synthesis48. The TfR is ubiquitously expressed on normal 
cells and its expression is sensitively increased on cells with a high proliferation 
rate that require large amounts of iron. Therefore, TfR is significantly upregulated 
in a variety of tumor cells (e.g. breast, prostate, pancreatic, ovarian, lung, chronic 
lymphocytic leukemia and non-Hodgkin’s lymphoma) and in many cases 
increased expression correlates with tumor stage and is associated with poor 
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prognosis48. Note that, the expression of TfR in cancer cells can be up to 100-fold 
higher than the average expression of normal cells50,51. Moreover, high levels of 
TfR were found on the brain capillary endothelium of the blood-brain barrier 
(BBB) where it plays a crucial role in the receptor-mediated transcytosis of the 
iron-loaded Tf across the BBB52. As a consequence, TfR is one of the most widely 
investigated targeted receptor for drug delivery across the blood–brain barrier53. 
Owing to its enhanced expression in specific districts of the body (such as BBB) 
or in malignant tumor cells, its extracellular accessibility, and its ability to 
internalize, transferrin receptor represents an attractive target for targeted drug 
delivery applications and is an ideal marker in cancer diagnosis. Particularly, both 
monoclonal antibodies-54 and transferrin- drug conjugates55 have been extensively 
investigated as nanocarriers for the treatment of several solid tumors and for 
delivering therapeutic cargoes to the brain compartment56. However both these 
strategies display several limitations due to (i) the intrinsic drawbacks of 
monoclonal antibody technology and (ii) the competition between endogenous Tf 
and the exogenous Tf-drug conjugates. Specifically, transferrin receptors are 
nearly saturated by endogenous Tf under physiological conditions (concentration 
of circulating Tf is about 2.4 mg/ml i.e. ~25 mM)57, and exceedingly high 
concentrations of exogenous Tf derivatives are necessary to ensure adequate 
delivery of payloads to target tissues58.  
1.3 Targeting ligands: the keys to open the gates of the diseased 
cells  
An insightful comparison has been recently introduced between the cell and the 
castle structure59: if the plasma membrane represents the walls of the cellular 
fortress, and its overexpressed receptors are the fortress gates, the ligands 
recognizing these markers and internalizing into the cells will be the “keys of the 
castle”. 
To date, there are several ways to unlock the fortress gates in the form of 
proteins (mainly antibodies and their fragments), oligonucleic acids (DNA and 
RNA aptamers), and other receptor ligands (peptides, vitamins, carbohydrates, and 
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protein-endogenous ligands such as transferrin, or epidermal growth factor)4,12. 
Here I shall describe the properties of the most investigated class of targeting 
ligands, the monoclonal antibodies (mAbs), shedding light on the antibody 
advantages and drawbacks. Then, I shall introduce a class of binders, the nucleic 
acid aptamers, which represents a promising alternative to the antibodies and that 
offers improved options for targeted delivery applications. 
1.3.1 Antibodies 
Over the past two decades the potential of mAbs as high-affinity binders for 
targeted therapy has been clinically demonstrated60 with several therapeutic mAbs 
approved by FDA61. To date, more than 200 antibody-based targeted platforms 
were successfully translated into the clinical environment and are currently in 
preclinical and clinical trials62. However, this class of ligands shows several 
limitations. For example they are produced through a complex and expensive 
process that is difficult to scale-up to large-scale manufacturing without affecting 
product properties18. They have limited stability, are rapidly inactivated under 
acidic conditions, in the presence of proteases or at elevated temperatures63. 
Moreover, their large size (150-160 kDa and 12-15 nm) results in slow tissue 
penetration64 and prevents access to many biological compartments, ultimately 
leading to an increase toxicity due to a long blood residence65. The most 
significant restriction, however, is related to their immunogenicity, which was 
observed mainly for first-generation of rodent antibodies. Indeed, injection of 
mouse mAbs into humans results in the production of human anti-mouse 
antibodies (HAMA), thus leading to serious immune reactions66. To overcome this 
limitation, recent developments in the field of antibody engineering have led to the 
production of antibodies that contain animal and human domains, called chimeric 
mAbs, then humanized mAbs, and fully human mAbs60  (Fig. 5). Overall, these 
structures present a gradually reduced immunogenicity, with fully human and 
humanized antibodies carrying lower risk to induce immune response in humans 
than mouse or chimeric antibodies67. However, other problematic immune 
responses still exist, such as anti-idiotypic responses, with the production of anti-
idiotypic antibodies, also called anti-drug antibodies, against humanized or fully 
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human antibodies that ultimately lead to the neutralization of their therapeutic 
effect67. 
Interestingly, the last frontier in the field of the antibody engineering led to the 
development of antibody fragments18, which include monomer of antigen-binding 
fragments, dimers of antigen-binding fragments, and single chain variable (Fig. 5). 
 
 
Fig. 5 Antibodies and antibody fragments. Targeting antibodies are normally 
monoclonal immunoglobulin G (IgG) (Aa) or IgG fragments (B–D). F(ab′)2 (B) or 
Fab′ (C) fragments can be made by enzymatic cleavage of the whole monoclonal 
antibody (mAb) (Aa) or by molecular biological techniques — for example, Fab′ (C), 
scFV (Da), bivalent (Db) or recombinant fragments (Dc). mAbs that are made from 
the traditional hybridoma technique are murine in origin. Recent developments have 
led to the production of chimeric, humanized or fully human antibodies or fragments 
(Ab–d). Fc, fragment crystallizable region; VH, variable heavy chain; VL, variable 
light chain. Adapted from T. M. Allen.18 Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cancer (Ref. 18), Copyright © 2002. 
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As shown in Fig. 5, only the antigen recognition domain is included in the 
antibody fragment structures, while the fragment crystallizable (Fc) region is 
removed in order to reducing their immunogenicity. Indeed the Fc domain is a 
double-edged sword: when mAb is bound to a tumor cell surface antigen, its Fc 
region can interact with Fc receptors expressed on the surface of effector cells of 
the immune system, such as natural killer cells,68 evoking antibody-dependent 
cellular cytotoxicity and complement-dependent-cytotoxicity18. Note that, these 
effects play a significant role in enhancing the anticancer effect69. However, 
interaction between the Fc region and Fc receptors expressed on normal cells, as 
occurs with macrophages, can elicit immune response leading to increased 
immunogenicity62,70. 
Although antibody fragments are less immunogenic than whole mAbs, 
unfortunately they are less stable and tend to aggregate due to the absence of Fc 
region, which plays a role in the structural stability of mAbs63,71. Furthermore, as 
shown in Fig. 5 most antibody fragments have only one epitope-binding site 
included in their structure, which reduce their binding avidity18,70. 
Despite many advancements mAbs and antibody fragments still suffer 
limitations that hamper their applicability. Particularly, the use of mAbs and 
antibody fragments is often restricted to conditions resembling their physiological 
environment. In the presence of organic solvents or in other non-physiological 
conditions (e.g. elevated temperature, high pH and high salt concentration), they 
generally lose their function63. Moreover, mAbs are not easily conjugated to 
therapeutic molecules, reporter tags, or engineered scaffolds to create complex 
biomolecular architectures that may be used as targeting delivery platforms. 
Indeed, the synthetic approaches required for antibody conjugation to molecular 
partners are stochastic and lead to product mixtures and reduced antibody 
activity72,73. 
1.3.2 Aptamers 
An alternative to antibodies should possess high stability, long-term storage, and 
ease of conjugation to molecular partners7475. In this context, it is worth noting 
that biological nucleic acids are not only able to store and code genetic 
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information assuming simple base pairing structures, but they can also fold into 
complex tertiary structures, and perform different functions including gene-
regulation76, catalytic activity77, and ligand-binding78. Although this is true for 
biological nucleic acids, in 1990 a series of technological advances allowed the 
development of an in vitro evolutionary method for the selection and identification 
of synthetic oligonucleic acids, called aptamers, that bind specifically to molecular 
targets79,80.  
Nucleic acid aptamers are composed of short structured RNA or single-stranded 
DNA sequences, and are emerging as attractive targeting tools with huge potential 
in diagnostics and therapeutics. Aptamers are able to recognize and bind a definite 
target molecule with high affinity and selectivity, owing to their exclusive spatial 
conformation. In this regard, they are often termed “chemical antibodies”9. In 
general, aptamers may act similarly to antibodies and they can be used as 
activating ligands81, therapeutic antagonists82, or as vectors to deliver therapeutic 
and diagnostic payloads, especially in the field of targeted cancer therapy9. 
Compared with antibodies, aptamers are non-immunogenic, easy to synthesize, 
modify, and manipulate. Furthermore, their small size -usually 8-20 kDa and 3-5 
nm- allows more efficient penetration into target tissues72,83. Importantly, 
aptamers do not include the Fc region of mAbs, thus avoiding undesired 
interactions with Fc receptors expressed on immune cells and other certain types 
of cells, which may result in immune stimulation or other unwanted side effects.  
Aptamer technology was born twenty-five years ago; despite being a relatively 
new technology, one therapeutic aptamer is already available in the clinic and 
various other aptamer-based drugs and aptamer nanocarriers are currently in 
different stages of preclinical and clinical trial for diseases that span from cancer84 
and heart disease85 to type II diabetes86. 
The first FDA-approved aptamer is called pegaptanib and it was approved in 
2004 for the treatment of age-related macular degeneration (AMD) in the U.S. and 
the EU82. Pegaptanib (Macugen®; Pfizer and Eyetech) is an RNA aptamer that 
specifically recognizes human VEGF with high affinity (Kd~50 pM) and 
selectivity87. VEGF promotes angiogenesis and may be up regulated under certain 
conditions, (e.g. wound healing) or diseases (e.g. AMD and cancer)88. Pegaptanib 
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binds to the heparin-binding site of VEGF and blocks the interaction between 
VEGF and its receptors, which results in the prevention or reduction of the 
neovascularization. In 2004, pegaptanib became the first anti-angiogenesis drug 
for wet AMD therapy under intravitreal administration with a dosage of 0.3 mg 
per eye every 6 weeks82,89. 
The FDA approval of Pegaptanib represents a landmark in the development of 
aptamers as biological agents with applications in therapeutics, diagnostics and 
basic research.  
In the next section, I shall mention the main groundbreaking studies that led to 
the aptamer discovery, and then I shall report an insightful analysis of the aptamer 
properties and the recent progresses in the development of targeted drug delivery 
platforms based on aptamer-drug conjugates or aptamer-nanomaterial assemblies2.  
1.4 Aptamers as novel “keys of the castle”  
The first evolutionary experiments involving nucleic acids were reported in the 
1960s by Spiegelman and his collaborators, which described the use of an RNA-
dependent RNA replicase for the replication of a given RNA species90. Several 
years later, in 1986, the innovative discovery of the polymerase chain reaction 
(PCR) by Kary Mullis and co-workers has led to a technological revolution of the 
most biological fields (i.e. molecular biology, biochemistry) including 
evolutionary biology91. In 1990, three independent research groups described in 
vitro evolutionary methods for the selection of small nucleic acid ligands as 
binding partners for defined molecular targets. Particularly, Ellington and Szostak 
isolated short RNA molecules that bind to a small organic dye79. These small 
nucleic acid ligands were called aptamers (from the Latin aptus – to fit and the 
Greek meros – part or region). Tuerk and Gold selected RNA molecules able to 
bind the bacteriophage T4 DNA polymerase and they named SELEX (systematic 
evolution of ligands by exponential enrichment) the iterative selection process 
they used80. Robertson and Joyce described the application of in vitro selection to 
convert a group I ribozyme having RNase activity into an enzyme able to 
preferentially cleave DNA than single stranded RNA92. These groundbreaking 
studies shed light on novel perspectives and opportunities for the in vitro selection 
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of functional nucleic acids with desired properties. Indeed, for the first time, it was 
demonstrated that artificial nucleic acids could be used as functional moieties 
besides as blueprints of the genetic code or as rigid scaffold for nanoarchitectures. 
Interestingly, Nature already makes use of several functional nucleic acids, such 
as noncoding RNA and riboswitches as regulatory elements to control gene 
expression in bacteria, eukaryotes, and higher organisms91.  
It is worth mentioning that few years later the aptamer discovery, the term 
“aptamers” was extended to include peptides with protein-binding properties93,94. 
However for the most part and for the purposes of this thesis the term is used to 
describe oligonucleotide molecules. 
Since the invention of SELEX technology, a plethora of high-affinity RNA and 
DNA aptamers have been selected towards a wide range of different targets 
ranging from small molecules (i.e. metal ions, organic dyes, amino acids, and 
peptides)95,96 to proteins72 to complex targets (whole cells2, viruses or bacteria97). 
Thus, during the last two decades aptamers found broad application across various 
biomedical fields: biomarker discovery, in vitro diagnosis, in vivo imaging, and 
targeted therapy9.  
Aptamers fold into distinct three-dimensional (3D) structures able to bind and 
recognize a particular molecular target with high affinity and specificity (Fig. 6a), 
with dissociation constants typically within the pico- to nanomolar range3. In fact, 
aptamers are not just linear nucleic acid molecules that simply carry genetic 
information, but rather they can assume a wide variety of secondary structures, 
such as hairpin loop, pseudoknot and G-quadruplex (Fig. 6b) generated by a 
combination of Watson–Crick and non-canonical intramolecular interactions that 
ultimately lead to complex spatial structures.  
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Fig. 6 Schematic representation of (a) aptamer–target interaction and (b) aptamer 
secondary structures. Figure (a) is reprinted from Biotechnology Advance 33 (2015) 
1141–1161, Darmostuk et al.98; Copyright © (2015), with permission from Elsevier. Figure 
(b) is reprinted from Biotechnology Advances 31 (2013) 1260–1274, Radom et al.99; 
Copyright © (2015), with permission from Elsevier. 
In contrast with other nucleic acid probes (such as antisense oligonucleotides 
and ribozymes), aptamers bind their targets through 3D structural recognition 
involving non-covalent interactions, similarly to the antigen-antibody reaction. 
Therefore, aptamers are also known as “chemical antibodies”9. However, aptamers 
possess significant advantages relative to their protein counterpart in terms of 
virtually no immunogenicity, thermal stability, low-cost chemical synthesis, and 
ease of conjugation or modification with different functional moieties3 (Table 1). 
Compared with antibodies, aptamer production exploits a chemical technology 
with high batch fidelity, which is not prone to viral or bacterial contamination100. 
In addition, the process of chemical synthesis allows the site-specific introduction 
Aptamers as tools for targeted drug delivery applications  19 
 
of non-nucleotide linkers (e.g. hexaethylene glycol), or chemical functionalities 
useful for conjugation (such as primary amines, thiol precursors and aldehyde 
precursors), and the addition of fluorescent or other reporter moieties72.  
Moreover, thanks to their small size (aptamers: 25-70 nt equals 8-25 kDa; 
antibodies ∼150–160 kDa), aptamers can penetrate into biological compartments 
more efficiently than antibodies, thus accessing target domains that might 
otherwise be inaccessible to bulky ligands.  
 
Table 1. Comparison of aptamers and antibodies. Adapted from Sun et al.3 
Reprinted by permission from John Wiley and Sons Copyright © 2015; Small 11 
(2015) 2352–2364 (Ref. 3)  
 
 
Lastly, the nature of nucleic acids provides another important advantage 
compared with protein ligands. Since the function of the aptamer is tightly 
dependent from their 3D structures, it can be modulated for desired therapy and 
drug delivery application simply by using the complementary oligo sequence. The 
complementary base pairing can alter the aptamer spatial structure and ultimately 
disrupt the interaction with its target. This approach, known as aptamer antidote 
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strategy, allows a precise control of the aptamer activity by a rational design of the 
antidote sequence, and was firstly introduced by Sullenger and coworkers in 2002. 
Briefly, they developed an aptamer that targets the blood coagulation factor 
IXa101, which induces anticoagulation in pigs and inhibits thrombosis in murine 
models102. However, a major risk associated with anticoagulant therapy is 
uncontrollable bleeding if reversal of the anticoagulation is not achieved103. 
Therefore, they also developed an antisense strand, complementary to 17 
nucleotides of the aptamer, which was able to interfere with the aptamer structure 
(Fig. 7), inhibiting its activity both in animal models of cardiovascular disease and 
surgical trauma and humans102,103.  
 
 
Fig. 7 Aptamer–antidote pair. The sequence and structure of the anti-factor IXa 
aptamer and its antidote are shown. Binding of the antidote to the aptamer 
inactivates the aptamer by disrupting its secondary and tertiary structure. 
Abbreviations: Ch, cholesterol; idT, inverse deoxythymidine. Reprinted from Current 
Opinion in Chemical Biology 10 (2006) 282–289, Lee et al.104; Copyright © (2006), with 
permission from Elsevier. 
The therapeutic potential of aptamers is largely influenced by their 
pharmacokinetic property. As small nucleic acid molecules, natural RNA and 
DNA aptamers are highly susceptible to the nuclease-mediated degradation and 
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size-dependent clearance via renal filtration. However, both limitations can be 
addressed with appropriate chemical modifications.  
Evidence shows that firstly the 2’-OH group of RNA and secondarily the 
phosphodiester bonds are the preferentially target sites of nucleases hydrolysis9. 
Note that, DNA molecules are naturally resistant to 2’-endonucleases owing to the 
lack of the 2’-OH group. Thus, the main approaches to overcome the nuclease 
sensitivity are aimed at increasing the in vivo stability of RNA aptamers. As seen 
for other therapeutic oligonucleotide agents105, nuclease resistance can be 
achieved with substitutions of the 2’-OH RNA group, internucleotide linkage 
substitutions of the phosphodiester backbone with either boranophosphate or 
phosphorothioate, conformationally restricted ribose (locked nucleic acids), 
generation of mirror RNA sequences (Spiegelmers), introduction of functional 
groups at the nucleobase level, and the combination of these modifications106 (Fig. 
8). Since serum nucleases responsible for RNA turnover are largely directed 
towards pyrimidine nucleotides107, the most prominent modification is the 
substitutions of 2’-OH group of pyrimidines by 2’-fluoro, 2’-amino, or 2’-O-
methyl (Fig. 8b) that lead to nuclease-stabilized RNA molecules. Particularly, 
whereas natural RNA aptamers exhibit a very short serum half-life (estimated at 
10 s), the widely used 2’ fluoropyrimidine-containing RNAs have a sensibly 
longer serum half-lives (estimated at 80 h)108. This approach relies on the effective 
incorporation into RNA transcript of 2’-modified nucleotides using mutant forms 
of T7 RNA polymerase during the in vitro transcription109,110.  
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Fig. 8 Subset of modified nucleotides used for increase nuclease-resistance of 
aptamers. (a) In addition to the unmodified nucleotides of DNA and RNA, a wide 
variety of modified nucleotides have been used for improving stability, chemical 
diversity, and target binding potential of selected aptamers. (b) The most commonly 
used modified nucleotides contain modifications of the ribose sugar such as 2′-Fluoro, 
2′-Amino, or 2′-OMethyl. (c) Locked nucleic acids (LNAs) contain modifications to 
the sugar phosphate backbone, and are more stable than DNA and RNA. (d) 
SOMAmers contain modifications (i.e., benzyl, napthyl, tryptamino, or isobutyl) on 
deoxyuridine nucleotide (dUTP), which improve the chemical diversity and thus the 
target interaction capacity of the  aptamers. (e) Spiegelmers are derived from mirror-
image (enantiomer) ribonucleotides. Spiegelmers are not recognized by natural 
nucleases that degrade wild type oligonucleotides. Adapted from Ozer et al. 111 
Reprinted by permission from Nature Publishing Group: Mol. Ther. Nucleic Acids (Ref. 
111), Copyright © 2014 The American Society of Gene & Cell Therapy.  
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Other approaches to the development of nuclease-resistant aptamers relies on 
modifications of the ribose motif using locked nucleic acid technology or generate 
“mirror” RNA sequence structures, termed Spiegelmers.  
Locked nucleic acids (LNAs) bear a methylene ether bridge between the 2’-
oxygen atom and 4’-carbon atom (Fig. 8c). Thus, in the LNA ribose the 3’carbon 
atom is locked in an endo (N-type) conformation with a consequent lower 
flexibility of the sugar motif and a high degree of nuclease resistance112. 
Spiegelmers are aptamers in which all the sugars are the enantiomers of wild-type 
nucleic acids (Fig. 8e). In the case of RNA Spiegelmers, the backbone is 
composed by L-riboses, instead of D-riboses present in native RNA, linked by 
phosphodiester bonds. As a consequence, nucleases are not able to recognize these 
molecules as substrates of their hydrolytic degradation. The first functional 
Spiegelmers were designed to bind to the small molecules arginine and 
adenosine113,114, and they exhibited the expected biostability, as demonstrated for 
the D-adenosine specific L-RNA spiegelmer. Indeed, no evidence of degradation 
in human serum were detected over 60 hours of incubation at 37°C 114. 
Modifications of nucleobases have also been reported, with derivatization at the 
C5-position of uridine and deoxyuridine being the most prevalent (see Fig. 8). 
Notably, the introduction of amino acid side chain-like groups (Fig. 8d) at this 
position conferred an increased chemical complexity together with a higher 
hydrophobic character of the aptamers, thus increasing both the range of available 
binding epitopes on the target proteins and the success rate of SELEX115. A class 
of DNA aptamers bearing these modifications is known as SOMAmer (Slow Off-
rate Modified Aptamers) owing their high affinity towards their biomolecular 
targets116.  
When appropriate modifications to control nuclease-mediated degradation are 
included in the aptamer sequences, elimination via renal filtration becomes the 
main limitation to aptamer pharmacokinetics. The molecular mass cutoff for the 
renal glomerulus is 30-50 KDa, thus aptamers (8-25 kDa) can be conjugated to 
bulky groups in this size range to reduce the renal filtration rate. The most 
common strategy is the conjugation of either 5’-end or 3’-end of the aptamers to 
high molecular mass polyethylene glycol (PEG) (from 5 kDa up to 60 kDa)108. 
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This method is better known as PEGylation and represents a typical modification 
when aptamers should be employed for in vivo applications. Importantly, 
nuclease-stabilized aptamer conjugated to 40 kDa-PEG can have circulating half-
lives up to 1 day in mice117 (Fig. 9).  
Alternatively, other bulky groups that have been directly conjugated to the 
aptamers are cholesterol derivates, streptavidin (via biotinylated aptamer), and 
liposomes (through conjugation to lipid tags). 
 
 
Fig. 9 The pharmacokinetics of aptamers conjugated to different molecular mass 
PEGs. Pharmacokinetic profiles of 39-mer 2′-deoxy purine, 2′-O-methyl pyrimidine 
composition aptamers. These aptamers were unconjugated or conjugated to either 20 
kDa polyethylene glycol (PEG) or 40 kDa PEG and administered intravenously to 
CD-1 mice (n = 3 per time point) at 10 mg per kg. Adapted from Keefe et al.72 Reprinted 
by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Ref. 72), 
Copyright © 2010 
1.5 In vitro selection of aptamers 
SELEX technology is based on an iterative process of amplification and 
enrichment, in which a very large (~1014) number of random oligonucleotide 
(either RNA or single-stranded DNA) is exposed to the target of interest for 
several repetitive rounds. During this process, the library is subjected to a 
selection pressure in parallel that allow an enrichment of the molecules with 
binding properties against the desired target. Typically, four main steps can be 
recognized into basic SELEX process (Fig. 10).  




Fig. 10 Schematic illustration of aptamer selection procedures by SELEX. Generally, 
in a typical SELEX procedure, the initial single-stranded DNA/RNA pool contains a 
20–60-nt random sequence to provide a sequence space that facilitates presence of 
structures with high binding affinity to the target protein. By repeating selection 
rounds, aptamers against any given targets can be routinely isolated from an initial 
combinatorial oligonucleotide library. A typical SELEX process consists of four main 
steps (1) binding to the target protein, (2) selective partitioning, (3) recovery of target-
bound sequences, and (4) re-amplification of recovered species. Reprinted from RNA 
Interference from Biology to Therapeutics Cap. 10 “Aptamer-Mediated siRNA Targeting” 
207–220, Zhou and Rossi118 Copyright © (2013), with permission from Springer. 
- The first step is the generation of the nucleic acid library. A single-stranded 
DNA library sequence that includes a random region composed by 20-50 
residues in length, and flanking conserved sequences required for enzymatic 
manipulation is first designed and then synthesized72. PCR amplification of 
this single-stranded DNA library generates a double-stranded PCR product 
with high sequence variability. The initial oligonucleotide selection pool (for 
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either DNA or RNA aptamers) usually contains 1013-1015 unique random 
molecules, although pools with a lower variability yielded functional 
aptamers119,120. In the case of DNA aptamer SELEX, the starting library of 
single-stranded DNA molecules is obtained after strand separation of double-
stranded PCR product. In the case of RNA aptamer SELEX, the RNA library 
is prepared by in vitro transcription of double stranded DNA templates, using 
recombinant wild type or mutant T7 RNA polymerase, as previously 
described. 
- The second step is the incubation of the oligonucleotide library with the target 
of interest for specific binding enrichment. Importantly, before this incubation 
the library is thermally denatured and cooled at room temperature to ensure 
proper oligonucleotide folding and consequently promote the formation of 3D 
structures. 
- Next, the unbound fraction is discarded and separated from the target bound 
species. 
- Finally, these binding oligonucleotide sequences are collected, purified and 
amplified by either PCR (for DNA aptamers) or by RT-PCR (for RNA 
aptamers) to generate a fresh oligonucleotide library ready for the next round 
of the in vitro selection. 
SELEX process usually requires 4-20 rounds of amplification and enrichment9 
to obtain high affinity aptamers. The number of SELEX rounds is strongly 
affected by the nature of the aptamer target (such as a purified protein or a living 
cell line), by the type of library used, as well as by the evolution of the aptamer 
library during each selection cycle. After the last round of selection, a rational 
strategy deeply examines the oligonucleotide sequences to disclose the ligands 
with the best properties. First, the enriched library is cloned and, after sequencing, 
candidate aptamers are classified in several groups on the basis of their sequence 
homology. High-throughput sequencing methods (Next-Generation Sequencing – 
NGS) and bioinformatics analysis (such as FASTAptamer121) allow the 
identification of candidate aptamers. Once the candidates are identified, they are 
explored in terms of binding affinity, specificity, and desired properties such as 
target inhibition, cell internalization, and stability. These latter steps are so far the 
Aptamers as tools for targeted drug delivery applications  27 
 
most time-consuming part of the aptamer generation process. Lastly, the best 
selected aptamers and their relative secondary structures are rationally investigated 
(by computer simulation, and both chemical and enzymatic probing) in order to 
find out the minimal aptamer binding sequence required for the specific 
recognition of the target. Post-SELEX modifications can also be introduced to 
increase the aptamer properties in terms of nuclease resistance, in vivo 
biodistribution, and other parameters affecting the aptamer pharmacokinetic 
behavior (as described in the previous section).  
Early SELEX protocols targeting proteins usually required several months to 
identify aptamers able to bind the desired target protein. Recently, the traditional 
SELEX method has been modified to improve the outcome of this technology. 
Particularly, some innovative SELEX strategies have been developed in order to 
(i) maximize affinity and selectivity (e.g. slow-off rate modified aptamers – 
SOMAmer)116, (ii) to improve the evolution of the library and consequently the 
speed of selection and success rate (e.g. capillary gel electrophoresis-122, 
microfluidic-123, bead-based SELEX124 and FACS-SELEX125), (iii) to provide 
additional properties to the selected ligands (e.g. cell-internalization SELEX126), 
(iv) to obtain aptamers against more complex targets (e.g Cell-SELEX127, in vivo 
SELEX128)111. A fruitful approach for increasing the activity of selected sequences 
is the “doped-SELEX”, in which an original, successful aptamer sequence is 
partially randomized at some or all positions and reselected129. For example, each 
position in a doped library could contain 55% of the initial selected nucleotide, 
and 15% each of the other three nucleotides (45% doping)130. Moreover, the 
biomolecular target of this second selection could be the same of the original 
SELEX or closely related. 
Table 2 shows a detailed scheme of the SELEX methods and offers a better 
comparison among these techniques. To date, thanks to these strategies, an in vitro 
selection takes only several days and aptamers are emerging as valid tools for 
basic research and biomedical applications. 
The main drawback of the SELEX technology is the uncertain prediction of the 
success of the selection. It is not possible to judge the ability of a target molecule 
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to be suitable for the selection process and whether an aptamer can be successfully 
raised against the target (aptamerogenicity) a priori91 
 
Table 2 Comparison of SELEX methods. Reprinted by permission from Nature 
Publishing Group: Mol. Ther. Nucleic Acids (Ref. 111), Copyright © 2014 The 
American Society of Gene & Cell Therapy.  
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1.6 Selection of aptamers recognizing cell-surface markers 
As mentioned in the previous section, in the recent years innovative strategies 
have been introduced to enhance both performance and outcome of the 
conventional SELEX process. Here, I shall focus on the in vitro selection methods 
to generate aptamers targeting cell-surface markers or specific cell-types to exploit 
as targeted drug delivery agents. Two main approaches are typically employed: (i) 
traditional purified membrane protein-based SELEX and (ii) live cell-based 
SELEX. 
In a typical protein-based SELEX the nucleic acid library is mixed with a target 
purified membrane protein, a cell surface antigen overexpressed and/or mutated in 
diseased cells. Traditional bead-, resin-, membrane-, or chip-based partition 
approaches are employed as affinity matrixes to separate target-bound sequences 
from unbound species. In this context, the immobilization of the recombinant 
purified protein on the affinity surface is the first step before the incubation of the 
target with the nucleic acid library. Protein-SELEX is a method in which low 
nonspecific binding and easy control of the conditions allow optimal enrichment 
of specific ligands. To date, most aptamers as targeting ligands have been 
successfully generated using purified membrane protein-based SELEX2. A strong 
limitation of this method is the conformational instability of target proteins, 
especially under the conditions of the selection process. Protein conformational 
changes can lead to a misleading selection with enrichment of oligonucleotide 
sequences that recognize a false 3D protein structure. Alternatively, a reduction of 
enrichment can also occur from one selection cycle to the other, in which the 
enriched pool suddenly is not more able to bind the target protein due to the 
conformational changes91. Additionally, purified recombinant proteins are 
generated by in vitro expression systems, which often not include the presence of 
post-translational modifications, such as glycosylation (N- and O-linked), 
phosphorilation of tyrosine, threonine or serine residues and addition of 
glycosylphosphatidylinositol (GPI), typically present in cell-surface receptors. 
Furthermore, in many cases cell-surface proteins are insoluble in their 
recombinant form, or they are functional only when tightly associated with other 
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cell components (e.g. G protein-coupled receptor) or when associated to form 
multimeric and/or multivalent structures131. Thus, RNA and DNA aptamers 
selected through a protein-SELEX approach might not be able to recognize the 
same target when embedded in a physiological milieu132. To overcome these 
limitations, an innovative SELEX method that uses whole living cells as target, 
termed live cell-based SELEX (or cell-SELEX) has been introduced127. This 
approach allows the identification of aptamers that bind cell-surface specific 
antigens in their native environment133. In contrast to protein-SELEX, cell-SELEX 
does not need information regarding native conformation, identity, and biological 
function of target proteins, and aptamers against unknown cell-surface antigens 
can be also generated. This method relies on the difference between the expression 
pattern of cell-surface receptors in target cell population (e.g cancer cells) and the 
receptor pattern in control cell line (e.g. healthy cells). Therefore, cell-SELEX 
involves two different selection steps (Fig. 11): (i) a negative selection (or counter 
selection) step to suppress nonspecific binding sequences, in which the 
oligonucleic acid library is incubated with non-target cells (or negative cells). 
Unbound sequences are recovered and (ii) a positive selection is performed with 
target cells (or positive cells) and target-bound ligands are recovered and 
amplified for the subsequent round of SELEX. 
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Fig. 11 Schematic illustration of cell-SELEX procedure. A live cell-based SELEX 
procedure consists of four main steps each round of selection: (1) counter-selection by 
incubating library with negative cells that do not express the target antigen, (2) 
positive selection by incubating recovered unbound sequences with positive cells 
expressing cell-surface receptors of interest, (3) recovery of target-bound sequences, 
and finally (4) re-amplification of recovered species. 
Overall, cell-SELEX provides aptamer sequences able to bind a pool of 
different cell-surface antigens overexpressed or exclusively present in target cells. 
Using this approach several groups generated aptamers able to discriminate a 
particular cell population2. Tan group introduced for the first time this new 
strategy to select DNA aptamers able to discriminate T cells (CCRF-CEM cells, a 
human precursor T-cell acute lymphoblastic leukemia cell line) from a B cell line 
(Ramos cells, human Burkitt’s lymphoma cells), in patient samples127. Despite the 
remarkable success of cell-based SELEX, one important drawback is related to the 
nonspecific binding to dead cells that can lead to low target-bound sequences 
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enrichment and sometimes even to the failure of aptamer selection2. Furthermore, 
the lack of knowledge about identity and expression level of the biomarker of 
interest might result in the enrichment of many unrelated/unwanted aptamers 
against off-target surface antigens coexpressed on the positive cells.  
This strategy can provide sufficient selective pressure to favor the enrichment of 
target-specific aptamers even when nonspecific antigens are coexpressed on the 
surface of target cells; however, recent findings introduced an enhanced in vitro 
selection method called crossover SELEX. This method combines cell-SELEX 
and protein-SELEX protocols and simplifies and increases the success rate of the 
in vitro selection. Notably, crossover SELEX is readily applicable when the 
identity of the cell-surface target is known, and its iterative cycles exploit a first 
traditional selection against a recombinant protein, followed by a second selection 
using whole living cells as target107. It is worth noting that Hicke et al. firstly 
introduced this methodology to select RNA aptamers against tenascin C (TN-C), 
an extracellular matrix protein overexpressed in tumor growth and other different 
cellular processes134. In this study, however, several rounds of live cell-based 
SELEX were first performed as primary selection using U251 glioblastoma cells 
overexpressing human TN-C. Then, the enriched pools were incubated with 
purified TN-C performing two additional rounds of the second protein-based 
SELEX. Thanks to the final selection pressure two high affinity RNA aptamers 
were selected and, in a subsequent investigation, shown to be able to discriminate 
tumor tissue from healthy tissue into in vivo model on the basis of the different 
expression of TN-C135.  
Crossover SELEX is becoming very attractive to generate aptamer ligands as 
tools for targeted drug delivery applications136, and has been recently exploited by 
Levy and coworkers to generate serum-stabilized RNA aptamers against human 
transferrin receptor (hTfR)137.After 4 rounds of protein-SELEX using the 
traditional nitrocellulose membrane filter as partition method, the RNA enriched 
pool was incubated with live cancer cells for one additional round of selection. 
Importantly, during this cell-based enrichment round, Levy and coworkers 
employed a modified cell-SELEX approach, termed cell internalization SELEX46. 
This novel strategy leads to selection of aptamers able to bind to and enter target 
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cells, known as cell-penetrating or cell-internalizing aptamers59,126. Thanks to this 
strategy, the authors generated a minimized 2’-fluoro RNA aptamer, termed 
c2.min able to bind with high affinity hTfR and showing cell-penetrating 
properties towards several hTfR (+) cancer cells.  
1.7 Cell-specific aptamer applications in targeted drug delivery 
Thanks to the advancement of SELEX technologies, many aptamers targeting 
cell-surface biomarkers have been generated in the last decade and exploited as 
nanovectors for targeted drug delivery2. In this section, I shall introduce the main 
approaches and the most representative applications of cell-specific aptamers. 
Particularly, I shall focus on the conjugation designs used to deliver traditional 
anticancer drugs and functional therapeutic oligonucleotides. The two main 
strategies for targeted delivery using cell-surface aptamers are: (i) aptamer-drug 
conjugates, in which the aptamer motif is directly conjugated to the therapeutic 
payloads via either a physical non-covalent intercalation or a covalent linker and 
(ii) aptamer-nanomaterials system in which the surface of high-molecular-weight 
bioavailable nanomaterials is coated with several aptamer molecules.  
1.7.1 Aptamer-chemotherapeutic conjugates 
Non-covalent conjugation by intercalation of hydrophobic drugs, such as 
Doxorubicin (Dox), has been extensively used to create aptamer-drug 
complexes138. This approach is straightforward and does not require any chemical 
modification of drugs or aptamers (Fig. 12). Dox is an anthracycline anticancer 
drug that intercalates preferentially into G-C rich double stranded region of 
nucleic acids via its aromatic rings. Taking advantage of this propensity, Dox can 
be intercalated into helical strand of the aptamers to form physical conjugates. In 
2006, Bagalkot and coworkers firstly used this strategy to generate a non-covalent 
complex between anti-PSMA RNA aptamer A10 and Dox139. Interestingly, 
compared with free Dox, the aptamer-Dox conjugate was selectively uptaken by 
PSMA (+) cells (LNCaP cells) and only negligible internalization was detected in 
a control cell line not expressing PSMA (PC3 cells). Most importantly, while free 
34 Aptamers as tools for targeted drug delivery applications 
 
Dox exhibited comparable anticancer effect towards both cell lines, aptamer-Dox 
was more cytotoxic towards LNCaP cells rather than to PC3 cells. After this 
pioneristic work, physical aptamer-Dox conjugates have been widely used in 
several other applications for targeted cancer therapy. For example, aptamers 
against HER2, Mucin1 (MUC1), and epithelial cell adhesion molecule (EpCAM) 




Fig. 12 Schematic diagram of non-covalent aptamer-chemotherapeutic drug 
conjugate. Chemotherapeutic drugs, such as Doxorubicin, can intercalate in double 
stranded region of either DNA or RNA. Thus, non-covalent approach exploits this 
feature to generate aptamer-drug conjugate.  
Recently, more sophisticated designs relative to aptamer-drug conjugates have 
been also explored138. Particularly, Tan group used monovalent DNA aptamers 
able to recognize different cancer cell lines (T and B lymphoma cells) as “building 
blocks” to produce bispecific and trispecific aptamer nanostructures by DNA self-
assembly (Fig. 13a)140. Thanks to this strategy a higher number of Dox molecules 
could be intercalated into the oligonucleotide structure, and the resulting complex 
showed enhanced specificity compared with parent monovalent aptamers. More 
recently, the same group elaborated a strategy to increase drug loading of the 
aptamer. A DNA trigger sequence was added as extended motif at 5’-end of a 
DNA aptamer (sgc8) against a cell-surface biomarker, protein tyrosine kinase 7 
(PTK7) (Fig. 13b). When two hairpin oligonucleotides, called M1 and M2, 
containing Dox intercalation sites were self-assembled with the DNA aptamer, a 
train-like structure was generated. They called this model aptamer-tethered DNA 
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nanotrains (aptNTrs), in which the aptamer acted as a targeting locomotive and the 
two hairpins provided the boxcars delivering the drug141. Up to 50 molar 
equivalents of Dox was intercalated into the aptamer-nanotrain structure. Most 
importantly, sgc8-NTrs-Dox complex showed selective delivery and anticancer 
effect both in vitro and in vivo.  
 
 
Fig. 13 Scheme for the self-assembly of two different aptamer-based drug carriers. (a) 
Bispecific SD-doxorubicin complex was self-assembled from molecularly engineered 
aptamers S and D, containing extended complementary sequences that lead to the 
formation of a double stranded DNA region upon hybridization. Then, Dox was 
intercalated in the DNA duplex motif. From “Self-Assembled Aptamer-Based Drug 
Carriers for Bispecific Cytotoxicity to Cancer Cells”. (b) Schematics of the self-
assembly of aptamer tethered DNA nanotrains (aptNTrs). Self-assembled from short 
DNA building blocks upon initiation from a chimeric aptamer-tethered trigger probe, 
significantly improve the drug payload capacity and the anti-tumor efficacy. Adapted 
from Zhu et al.138; Copyright © Ivyspring International Publisher (2014). 
Non-covalent approaches have shown to be a promising strategy in targeted 
drug delivery applications; however, covalent conjugation of the drug is being 
investigated as a valid alternative method (Fig. 14). Indeed, the stability of 
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aptamer-chemotherapeutics complexes is affected by the intrinsically reversible 
nature of non-covalent interaction. Furthermore, intercalation of anticancer drugs 
in double stranded regions of the aptamer might alter the aptamer 3D structure, 
thus adversely affecting its biological activity.  
 
 
Fig. 14 Schematic diagram of covalent aptamer-drug conjugate.  Aptamer bearing a 
functionalizing linker is covalently conjugated with a chemotherapeutic drug at 1:1 
stoichiometry.  
Various functional groups (e.g. amino, thiol, azide groups) can be readily 
included on the oligonucleotide sequence during the chemical synthesis of the 
aptamers. Thanks to the functionalization of these groups, a host of molecular 
payloads and nanomaterials has been covalently conjugated to nucleic acid 
aptamers142. For example, the sgc8 aptamer-Dox complex has been generated 
through an acid-labile acylhydrazone linker at 1:1 stoichiometry143. Upon binding 
with the aptamer target PTK7, the sgc8-Dox conjugate is internalized in target 
cells (CCRF-CEM T cells) through an endocytosis pathway, where the acid-labile 
linker is cleaved in the acidic endolysosomal compartment, releasing Dox and 
exhibiting antitumor activity. In another study, Boyaciogul and coworkers 
increased the aptamer payload capacity involving the assembly of polyvalent 
aptamers144. Dox was covalently conjugated through a different pH-sensitive 
linker (formaldehyde) to dimeric aptamer complexes (DACs) constituted by a 
DNA aptamer against PSMA. Formaldehyde-based linker leads to Dox release 
upon acid-mediated dissociation and promotes Dox binding to genomic DNA by 
formation of covalent adducts, increasing Dox-mediated apoptosis145. Compared 
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with the previously described sgc8 aptamer-Dox conjugate, each DAC could bind 
up to 4 molecules of Dox and the DAC-Dox assembly was stable under 
physiological conditions for ∼8 hours. Lastly, DAC could perform selective 
delivery of Dox to PSMA (+) cells (C4-2 cells), where Dox localized in the 
nucleus after endolysosome release. As for other aptamer-Dox conjugates, DAC-
Dox showed selective cytotoxicity towards target cells. Interestingly, a highly 
localized cytotoxicity was observed even when target tumor cells were cultured in 
close proximity to PSMA (-) cells (PC3 cells) within a co-culture model.  
1.7.2 Aptamer-therapeutic oligonucleotide conjugates 
In 1998 a groundbreaking study shed light on the role of RNA interference 
(RNAi) as potent genetic regulator146. Small interfering RNA (siRNA) and 
microRNA (miRNA) molecules are the main classes of small regulatory RNAs 
that inhibit gene expression by silencing target messenger RNA (mRNA) in a 
sequence-specific manner147,148. These powerful gene-silencing tools have been 
extensively studied along the last 15 years as a novel class of therapeutics149. 
However, these therapeutic oligonucleotides, as well as traditional drugs, lack of 
selectivity towards diseased cell/tissues. Therefore, cell-specific internalizing 
aptamers have been combined with RNAi technology to achieve selective gene 
targeting through covalent conjugation or physical assembly strategies. 
In 2006, Sullenger and coworkers described the first-generation of aptamer-
siRNA chimera150; the anti-PSMA RNA aptamer A10 (targeting motif) was 
conjugated to the sense strand of a siRNA and then annealed with unmodified 
antisense strand to generate the double stranded siRNA (payload motif) (Fig. 15). 
They demonstrated that conjugation did not affect the functional properties of 
either aptamer or siRNA. Indeed, the resulting RNA chimera is selectively 
internalized in PSMA (+) cells through the aptamer motif, and the siRNA portion 
knocks down the expression of tumor survival genes polo-like kinase 1 (Plk1) and 
Bcl-2 both in vitro and in vivo.  
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Fig. 15 First- and second- generation of covalent aptamer-therapeutic oligonucleotide 
conjugates. On the left, schematic of the first-generation anti-PSMA aptamer-siRNA 
chimeras. The 2’-Fluoro-modified aptamer and siRNA sense strand were co-
transcribed, followed by annealing of the complementary siRNA antisense strand to 
complete the chimeric molecule. On the right, schematic of the optimized second-
generation chimeras. Compared with the first generation chimeras, the aptamer 
portion of the chimera was truncated from 71 to 39 nucleotides, and the sense and 
antisense strands of the siRNA portion were swapped. A 2 nucleotide (UU)-overhang 
and a polyethylene glycol tail were added to the 3’-end of the guide strand and the 5’-
end of passenger strand, respectively. Adapted from Zhou and Rossi151. Copyright © 
2010 Zhou and Rossi; licensee BioMed Central Ltd.  
Starting from this first design, Giangrande and colleagues rationally designed a 
second-generation aptamer-siRNA chimera152 (Fig. 15). Three main differences 
were included in the A10-Plk1 chimera: (i) minimization of the aptamer portion 
(from 71 to 39 nucleotides) without affecting the high binding activity to generate 
aptamer sequences by large-scale chemical synthesis. (ii) 2-nucleotide (UU)-
overhang were added at the 3’ end of the antisense strand, and then sense and 
antisense strands of the siRNA portion were swapped to allow a more efficient 
incorporation of the siRNA by the cellular RNAi machinery. (iii) PEG tail were 
added to the 5’-end of passenger strand (sense strand) to extend the serum 
circulating half-life of the chimera. This optimized version of the aptamer-siRNA 
chimera was administered to a mouse model bearing human prostate cancer and 
resulted in a major growth suppression of PSMA-expressing tumor compared with 
the first-generation system. Most importantly, the therapeutic dose of the second-
generation chimera was dramatically reduced from 1 nmol at every other day up to 
ten injections (first generation treatment) to 0.25 nmol at every other day for a 
total of ten days (second-generation treatment), minimizing both the cost of 
treatment and the risk of harmful side effects152. 
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Non-covalent approaches are an alternative and elegant strategy to obtain 
aptamer-siRNA chimera. Different molecular connectors have been used to 
assemble aptamer and siRNA modules (Fig. 16). In 2006, Chu and coworkers 
focused on the highly specific non-covalent interaction between biotin and 
streptavidin to generate a multivalent construct composed by an anti-PSMA 
aptamer (A9) and 27-mer DsiRNAs against lamin A/C and GAPDH (Fig. 
16a)153.Thanks to the four biotin-binding sites present on this protein, two 
biotinylated aptamers were connected with two biotinylated siRNAs into a 
modular streptavidin connector. Moreover, a reducible disulfide linker was 
included between the sense strand of siRNA and the biotin group to enhance 
siRNA release in the cytoplasm. This multivalent aptamer-streptavidin-siRNA 
construct displayed PSMA receptor-mediated internalization via the aptamer 
module and specific silencing of the targeted mRNA transcripts in PSMA-
expressing tumor cells via siRNA motif.   
 
 
Fig. 16 Non-covalent aptamer-therapeutic oligonucleotide conjugates. (a) Schematic 
of the aptamer-streptavidin-siRNA conjugate. The two biotinylated siRNAs and two 
aptamers are non-covalently assembled via a streptavidin connector. (b) Schematic of 
the aptamer-sticky bridge-siRNA conjugate. The aptamer and siRNA that bearing 
extended complementary sequences are hybridized by simple Watson-Crick base 
pairing. Adapted from Zhou and Rossi2. Reprinted by permission from Nature Publishing 
Group: Mol. Ther. Nucleic Acids (Ref. 2), Copyright © 2014 The American Society of 
Gene & Cell Therapy. 
Recently, Rossi group identified new anti-gp120 aptamers and introduced a 
‘sticky bridge’ strategy to connect siRNA motif to the aptamer module154 (Fig. 
16b). In details, an extended short GC-rich sequence was added to the 3’-end of 
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the gp120 aptamer and its complementary sequence was included at the 3´-end of 
one of the siRNA strands. After annealing of these two strands by Watson-Crick 
base pairing, a double helix region was generated and exploited as bridge between 
the two modules. A flexible three-carbon atom linker (C3) was added as spacer 
between the extended GC-rich sequence and the 3’-end of the aptamer to allow 
spatial and structural flexibility both for the aptamer module and the sticky region. 
Most importantly, this strategy allows the interchange of various siRNAs with the 
same aptamer, without virtually altering the aptamer conformation. Indeed, in this 
proof-of concept study, three different siRNAs targeting HIV-1 dependency 
factors were combined with a single gp120 aptamer. The resulting aptamer-
bridge-siRNA cocktail was selectively uptaken via gp120 into HIV-1 infected 
cells (CEM-T cells and human PBMCs), leading to suppression of HIV replication 
by targeted gene silencing. 
1.7.3 Aptamer-conjugated nanomaterials 
An effective strategy to generate aptamer-mediated drug delivery platforms with 
enhanced properties, lies on the aptamer conjugation on the surface of smart 
biocompatible nanomaterials. Besides sharing the common properties of 
nanomaterials, such as large surface area, uniform size and shape for an excellent 
biodistribution, the resulting aptamer-nanomaterials display several additional 
features: (i) improved nuclease resistance owing to the higher steric hindrance that 
hampers the nucleic acid sequence recognition by nucleases, (ii) reduced renal 
clearance rates with prolonged circulating half-life due to the molecular mass of 
this platform, (iii) enhanced aptamer affinity for their targets based on the 
presence of multiple aptamer copies on the nanomaterial surface, which leads to 
an increased aptamer local concentration, and (iv) higher drug payload capacity 
compared with aptamer-drug conjugates owing to the large surface area of the 
nanomaterials.  
Importantly, several physicochemical properties of aptamer-nanomaterials, such 
as, ligand–receptor interaction valency, aspect ratios, orientation, and spacing of 
ligands need to be considered to obtain a proper recognition of the aptamer target 
receptors that ultimately triggers an intracellular uptake into target cells. For 
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example, rod-like particles with high aspect ratios are internalized more efficiently 
in vitro through receptor-mediated endocytosis compared with  particles with low 
aspect ratios, such as spheres and cubes155. 
To date, various nanomaterials such as copolymers156, liposomes157, metal 
nanomaterials158, and virus-like particles159 have been combined with cell-specific 
aptamers for targeted delivery of diagnostics and therapeutics. Here, I shall briefly 
mention the more relevant studies, in which gold nanoparticles, 
superparamagnetic iron oxide nanoparticles, polymeric nanoparticles, and 
quantum dots were used as nanomaterials. 
Gold nanoparticles. Thanks to their favorable characteristics, which include 
high stability, good biocompatibility, and straightforward conjugation, gold 
nanoparticles (AuNPs) have been widely explored in combination with targeting 
aptamers. For example, Ellington and colleagues combined an RNA aptamer 
against Epidermal Growth Factor Receptor (EGFR) with AuNPs using a non-
covalent conjugation approach160. In details, short DNA capture sequences were 
first covalently conjugated to the surface of AuNPs, and then hybridized by 
Watson-Crick base pairing with complementary extended sequences tethered to 
the 5’-end of the anti-EGFR RNA aptamers (Fig. 17). This double stranded DNA 
spacer reduced the nonspecific interaction between the surface of the AuNPs and 
the aptamer molecules without affecting aptamer 3D conformation that could 
retain its biological activity. Indeed, AuNP-aptamer complexes were selectively 
internalized via receptor-mediated endocytosis in EGFR (+) cells. Most 
importantly, the nonspecific uptake exhibited by AuNPs was markedly reduced 
after conjugation with the RNA aptamer. 
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Fig. 17 Aptamer-functionalized gold nanoparticles. AuNPs are first coated with short 
capture DNA sequences (green) and then are hybridized with corresponding 
complementary sequences tethered to the 5′-end of the aptamer.  
In a recent study, an RNA aptamer against CD30 -a diagnostic biomarker for 
Hodgkin’s lymphoma and anaplastic large cell lymphoma- was chemically 
conjugated with negatively charged hollow gold nanospheres (HAuNS) via thiol-
gold linkers161. The resulting aptamer-HAuNS conjugates were partially coated 
with PEG to enhance their biostability. Lastly, doxorubicin molecules were 
absorbed on the surface of these conjugates exploiting electrostatic interaction at 
physiological pH (7.4) between the positive amino group of Dox and the negative 
citrate present on the surface of HAuNS22. The aptamer-HAuNS-Dox complexes 
were sensitive to pH changes: they were quite stable at pH 7.4 but they released 
80% of their drug payloads within 2 h at pH 5.0, a value similar to that found into 
lysosomal compartment. Most importantly, when incubated in mixed cell cultures 
(i.e. co-culture composed of both CD30-expressing lymphoma cells and CD30-
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negative control cells), the aptamer-HAuNS-Dox was able to internalize and 
selectively kill lymphoma tumor cells without unwanted off-target toxicity. 
Superparamagnetic iron oxide nanoparticles. Because of their 
superparamagnetic properties and their wide range of potential applications in 
catalysis, sensors, and MRI (magnetic resonance imaging), superparamagnetic 
iron oxide nanoparticles (SPIONs) have attracted a growing interest. SPIONs are 
iron oxide particles included α-Fe2O3 (hematite), γ- Fe2O3 (maghemite) and Fe3O4 
(magnetite) of 1-100 nm or greater diameters162. The surface of the SPION can be 
coated with few layers of organic polymers to confer both anti-biofouling property 
that prevents the adsorption of plasma proteins or cells onto their surface and 
targeting capability with specific chemical groups. These functional groups can be 
covalently conjugated with targeting ligands to generate targeted nanoparticle 
platforms. In 2008, Farokhzad and coworkers designed and assembled a 
multifunctional theranostic system combining the anti-PSMA RNA aptamer 
targeting properties for targeted drug delivery and the SPION magnetic properties 
as diagnostic agent163. In details, the anti-PSMA RNA aptamers bearing an amino 
group at the 3’-end was conjugated via EDC/NHS coupling chemistry to the 
carboxyl groups of an antibiofouling polymer that coated the surface of the 
SPION. Doxorubicin was loaded into the aptamer-SPION conjugates both by 
intercalation into the duplex region of the aptamer module and by absorption onto 
the surface of the SPION through electrostatic interactions (Fig. 18). The potential 
of the aptamer-SPION conjugate as a targeted MR contrast agent was investigated 
by Nuclear Magnetic Resonance (NMR) studies. Particularly, by monitoring the 
longitudinal relaxation time (T1), and the transverse relaxation time (T2) of both 
the aptamer-SPION conjugate and non-targeted SPION in living cells, the aptamer 
targeted platform led to selective detection of PSMA-expressing tumor cells with 
high sensitivity. Furthermore, targeted drug delivery properties were assessed by 
in vitro cell viability measurements. Interestingly, Doxorubicin was selectively 
released from the aptamer-SPION platform in target prostate cancer cells leading 
to a specific anticancer effect. 
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Fig. 18 Aptamer-functionalized SPIONs. The aptamer is covalently conjugated onto 
the surface of a SPION and then Dox is intercalated in the duplex region of the 
aptamer and also complexed with the SPION through charge interactions.  
Polymeric nanoparticles. In the last decade, several groups have exploited 
aptamer-functionalized natural or organic polymeric materials for targeted drug 
delivery applications. Polymeric nanoparticles (polymeric NPs) exhibit excellent 
opportunities in terms of enhanced biodegradability and biocompatibility. Indeed, 
most of the first-generation nanomedicines approved for clinical applications are 
based on polymeric and liposomal formulations. In 2004, a pioneering work 
described the synthesis of an aptamer-polymeric NP platform as tool for targeted 
drug delivery156. Particularly, the anti-PSMA RNA aptamer was conjugated with 
biocompatible and biodegradable poly(lactic acid)-block-PEG copolymer 
tethering a terminal carboxylic acid functional group (PLA-PEG-COOH) Notably, 
using conventional EDC/NHS coupling chemistry, the amino group at the 5’-end 
of the aptamer was linked to the carboxyl acid on the polymer. The resulting 
aptamer-polymeric NP conjugate was internalized specifically in PSMA-
expressing cells with an enhanced uptake up to 77-fold compared with control 
pegylated polymeric NPs. Exploiting this strategy, the same group generated a 
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nanoscale platform for targeted therapy having both targeting properties and 
controlled drug release properties164. In details, the anti-PSMA RNA aptamer A10 
were used to functionalize the surface of biodegradable and biocompatible 
poly(lactic-co-gycolic acid)-block-PEG with a terminal carboxylic acid group 
(PLGA-PEG-COOH). Then, the complex was loaded in the inner part of the 
polymeric NP structure with Docetaxel, a hydrophobic chemotherapeutic drug 
(Fig. 19). Notably, in this platform PLA or PLGA helps to encapsulate and control 
drug release, while PEG enhances circulating half-life conferring anti-biofouling 
properties of the bioconjugate. Targeted drug delivery properties were observed 
both in vitro and in vivo. In cultured cells the aptamer-polymeric NP-Docetaxel 
conjugates showed enhanced selective cytotoxicity towards PSMA expressing 
prostate cancer cells. Most importantly, a single intratumoral injection of this 
platform in a xenograft tumor model resulted in significant tumor reduction with 
negligible off-target effect in the mice. 
 
 
Fig. 19 Aptamer-functionalized polymeric nanoparticle. The aptamer is covalently 
functionalized onto the surface of the polymeric NPs. Antitumor drug, Docetaxel, is 
encapsulated into the hydrophobic core of the PLGA NPs.  
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An emerging trend in cancer therapy is the use of combinations of two different 
drugs to achieve a synergistic effect and improve the therapeutic index. This 
strategy is becoming really significant mostly for the treatment of chemotherapy-
resistant tumors. However, the codelivery of two different drugs having different 
physicochemical properties is extremely difficult. An elegant approach based on 
aptamer-functionalized polymeric NPs was exploited to selectively deliver both 
hydrophilic doxorubicin and hydrophobic docetaxel in tumor cells overexpressing 
PSMA165. Particularly, docetaxel was first encapsulated in PLGA-PEG-COOH. 
Simultaneously, the 5’-NH2-anti-PSMA RNA aptamer module was preloaded with 
doxorubicin by its intercalation into the double stranded region. Then, the final 
complex was formed through EDC/NHS chemistry coupling as previously 
described. The resulting drug-delivery platform was able to selectively deliver 
both doxorubicin and docetaxel into PSMA (+) prostate cancer cells. Most 
importantly, the codelivery strategy resulted in significantly higher cytotoxic 
effect compared with the treatment of the cultured cells after aptamer polymeric 
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As stated in the previous chapter, most therapeutic agents currently in clinical 
use are in general not engineered to selectively target the site of the disease. So 
far, targeting strategies using ligand-bound cell-surface markers to deliver small 
therapeutic agents have enhanced the selectivity of these drug delivery platforms. 
In this context, aptamers are emerging as a valid alternative to monoclonal 
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antibodies. As previously described, recent studies led to the development of a 
variety of targeted systems based on aptamer-chemotherapeutic drug conjugates, 
aptamer-therapeutic oligonucleotides conjugates or aptamer-nanomaterial 
assemblies. Although these platforms have been successfully used especially 
against many different types of cancer, intrinsic or acquired resistance to the 
cytotoxic effects of chemotherapy has emerged as a significant hurdle to effective 
cancer treatment. Indeed, tumors usually consist of mixed populations of 
malignant cells; a fraction of these cells is drug-sensitive while the other one is 
drug-resistant166. Therefore, chemotherapy kills only drug-sensitive cells, but is 
not able to overwhelm drug-resistant cells166. 
A key factor involved into chemoresistance is the nuclear factor κB (NF-κB), a 
ubiquitous transcription factor that inhibits apoptosis through induction of anti-
apoptotic proteins and/or suppression of pro-apoptotic genes. In details, NF-κB is 
the generic name for a family of dimers formed by several proteins: NF-κB1 (also 
known as p50/p105), NF-κB2 (also known as p52/p100), REL, RELA (also 
known as p65/NF-κB3) and RELB. The different heterodimers can bind specific 
promoters to initiate transcription of a wide range of genes involved into 
inflammatory response as well as cell death and survival and tissue repair167. NF-
κB is active in the nucleus and is inhibited through its sequestration in the 
cytoplasm by the inhibitor of κB (IκB), which binds NF-κB through a specific 
binding motif (Fig. 1). Several stimuli including growth factors, cytokines (such as 
interleukin-1 and tumor necrosis factor), hormones and other signals activate NF-
κB by the phosphorylation of IκB. Indeed, the phosphorylated IκB is released 
from NF-κB, which can freely translocate to the nucleus where it promotes 
transcription of antiapoptotic genes such as X-linked inhibitor of apoptosis protein 
(XIAP) and Bcl-2 family genes, ultimately conferring resistance toward apoptotic 
stimuli. 
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Fig 1 A scheme of the nuclear factor-κB (NF-κB) pathway activated by anticancer 
drugs. Anticancer drugs induce nuclear translocation of NF-κB, activation of NF-κB 
target genes, and the secondary production of NF-κB activators such as reactive 
oxygen species (ROS), interleukin-1 (IL-1) and tumor-necrosis factor-α (TNFα). All of 
these effects can lead to enhanced cell proliferation, angiogenesis, motility, migration, 
adhesion, immortality, inflammation and inhibition of apoptosis, through expression 
of genes coding for anti-apoptotic proteins, membrane transporters, cytokines, 
growth factors, cell-cycle regulators, cell-adhesion molecules and cell-surface 
proteases. Nitric oxide synthase 2 (iNOS2): 26S, 26S proteasome; BCL2, B-cell 
CLL/lymphoma 2; COX2, cyclooxygenase-2; GM-CSF, granulocyte–macrophage 
colony-stimulating factor; IAP, inhibitor of apoptosis protein; ICAM1, intracellular 
adhesion molecule 1; IEX1L, immediate early response gene X-1 longer transcript; 
IKK, IκB kinase; IL-1Rs, IL-1 receptors; IκB, inhibitor of κB; MDR1, multidrug 
resistance gene 1; MEKK, MAPK/ERK kinase kinase; MHC, major 
histocompatibility complex; MMP, matrix metalloproteinase; NF-κB, nuclear factor-
κB.; PI3K, phosphatidylinositol 3-kinase; TNFR, tumor-necrosis factor receptor; 
ULS, ubiquitin ligase system; uPA, urokinase-type plasminogen activator; UV, 
ultraviolet; VCAM1, vascular cell-adhesion molecule 1; VEGF, vascular endothelial 
growth factor; XIAP, X-linked inhibitor of apoptosis protein. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Cancer (Ref. 168), Copyright © 2005. 
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Constitutive NF-κB activation observed in many malignant tumors protects the 
cells from apoptotic stimuli, including anticancer treatments and might have a 
crucial role in the intrinsic chemoresistance. Genetic alterations affecting the 
genes encoding NF-κB or IκB are the main causes responsible for this constitutive 
activation. Intriguingly, several anticancer agents (such as doxorubicin) stimulate 
NF-κB activation, which can potentially lead to acquired chemoresistance168. 
Recent studies demonstrated that inhibition of NF-κB sensitizes tumor cells to 
doxorubicin-induced apoptosis in various cancer cells (breast cancer, pancreatic 
cancer, renal and hepatocellular carcinoma)169,170. 
In this scenario, a codelivery strategy, in which two or more therapeutics are 
simultaneously administered could represent an effective way to treat cancer and 
overcome both intrinsic and acquired chemoresistance. Drugs with distinct 
mechanisms of action can be combined in a precisely controlled manner leading to 
a synergistic therapeutic efficacy, to minimize side effects and inhibit specific 
effectors of chemoresistance171.  
In this chapter, I shall describe a molecular-engineering strategy to develop a 
drug-delivery system composed uniquely by oligonucleotide modules able to 
perform codelivery of therapeutic payloads towards human pancreatic tumor cells. 
This platform is composed by three main domains: (i) a targeting motif, i.e. an 
RNA aptamer against the human transferrin receptor (hTfR) (ii) a drug-loading 
region for a traditional chemotherapeutic drug, i.e. doxorubicin (Dox) and (iii) an 
oligonucleotide decoy having inhibitor properties towards NF-κB as secondary 
molecular payload. The whole system was designed with labile (pH and redox) 
linkers able to promote conditional release of the therapeutic payloads upon 
internalization in cells.  
TfR was chosen as cell-surface marker owing to (i) its upregulation in many 
solid tumors and (ii) its constitutive endocytic pathway. Thus, aptamers targeting 
TfR can be easily internalized into the cells upon binding to TfR via a receptor-
mediated endocytosis.  
To reduce the chemoresistance of tumor cells and to increase the cytotoxic 
effect of Dox, as second molecular payload we decided to use NF-κB decoy 
oligonucleotide. Decoys are synthetic, double-stranded oligonucleotides (ODNs) 
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that selectively inhibit biological function of targeted transcription factors. In 
particular, NF-κB decoy ODNs are designed to mimic the κB consensus sequence 
recognized by NF-κB to the promoter regions of its target genes, thus ultimately 
preventing NF-κB binding to these sequences and hampering its transcriptional 
activity. 
2.1 Rational design of aptamer–Dox conjugate 
Our rational design of the therapeutic assembly started with the modification of 
a known cell penetrating RNA aptamer (c2.min) recognizing hTfR to generate an 
aptamer-Dox conjugate. In details, c2.min is the truncated version of a selected 
RNA aptamer against the hTfR137. Interestingly, despite the sequence homology 
between the human and mouse TfR is about 77%, c2.min is not able to bind the 
murine TfR and to internalize into mouse cells, being selective for the human 
receptor. Additionally, c2.min competes with the natural ligand, Tf, both for 
receptor binding and cell uptake. However, c2.min performs approximately 
twofold better than Tf in competition experiments, demonstrating that the aptamer 
binds to the receptor better than the natural ligand. As described in the first 
chapter two main strategies are reported in literature to generate aptamer-Dox 
conjugates: (i) non-covalent and (ii) covalent approach. In our design we decided 
to exploit the natural tendency of Dox to intercalate within DNA duplex through 
its aromatic rings (Fig. 2).  
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Fig 2 Doxorubicin intercalation in double-stranded DNA. The left panel reports the 
doxorubicin structure. On the right, the DNA-doxorubicin complex is shown with the 
two molecules of doxorubicin in blue, and the DNA bases that are depicted as follows: 
C in green, G in orange, A in red, T in yellow. The PDB code of the structure is 
234D172. 
It is known that Dox preferentially binds to CG steps of double-stranded DNA 
regions with 5’-GC-3’ or 5’-CG-3’ sequences173 (Fig. 2). Two trinucleotides are 
mainly involved in Doxorubicin intercalation within CG steps: CGA, which shows 
high flexibility, and the CGT, a rigid trinucleotide174. However, intercalation into 
the CGA trinucleotide shows tighter binding due to the formation of inter- and 
intra-molecular hydrogen bonds that are not observed with the CGT sequence174.  
It is worth noting that an analysis of c2.min secondary structure prediction 
evidenced only one Dox binding site with 5’-CG-3’ sequence within the RNA 
aptamer (Fig. 3).  
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Fig 3 Secondary structure prediction of c2.min RNA aptamer recognizing human 
transferrin receptor obtained using NUPACK (Nucleic Acid PACKage)175 tool. 
Yellow box on the secondary structure indicates possible Dox binding sites with 5’-
GC-3’ or 5’ CG-3’ sequences. 
Thus, to improve the Dox-loading capacity of c2.min, we designed an elongated 
aptamer bearing a short DNA tail composed by CGA repeating units at 3’end to 
create a duplex GC-rich region upon hybridization with its complementary DNA 
sequence, hereafter called anti-tail. As shown in Fig. 4a, NUPACK secondary 
structure prediction of the hybridized complex composed by the extended c2.min 
(i.e. c2.min-tail) and anti-tail highlighted two distinct regions: (i) the RNA 
aptamer portion still in its proper fold and (ii) a drug-loading domain composed by 
a DNA double helix. The resulting oligonucleotide carrier structure (hereafter 
c2C) includes one Dox binding site on the RNA motif and six to seven possible 
binding sites on the duplex region, which raise the final loading to seven to eight 
Dox molecules/c2C. Additionally, NUPACK calculation was also able to provide 
a depiction of the helicity of the hybridized oligonucleotide c2C (green and red 
color, respectively for c2.min-tail and the anti-tail sequence in Fig. 4a). Most 
importantly, as shown in overall representation of the secondary structure, the 
DNA duplex domain does not interfere with the correct RNA aptamer folding (as 
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shown by a comparison between Fig 2 and 3a), in agreement with previous studies 
involving the same DNA extension158.  
 
Fig 4 Rational design of c2C–Dox conjugate: (a) From left to right, secondary 
structure prediction of the hybridized assembly composed by the extended RNA 
aptamer (c2.min-tail) and anti-tail. Yellow boxes on the secondary structure indicate 
possible Dox binding sites within oligonucleotide structure. Note that each 
oligonucleotide is represented as an RNA sequence. (b) Fluorescence spectra of Dox 
solution (1.5 µM) incubated with: buffer, anti-tail, c2.min, and c2C (7.5 molar ratio 
Dox/c2C); Dox fluorescence in the conjugated molecule is quenched because of its 
intercalation in DNA duplex.  
Note that the great advantage to use a non-covalent strategy lies in a 
straightforward and quick formation of the conjugate between c2C and Dox which 
can be easily monitored in real time. To this end, we evaluated Dox loading 
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efficiency by evaluating variation of its fluorescence emission, which is known to 
decrease upon intercalation into DNA duplex due to a Förster resonance energy 
transfer between the anthracycline ring and DNA double stranded139. 
As shown in Fig. 4b, Dox fluorescence sensibly decreased upon incubation with 
the hybridized oligonucleotide c2C (7.5 molar ratio Dox/c2C) in agreement with 
the predicted presence of seven to eight Dox binding sites. Most importantly, only 
minor fluorescence quenching was detected in presence of c2.min and no 
quenching effect was observed in absence of the hybridization between the tail 
and anti-tail portions (Fig. 4b). This result confirms the formation of the correct, 
predicted c2C fold, in which the essential role of Dox loading is tightly related to 
the DNA duplex region. An electrophoretic mobility shift assay (EMSA) using a 
native polyacrylamide gel was also performed to confirm the effective formation 
of the hybridized complex c2C. As shown in Fig. 5, the band of the 
oligonucleotide assembly, c2C, migrated more slowly than the band of the free 
c2.min-tail owing to the larger size of the complex that reduces its migration rate 
during the electrophoresis analysis176. Importantly, no band of c2.min-tail was 
detected in the mixture of the two oligos (lane 3), suggesting the complete 
hybridization between c2.min-tail and anti-tail.  
 
Fig 5 Electrophoretic mobility shift assay EMSA) to assess the formation of the 
oligonucleotide complex among the extended aptamer (c2.min-tail) and the anti-tail. 
Lane 1: 100 bp range DNA ladder. Lane 2: c2.min-tail. Lane 3: c2.min-tail+anti-tail. 
Native PAGE 8%; Band detection was performed by ethidium bromide staining. 
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Next, we evaluated the stability of the c2C-Dox conjugate in a serum-containing 
medium to quantify Dox release from the complex. This experiment aimed at 
evidencing the correct formation of the oligonucleotide carrier structure and to 
evaluate the stability of this complex and its potential use in an in vitro tumor 
model. After the physical assembly of the conjugate, the c2C-Dox was added with 
either 1% or 5% serum-containing medium and incubated at 37°C for 0, 0.5, 1, 2, 
and 24 hours.  Fluorescence emission of Dox was measured at each specific time 
to evaluate the extent of Dox release from the double helix (Table 1). 
Interestingly, c2C-Dox complex did not release Dox after 1h incubation in serum-
containing medium (1% and 5%) at 37°C, and only minor leakage was observed 
(<10%) after 2h incubation. Most importantly, even at longer incubation (24h) the 
assembly is quite stable, and the leakage from the double helix was about 25% in 
both serum conditions. Notably, no serum-concentration dependence was 
observed; this might suggest that leakage is likely due to a slow Dox thermally-
driven desorption from double helix that does not involve interaction with serum 
proteins. 
 
Table 1: Doxorubicin release from aptamer in serum-containing media 
Time 
Dox released (%) (1% 
serum)  
Dox released (%) (5% 
serum) 
0 min 0.0 0.0 
30 min 0.5 5.7 
60 min 1.4 3.3 
120 min 8.5 11.4 
24 h 27.0 26.5 
 
Then, we investigated whether c2.min still conserved its activity to bind hTfR 
and internalize into hTfR-expressing cells even when bearing the sterically 
demanding drug-loading region, i.e. GC-rich DNA duplex. To this end, we 
performed an internalization assay in living cells using a dual-labeled c2C 
assembly. Both c2.min-tail and anti-tail bear an amino group at the 5’-end. Each 
group was conjugated with a small organic dye, namely ATTO 633 to c2.min-tail 
and Alexa Fluor 488 to the anti-tail module. The dual labeling of the c2C complex 
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allows a simultaneous visualization of the two components, which is essential to 
evaluate the structural integrity of c2C complex inside the cells.  
We assessed uptake of this dual-labeled c2C in human pancreatic tumor cells 
(MIA PaCa-2), which are known to overexpress hTfR177. The endocytosis process 
of dual-labeled c2C was monitored by confocal microscopy (Fig. 6). Complete 
colocalization of the two dyes in subcellular vesicles was observed 20 minutes 
after the addition of the dual-labeled c2C, consistently with the uptake and 
retention of the entire complex144. Interestingly, considerable perinuclear 
localization was observed at longer times (120 minutes) for both dyes, suggesting 
that at least a fraction of c2C is not recycled during the endocytosis process. 
Overall, the endocytosis of the whole complex demonstrates the capability of 




Fig. 6 Cellular uptake of dual-labeled c2C (Alexa Fluor 488, green and ATTO 633, 
red) in pancreatic tumor cells (MIA PaCa-2). Extensive colocalization was observed 
both at early (20 minutes) and at longer (120 minutes) times. Scale bars: 10 µm 
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Taken together, these results highlight that our aptamer-Dox conjugate is easily 
generated by (i) a straightforward Watson-Crick base pairing and (ii) by a 
subsequent intercalation with Dox. Additionally, both targeting motif and drug 
loading region retain their proper structural folds that are tightly connected with 
their activities. Most importantly, Dox leakage from the construct in serum-
containing media is negligible at short times and limited ad longer times. This fact 
evidences the good stability of the assembly in conditions usually employed in cell 
treatment, and promotes its suitability for live cell applications. 
2.2 Aptamer-mediated tumor targeting and Dox release 
mechanism 
The first step in the preparation of a drug delivery platform for codelivery is 
represented by the evaluation of its ability to effectively deliver each single drug. 
Thus, we started to evaluate whether our non-covalent aptamer-Dox conjugate 
(c2C-Dox) could be selectively uptaken in tumor cells (MIA PaCA-2). 
Nontumoral mouse fibroblasts (NIH-3T3) were used as negative control to 
monitor the extent of the off target effect178. To this end, we monitored Dox 
fluorescence by confocal imaging microscopy after cell treatment with either the 
whole complex or free Dox, keeping constant both Dox concentration (1.5 µM) 
and Dox/c2C ratio (7.5:1). This approach allows a better comparison of the 
internalization pathway and efficiency, especially between free Dox and c2C-Dox. 
As expected, free Dox readily diffuses through the plasma membrane and 
accumulates into the nuclei of both hTfR(+) and hTfR(-) cells with nearly 
identical efficiency (Fig. 7). In contrast, when c2C-Dox conjugate is added to the 
cells, the aptamer-mediated uptake of Dox is markedly different in tumor and 
control cells. Indeed, c2C-Dox is readily internalized in MIA PaCa-2 cells, as 
shown by Dox fluorescence detected both in endocytic vesicles and into the 
nucleus, whereas only a weak cytoplasmic signal was detected in control cells 
(NIH-3T3), likely due to either negligible nonspecific internalization of the 
complex or minimal Dox release from the double helix during the 2h incubation.  
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Most importantly, free Dox and c2C-Dox display different uptake mechanisms 
by MIA PaCa-2 cells. Free Dox mainly accumulates in the nuclear region, while 
c2C-Dox shows both nuclear fluorescence and vesicular signal, in keeping with a 
subcellular compartmentalization of Dox within endosomes and lysosomes 
(endolysosomes). This behavior is in agreement with previous studies that showed 
cytoplasmic localization of Dox released from transferrin-Dox conjugates179. 
Overall these results and observations suggest that c2C-Dox is effectively 
internalized in human tumor cells via a receptor-mediated endocytosis. 
 
 
Fig. 7 Selective internalization of the c2C–Dox conjugate in targeted tumor cells. 
Confocal imaging microscopy shows the intracellular distribution of free Dox and 
Dox released from c2C–Dox complex (red fluorescence) in tumor cells (MIA PaCa-2) 
and control cells (NIH-3T3). Scale bars: 10 µm. 
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Next, we evaluated the intracellular release of Dox from the oligonucleotide 
complex in both cells at longer times (24 hours after treatment). As shown in the 
magnification of Fig. 7, a higher fluorescence signal was observed both in the 
cytoplasm and in the nucleus of MIA PaCa-2 cells. Conversely, only a slight 
increase of fluorescence was detected in NIH 3T3 cells, in agreement with a 
markedly lower uptake of c2C-Dox. 
The fluorescence enhancement observed in tumor cells suggests releasing of 
Dox from DNA duplex during late stages of the endocytosis pathway. Indeed, 
upon release of Dox from the double helix, the quenching effect due to the Dox 
intercalation may disappear and its fluorescence is restored.  
To investigate the nature of this fluorescence enhancement, we reproduced in 
vitro conditions matching those found in physiological conditions during late 
stages of TfR-mediated endocytosis pathway, and we monitored the fluorescence 
of c2C-Dox sample within this environment. As described in the first chapter, the 
intravescicular pH sensitively drops along the endocytic pathway from pH 6.0–6.5 
in early endosomes to pH 4.5–5.5 in late endosomes and lysosomes180. Therefore, 
c2C-Dox (1.5 µM Dox concentration) was incubated in solutions at different pH 
(7.4, 6.5, 5.8, 5.5, 5.0) and its fluorescence was monitored spectrophotometrically 
in real time. A free Dox sample at the same concentration was used as control to 
compare the variation of Dox fluorescence at each pH value.  
As shown in Fig. 8, Dox release was negligible (<10%)in a simulated early 
endosomal environment (pH 6.0-6.5). However, considerable Dox fluorescence 
enhancement related with a Dox release of ∼40% at pH 5.5 and ∼55% at pH 5.0 
occurred at lower pH values, which mimic those found in the late endosomes and 
lysosomes (5.0-5.5). Interestingly, this result is in excellent agreement with 
previous observations regarding Dox release in acidic solution181. It is well known 
that lysosomes contain several types of digestive enzymes including nucleases182. 
Thus, to better simulate the physiological condition of a lysosomal compartment, 
we added DNA nucleases (i.e DNase II) to the c2C-Dox sample at pH 5.0. As 
expected, Dox release increased from ∼55% to ∼98% within 2 hours at room 
temperature due to the degradation of the DNA duplex region on c2C structure. 
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These findings highlight the essential role of these hydrolytic enzymes in the 
mechanism of Dox release. 
We hypothesized that the observed pH dependency might be tightly related to 
the protonation of –NH2 groups on Dox that occurs at low pH (<6)22. This event 
might reduce the hydrophobic π stacking interaction between the aromatic ring of 
Dox and the nitrogenous bases of DNA duplex.  
It is worth noting that this pH- and nuclease-dependent Dox release from c2C-
Dox conjugate is consistent with the Dox fluorescence enhancement detected in 
MIA PaCa-2 cell cytoplasm at longer times (24 hours after treatment). Overall, 
these results support the hypothesis of pH- and enzymatic Dox release at 
endolysosomal level during receptor-mediated endocytosis pathway. 
 
Fig. 8 pH- and nuclease-triggered Dox release. On the top are shown the fluorescence 
spectra of Dox solution (1.5 µM) incubated with: buffer (pH 7.4), and c2C (7.5 molar 
ratio Dox/c2C) at different pH: 7.4, 6.5, 5.8, 5.5 and 5. The fluorescence of Dox at pH 
5 was measured either before or after DNase treatment.  
2.3 Antitumor efficacy of c2C-Dox 
Next, we assessed the therapeutic potential of this promising c2C-Dox 
conjugate. Thus, to evaluate whether the observed selective internalization could 
be translated to a specific anticancer effect we measured c2C-Dox cytotoxicity 
towards both tumor and control cells. To this end, we performed a standard water-
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soluble tetrazolium salt (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt, WST-8) assay to monitor the 
cell viability183 after treatment with either free Dox or c2C- Dox. Additionally, a 
c2 scrambled sequence (i.e. c36), which is known to be unable to recognize 
hTfR137 was used as control. This ODN sequence bears the same extended tail at 
the 3’-end, and a c36C-Dox was easily prepared by using the same straightforward 
procedure, previously described to generate c2C-Dox. Furthermore, a cervical 
cancer cell line (HeLa) was also employed to assess the cytotoxicity effect in a 
different tumor model, which may show a different sensitivity towards Dox.  
Dose dependence was demonstrated for all cell lines using the WST-8 assay 
(Fig. 9).  
 
 
Fig. 9 Cell viability assay of MIA PaCa-2, HeLa, and NIH-3T3 cells after treatment 
with free Dox (red), c2C–Dox (blue), and c36C–Dox (gray). Cells were incubated with 
the drugs for 2 hours and cell viability was assessed after 24 hours. Cell viability on 
incubation with c2C alone (see experimental part for further details) was 93.4 ± 2.0, 
90.7 ± 2.6, and 88.7 ± 3.2 for MIA PaCa-2, HeLa, and NIH 3T3, respectively. Error 
bars represent the SD from three or more independent experiments 
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As depicted in Fig. 9, free Dox shows an expected dose-dependent cytotoxicity 
in all cell lines. Conversely, c2C-Dox shows selective dose-dependent cytotoxic 
effect only towards MIA-PaCa-2 and HeLa cells and a remarkable lower 
cytoxicity in control cells. In contrast, c36C-Dox did not show appreciable 
cytotoxicity in any cell line. Interestingly, the very low cytotoxicity exhibited by 
this scrambled sequence was comparable with the effect displayed by c2C-Dox 
towards control cells. This might suggest that this minor contribution is due to 
either partial Dox leakage from the complex during incubation, or nonspecific 
uptake. This result demonstrates that the observed cytotoxicity shown by c2C-Dox 
towards tumor cells is actually related to an active targeting process.  
To further confirm that the observed cytotoxicity was actually an apoptotic 
effect related to the intracellular Dox release, we performed a fluorescence-based 
assay for apoptosis detection (Alexa Fluor 488-Annexin V/Propidium 
Iodide)184,185. This well-assessed assay allows discriminating among early 
apoptotic, late apoptotic, necrotic, and viable cells (green, green/red, red, and no 
fluorescence, respectively) on the basis of signals arising from annexin V and 
propidium iodide. In details, MIA Paca-2 cells were treated with either c2C-Dox 
or free c2C, and fluorescence emission was monitored by confocal microscopy. 
As shown in Fig. 10, treatment of cells with c2C-Dox evidenced the presence of 
both green fluorescence, mainly on the plasma membrane, and red fluorescence 
arising from nuclei, a pattern typical of the late apoptotic cells. Conversely, 
treatment with free c2C did not induce appreciable fluorescence, indicating non-
apoptotic cellular condition. 
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Fig. 10 Cell apoptosis assay. MIA PaCA-2 cells were incubated with Apt-Dox 
conjugate (1.5 µM Dox concentration) or aptamer alone (0.2 µM aptamer 
concentration) for 24 hours. Scale bars: 10 µm 
It is worth noting that the cervical cancer cells displayed a higher Dox 
sensitivity when compared with the pancreatic tumor model (see Fig. 9). As a 
consequence of this effect, both free Dox and c2C-Dox showed a higher -and 
similar- cytotoxicity towards HeLa compared with MIA PaCa-2. This effect 
strongly suggests the presence of a different chemoresistance efficacy by these 
two cell lines against Dox. Despite its lower effect against pancreatic tumor cells, 
Dox is sensitively more effective than c2C-Dox in this cell line. This behavior 
might be ascribed to the presence of a subset of pancreatic cancer stem cells 
expressing lower TfR levels and hence recognized with minor efficacy by the 
aptamer-Dox conjugate186,187. Notably, some cancer stem cells are maintained in a 
quiescent state, which preserves their self-renewal capacity188 while TfR is 
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expressed mainly in proliferative cells187. Conversely, the passive translocation 
process of free Dox does not discriminate among different subsets of cells, thus 
targeting the whole cell population.  
Another hypothetical explanation could be related with different internalization 
mechanism of the two systems. Notably, free Dox diffuses freely through the 
plasma membrane and accumulates in the nuclear domain. In contrast Dox 
released from c2C-Dox can accumulate into cytoplasm and consequently into the 
nucleus only after a receptor-mediated endocytosis, release from DNA duplex and 
a subsequent diffusion across the vescicular membranes of the endolysosomal 
compartment. Moreover, since the internalization route of c2C-Dox is different 
than free Dox, the chemoresistance mechanism into the cells can play different 
role in response to the Dox chemotherapeutic effect, and this effect is cell line-
dependent as observed by the different Dox sensitivity exhibited by HeLa and 
MIA PaCa-2 cells.  
2.4 Design, synthesis and Dox-loading of a novel aptacoy 
chimera 
Although c2C-Dox conjugate retains a potential interest as drug delivery 
platform, its therapeutic effect towards resistant pancreatic tumor cells was barely 
convincing to be taken in consideration for further clinical investigations. Indeed, 
as shown in Fig. 9 the cytotoxicity of the aptamer-Dox conjugate was less than 
50% even at the highest Dox concentration (5.5 µM). Thereby, the anticancer 
effect of the released Dox should be enhanced, still retaining the targeting 
properties of c2C-Dox. To this end, an intriguing option lies on the inhibition of 
pro-survival pathways tightly involved in chemoresistance.  
As described in the first section of this chapter, NF-κB is one of the most 
important molecular effector involved in both intrinsic and acquired 
chemoresistance. It was also extensively demonstrated that NF-κB activation 
suppresses the apoptotic potential of Dox, ultimately leading to increased 
chemoresistance. Moreover, recent studies demonstrated that inhibition of NF-κB 
sensitizes tumor cells to Dox-induced apoptosis in various cancer cells (breast 
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cancer, pancreatic cancer, renal and hepatocellular carcinoma)168,189. Therefore, 
we investigated a novel codelivery strategy to selectively release two synergistic 
drugs, i.e. Dox and an inhibitor of NF-κB in tumor cells. To date, several 
approaches were proposed to inhibit NF-κB activation168,190,191. One elegant 
strategy is to block NF-κB activity by interfering with its nuclear translocation. 
Indeed, during translocation NF-κB is potentially susceptible to hijacking by 
decoy molecules bearing the consensus binding sequence recognized by NF-κB192. 
Upon binding, nuclear translocation of NF-κB – and hence downstream activation 
of antiapoptotic genes- is inhibited (Fig. 11). Synthetic double-stranded DNA 
oligonucleotides with high affinity for NF-κB, known as NF-κB decoys, have 
been extensively used to block NF-κB-mediated induction of gene expression both 
in vitro and in vivo193,194.  
 
 
Fig. 11 Schematics of the NF-κB decoy mechanism. Anticancer drugs, such as 
doxourbicin induce nuclear translocation of NF-κB, which leads to the NF-κB-
mediated activation of target genes. Upon binding between the transcription factor 
and NF-κB decoy, the nuclear translocation is inhibited as well as the NF-κB 
transcriptional activity.  
As stated in the first chapter, several designs of aptamer-therapeutic ODN 
conjugates are reported in literature. Inspired from the most relevant studies, we 
designed a novel chimeric oligonucleotide, named aptacoy, composed by c2C 
portion directly conjugated to a NF-κB decoy by a disulfide linker. This latter is a 
critical part of our design: the linker is stable in the extracellular medium but is 
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easily cleaved in reducing intracellular environment, such as cytoplasm and 
lysosomes195. Furthermore, there are many evidences in which TfR-based vector 
have shown enhanced delivery efficacy of molecular payloads when a disulfide 
bond is included within the vector design196. 
We designed NF-κB decoy with a self-complementary sequence to obtain the 
suitable double-stranded DNA recognized by NF-κB simply via intramolecular 
folding197. As shown in Fig. 12, the secondary structure prediction of this ODN 
results very stable and does not affect the overall folding of c2C owing to the 
presence of thirteen intramolecular Watson-Crick base pairings. Additionally, we 
decided to use a whole phosphorothioate ODN to increase the nuclease resistant of 
this sequence. Several groups have successfully used this type of modification 
within the decoy backbone for inhibiting NF-κB198,199. Most importantly, the 
nature of the phosphorothioate bond increases the hydrophobic properties of NF-
κB decoy compared with the traditional phosphodiester ODNs200 and may allow 
overcoming many physiological barriers, such as plasma membrane and 
membrane vesicles of the endocytic pathway201. This feature might provide a 
significant aid to the endosomal escape of this molecular payload.   
The oligo conjugation between NF-κB decoy and anti-tail was performed 
through two sequential steps (Fig. 12). 
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Fig. 12 Synthesis of NF-κB decoy-anti-tail conjugate. On the top is depicted the 
secondary structure prediction of NF-κB. The yellow box highlights the consensus 
region recognized and bound by NF-κB.  The first reaction is the conjugation of the 
DSP linker to the amino residues at 5’-end of the NF-κB decoy. Next, a two-step 
process affords the chemical conjugate between carboxyl residue of the linker on 
derivatized decoy and the amino group at 5’-end of the anti-tail. Purified conjugate 
was hybridized with the extended sequence of RNA aptamer to generate the Aptacoy 
complex (bottom) represented on the basis of its helicity 
First, the amino residue at 3’-end of NF-κB decoy was derivatized with dithio-
bis(succinimidyl propionate) (DSP), an amine-reactive homobifunctional 
crosslinker with a cleavable disulfide bond in its spacer arm. Then, the conjugate 
was further reacted with 5’-amino anti-tail using standard EDC/NHS conjugation 
protocols. The desired product was purified by anion exchange HPLC (Fig. 13a). 
After this process, the resulting conjugated ODN was hybridized with the tail 
portion of c2, to obtain the aptacoy structure, hereafter c2C-d.  
Aptamer-mediated codelivery of Doxorubicin and NF-kB decoy  69 
 
To verify the correct folding of c2C-d, we incubated c2C-d and free decoy with 
a suitable amount of Dox (Dox/c2C-d ratio 7.5:1) and we compared their 
quenching effect. Indeed, the presence of a double-stranded helix in the decoy 
domain of the construct might introduce additional sites for Dox intercalation and 
at same time could affect the folding of the entire structure. The physical 
conjugate between c2C-d and Dox, hereafter c2C-d-Dox (i.e. aptacoy-Dox) 
showed a quenching effect comparable with c2C-Dox (Fig. 13b). In contrast,  this 
effect was quite smaller than that shown by hybridized complex (Fig. 13c) albeit 
we detected a noticeable Dox fluorescence quenching when free decoy was 
incubated with Dox. Overall, these results confirmed that maximum quenching 
effect was due to the formation of the aptacoy-Dox complex.  
Despite the presence of additional binding sites, Dox/c2C-d molar ratio was 
kept constant at 7.5 in subsequent experiments to obtain a fair and unbiased 
comparison of the therapeutic efficiency of both complexes (c2C-Dox vs c2C-d-
Dox). However, it is worth noting that greater Dox/c2C-d ratios could be easily 
achievable by exploiting the additional binding sites present on the double-
stranded decoy.  
 
Fig. 13 (a) HPLC traces of conjugation crude reaction mixture and (b) Dox quenching 
after intercalation with c2C, c2C-d and (c) decoy alone. 
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2.5 Codelivery of Dox and NF-κB decoy via anti-TfR aptamer 
in living cells 
Next, we investigated whether the NF-κB decoy could be effectively released in 
cytoplasm from the chimera, and whether it could bind to NF-κB, inhibiting its 
nuclear translocation. To this end, MIA PaCa-2 cells were treated with the aptacoy 
or with control assemblies, and the intracellular localization of NF-κB after each 
treatment was detected by a fluorescence immunostaining and compared with an 
assessed nuclear marker, DAPI, via a colocalization experiment.  
NF-κB was found mainly in the cell cytoplasm of resting MIA PaCa-2 cells 
(treated only with c2C, Fig. 14a), as confirmed by the lack of colocalization 
between NF-κB and DAPI. However, stimulation with the most important NF-κB 
inducer, Tumor Necrosis Factor-α (TNF-α)202 (20 ng/mL) led to estensive 
accumulation of NF-κB in cell nuclei, as shown by the complete colocalization 
between NF-κB and DAPI (Fig. 14b). Interestingly, when MIA PaCa-2 cells were 
pretreated with c2C-d and then stimulated with TNF-α, nuclear translocation of 
NF-κB was significantly reduced and NF-κB was found both in the cytoplasm and 
nucleus (Fig. 14c). The inhibition of TNF-α-induced NF-κB activation indicates 
that NF-κB decoy was actually released in the cytoplasm where it could bind NF-
κB, ultimately hampering its nuclear translocation202.  
Additionally, cell treatment with free doxorubicin triggered a prominent nuclear 
translocation of NF-κB (Fig. 14d), in agreement with previous studies on different 
cell lines169,170. However, when MIA PaCA-2 cells were co-treated with free Dox 
and c2C-d, we observed a remarkable decrease of doxorubicin-induced NF-κB 
nuclear translocation (Fig. 14e), thus confirming the inhibitory activity exhibited 
by the decoy towards NF-κB. 
It is worth mentioning that the actual mechanism of endosomal escape remains 
unknown for most therapeutic oligonucleotides (siRNAs, miRNAs, antagomirs, 
antisense oligos and hammerhead ribozymes)203–205. In the case of our NF-κB 
decoy, we could hypothesize that its enhanced hydrophobic character owing to the 
phosphorothioate linkages can increase the likelihood of NF-κB decoy to freely 
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diffuse through the membrane of the endocytic vesicles and enter into the 
cytoplasm. 
 
Fig. 14 c2C-d conjugate inhibits NF-κB activity and sensitizes MIA PaCa-2 cells to 
Dox-induced apoptosis. Immunofluorescent staining of NF-κB assesses its cellular 
localization. MIA PaCA-2 cells were incubated with c2C-d or c2C alone for 24 hours 
and stimulated either with TNF-α (20 ng/ml) for 1 hour or with Dox for 24 hours 
before immunofluorescent staining of NF-κB (red). The nuclei were stained blue with 
DAPI. Scale bars: 10 µm 
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Once demonstrated that the NF-κB decoy is effectively released from the 
aptacoy chimera, we performed a codelivery application of Dox and NF-κB decoy 
via our platform, i.e. c2C-d-Dox. Our aim was to evaluate whether c2C-d-Dox 
could improve sensitization of tumor cells to the apoptotic effect of released Dox. 
To this end, we performed cell-viability assays on pancreatic tumor and control 
cells, comparing the cytotoxicity of c2-Dox and c2C-d-Dox. To assess the 
nonspecific cytotoxicity of a phoshorothioate ODN, we also examined the effect 
induced by a scrambled decoy sequence, which does not bear the consensus 
sequence recognized by NF-κB. The scrambled decoy (sd) was chemically 
conjugated to c2C module, via the two-step procedure previously described, to 
generate a c2C-sd chimera, and the final c2C-sd-Dox was obtained after Dox 
intercalation within DNA duplex.  
Pancreatic tumor cells were treated with either c2C-d-Dox or c2C-sd-Dox and 
dose dependence was observed for each treatment (Fig. 15a). Notably, 
cytotoxicity of c2C-d-Dox significantly exceeded in a dose-dependent manner that 
found for c2C-Dox and was quite comparable with free Dox. Most importantly, 
c2C-sd-Dox did not show an increased cytotoxicity, yielding analogous effects to 
the administration of c2C-Dox. This behavior evidences a negligible impact of the 
phosphorothioate on the cell viability, and highlights the essential role of NF-κB 
decoy in the enhanced cytotoxicity of aptacoy-Dox towards MIA PaCa-2 cells.  
Besides showing increased cytotoxicity, the aptacoy-Dox platform should also 
display targeting properties to specifically deliver Dox in tumor cells. Therefore, 
we treated tumor and control cells with the c2C-d-Dox and we evaluated its 
cytotoxic effect after continuous treatment (24 h). Cell viability assay highlights 
that our platform still retains unaltered its capability to target pancreatic tumor 
cells, showing negligible cytotoxicity towards NIH-3T3 cells (Fig 15b). Tumor 
and control cells were also treated either with free Dox or c2C-Dox using the same 
conditions. Interestingly, c2C-d-Dox shows higher cytotoxic effect than c2C-Dox 
even at a single killing dose and after continuous treatment, demonstrating to be 
able to increase the sensitivity of MIA PaCa-2 cells towards the chemotherapeutic 
effect of Dox.  
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Fig. 15 (a) Cell viability assay of MIA PaCa-2 cells after treatment with free Dox 
(red), c2C-Dox (blue), c2C-d-Dox (green) and c2C-sd-Dox (black). Cells were 
incubated with the drugs for 2 hours and cell viability was assessed after 24 hours. (b) 
Cell viability assay of MIA PaCa-2 (blue) and NIH-3T3 (grey) cells after treatment 
with free Dox, c2C-Dox, c2C-d-Dox or c2C for 24 hours. Error bars represent the SD 
from three or more independent experiments (P < 0.05).  
To better understand the nature of this enhanced cytotoxicity, we evaluated by 
Western blot analysis the expression of two parameters in MIA PaCA-2 cells: (i) 
the extent of poly-(ADP-ribose) polymerase (PARP) cleavage, an assessed 
apoptotic marker206 and (ii) the expression of X-linked inhibitor of apoptosis 
protein (XIAP) whose expression is tightly regulated by NF-κB190 (Fig. 16a). 
Particularly, PARP cleavage was monitored to demonstrate that the enhanced 
cytotoxic effect was actually related to an increased apoptotic process. On the 
other hand, through the expression of XIAP we could measure the extent of NF-
κB inhibition to demonstrate that the improved sensitivity of pancreatic tumor 
cells towards Dox was tightly associated to the NF-κB decoy inhibition 
mechanism. 
As shown in Fig. 16b remarkable PARP cleavage was observed upon treatment 
with either free Dox or c2C-d-Dox. Conversely, resting cells and c2C-treated cells 
did not present significant accumulation of cleaved PARP. Most importantly, by 
measuring the band intensity of the cleaved and full-length bands, we found that 
PARP cleavage (calculated using the following formula: cleaved band / (cleaved + 
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full-length bands)*100) was ∼40% and ∼30% in cells treated with c2C-d-Dox and 
unconjugated Dox, respectively. This outcome highlights that the apoptotic 
processes are enhanced after treatment with c2C-d-Dox compared to unconjugated 
Dox.  
It is worth noting that, although aptacoy-Dox shows higher apoptotic effect than 
free anthracycline, their cytotoxicity (measured by WST-8 assay) is quite similar. 
Taken together, these results might confirm our hypothesis about the presence of a 
subset of pancreatic cancer stem cells, recognized with minor efficacy by the 




Fig. 16 (a) Schematics of NF-κB pathway involved in apoptosis process. TRAIL (TNF-
related apoptosis-inducing ligand) triggers apoptosis via both the death-receptor 
(DR4/DR5) and mitochondrial pathways, by activating initiator caspase-8 and -9, and 
effector caspase-3. Furthermore, both Bid and PARP are cleaved by caspases, which 
are typical apoptosis markers. NF- κB activates gene expression of XIAP and cIAP-1, 
which are involved in the inhibition of the caspase cascade, ultimately leading to a 
pro-survival effect. Adapted from Dai et al.207 Copyright © Dai et al. 2009; licensee 
BioMed Central Ltd. On the left is shown the western blot analysis performed on MIA 
PaCa-2 cells using antibodies specific for (b) PARP and (c) XIAP. Note that, α-
Tubulin was used as loading control in both evaluations.  
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It is commonly accepted that chemoresistant pancreatic cancer cells display both 
enhanced NF-κB activity and consequent upregulation of XIAP190,208. Therefore, 
we investigated the extent of decoy-mediated NF-κB inhibition monitoring the 
expression of this downstream product. XIAP is a protein belonging to the family 
of inhibitor of apoptosis proteins (IAPs) and is directly involved in caspases 
inhibition to protect cell against death (Fig. 16a). Interestingly, western blot 
analysis displayed a substantial decrease of XIAP expression in cells treated with 
c2C-d-Dox compared to resting and c2C-Dox treated cells (Fig. 16c). In details, 
from a comparison of the band intensity, XIAP expression was ∼75% and ∼50% 
compared to the one related to resting cells upon treatment with c2C-Dox and 
c2C-d-Dox, respectively. This trend perfectly matches with the reported 
repression of XIAP gene expression induced by doxorubicin209, which is 
significantly improved by the effective inhibition of NF-κB activity after aptacoy-
Dox treatment. This result further confirms that the increased cytotoxicity of 
aptacoy-Dox complex was due to the effective inhibition of NF-κB, which 
ultimately leads to sensitization of pancreatic tumor cells towards Dox-mediated 
apoptosis. 
2.6 Concluding remarks 
In this chapter, I presented a molecular-engineering strategy to design a drug-
delivery platform composed uniquely by oligonucleotides. This assembly exploits 
receptor-mediated internalization to perform selective delivery of doxorubicin in 
tumor pancreatic cells, and sensitizes them to Dox-induced apoptosis. We 
combined the targeting ability of an RNA aptamer that recognizes tumor cells 
expressing human TfR, and the inhibitory effect of a DNA decoy towards NF-κB. 
The complex was generated by DNA self-assembly between two complementary 
single-stranded DNA sequences: one located within targeting RNA aptamer and 
one covalently linked to NF-κB decoy with a disulfide bridge. Both payloads were 
released under conditions found in the receptor-mediated endocytic pathway, such 
as low pH and reductive environment. 
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This platform is able to perform a targeted codelivery of Dox and decoy towards 
resistant pancreatic tumor cells; in this strategy, NF-κB decoy inhibitsconstitutive 
NF-κB activity in target cells, ultimately leading to enhancement of doxorubicin-
mediated apoptotic effect. 
 
 
Fig. 17 Schematic representation of codelivery of Dox and NF-κB decoy via an RNA 
aptamer recognizing hTfR 
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2.7 MATERIALS AND METHODS 
2.7.1 Materials  
All chemicals were purchased from Sigma Aldrich unless otherwise specified, 
and were used as received. RNA and DNA oligonucleotides were purchased from 
Integrated DNA Technologies (IDT, Coralville, IA, USA). They were stored in 
lyophilized form and suspended before use in the appropriate volume of nuclease-
free water to reach a concentration of 100 µM. 
2.7.2 Oligonucleotide sequences  
The sequence of the anti-TfR RNA aptamer (c2.min) with a short DNA tail 
(CGA)7 at the 3’end was the following (tail sequence is underlined):  
5’-G G G G G A U C A A U C C A A G G G A C C C G G A A A C G C U C C C U U A C A C C C C C G A 
C G A C G A C G A C G A C G A C G A-3’ 
The sequence of the scrambled aptamer (c36) with a short DNA tail (CGA)7 at 
the 3’end was the following (extended sequence of aptamer is underlined):  
5’-G G C G U A G U G A U U A U G A A U C G U G U G C U A A U A C A C G C C C G A C G A C G A 
C G A C G A C G A C G A-3’ 
All pyrimidines of the RNA aptamer motif were substituted by 2’-fluoro-
pyrimidines. All synthesized oligonucleotides contained a 5’amino group attached 
by a C-6 alkyl chain. 
The anti-tail sequence was the following: 
5’-TCGTCGTCGTCGTCGTCGTCG-3’  
The sequence of the phosphorothioate NF-κB decoy was the following 
(consensus sequences are underlined):  
5’-CCTGGAAAGTCCCGAAAGGGACTTTCCAGG-3’ 
The sequence of scrambled phosphorothioate NF-κB decoy was the following 
(complementary sequences are underlined) 
5’-GCCGTACCTGACTTAGCCGAAAGGCTAAGTCAGGTACGGC-3’ 
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 All synthesized phosphorothioate oligonucleotides contained a 3’amino group 
attached by a C-6 alkyl chain. 
2.7.3 Absorption and fluorescence measurements 
Absorption data were recorded at 25°C in a JASCO V550 spectrophotometer 
(JASCO Europe, Cremello, Italy) using 1 nm band-pass, 0.5 nm step-size and 
0.25s integration time. Appropriate quartz cuvettes (Hellma, Milan, Italy) 
displaying an absorption/excitation optical path of 1 cm were used in all 
experiments. Fluorescence intensity was carried out with a Cary Eclipse 
fluorometer (Varian, Palo Alto, CA), using 1 nm step-size and 1.0 s integration 
time. Slits for both excitation and emission were set at 10 nm. A 100 µl quartz 
cuvette (Hellma, Milan, Italy) with an optical path of 1 cm was used in all 
experiments. 
2.7.4 Cell culture 
Mouse embryonic fibroblast cells (NIH-3T3) and human pancreatic carcinoma 
cells (MIA PaCA-2) were purchased from the American Type Culture Collection 
(ATCC). NIH-3T3 cells were grown in Dulbecco’s modified Eagle Medium 
(DMEM) purchased from Invitrogen (Carlsbad,CA) with 10% calf serum (CS) 
and MIA PaCa-2 were grown in DMEM with 10% fetal bovine serum (FBS). 
Culture media were supplemented with 4mM L-Glutamine, 100 U/ml penicillin 
and 100 mg/ml streptomycin (Invitrogen). Cells were maintained at 37°C in a 
humidified 5% CO2 atmosphere. For live cell microscopy cells were plated onto 
glass-bottom petri dishes (WillCo®-dish GWSt-3522) and imaged at 37°C, 5% 
CO2.  
2.7.5 HPLC analyses 
All HPLC analyses were performed on a Dionex Ultimate 3000 HPLC, 
equipped with automated analytical Autosampler with Fraction Collector WPS-
3000FC, UltiMate 3000 Diode Array and Multiple-Wavelength Detectors, 
UltiMate 3000 Thermostated Column Compartment Series and controlled by 
Chromeleon Management Software. 
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2.7.6 Confocal imaging of cells 
Cells were imaged using a Leica TCS SP5 SMD inverted confocal microscope 
(Leica Microsystems AG) interfaced with a diode laser (Picoquant) for excitation 
at 405 nm, with Ar lasers for excitation at 488 and 561 nm and with a HeNe laser 
for excitation at 633 nm. Glass bottom Petri dishes containing cells were mounted 
in a thermostated chamber at 37°C (Leica Microsystems) and viewed with a 63x 
1.2 NA water immersion objective or 40x 1.5 NA oil immersion objective (Leica 
Microsystems). The pinhole aperture was set to 1.0 Airy. All data collected were 
analyzed by ImageJ software version 1.44o. 
2.7.7 Secondary structure and hybridization predictions  
Oligonucleotide secondary structure predictions were obtained using the 
Internet tool NUPACK nucleic acid package (http://www.nupack.org/)175 with the 
default settings.  Hybridization prediction between the tail sequence on the RNA 
aptamer structure and its short DNA complementary sequence (anti-tail) were 
obtained with NUPACK analysis algorithms software, representing each 
oligonucleotide as an RNA sequence. The NUPACK generated secondary 
structures were used to obtain three-dimensional structures exploiting the utilities 
of the NUPACK software. 
2.7.8 Oligonucleotide labeling 
The amino residues at 5’-end of the extended RNA aptamer  (c2.min-tail) and 
anti-tail were conjugated respectively to the ATTO 633 NHS fluorophore (ATTO-
TEC GmbH, Germany) and Alexa Fluor 488 NHS fluorophore (Invitrogen, 
Carlsbad, CA) by means of standard NHS coupling procedures between the 
primary amine of the oligonucleotides and NHS-derivative of the fluorophores. 
The labeling reaction was performed as follows: 10 nmoles of aptamer sample 
were dissolved in sodium bicarbonate buffer 150 mM at pH 8.5 and mixed with 
20-fold molar excess (100 nmol, 75 µl in DMSO) of dye NHS ester derivative, in 
a final volume of 200 µl. The reaction mixture was stirred overnight at 4°C. 
Analytical evaluation of labeling reaction and purity of the labeled aptamer 
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samples was performed at 25°C using a RP-HPLC on a Clarity® 5 µm Oligo-RP, 
LC Column 250 x 4.6 mm (Phenomenex) using Triethylammonium bicarbonate 
(TEAB) 50 mM pH 9 (Eluent A) and acetonitrile (Eluent B) at 1.0 ml/min. 
Purified labeled aptamer was freeze-dried, resuspended in DNase-free water and 
quantified by UV-VIS. Dye-to-oligo ratio was evaluated from absorbance 
measured at 260 and 488 (or 633) nm and was 1 within experimental error. 
2.7.9 Oligonucleotide annealing protocol 
To assemble the extended sequence of the RNA aptamer with its 
complementary DNA sequence, these two oligonucleotides were mixed with equal 
molar concentration in a buffer solution, (PBS 1X containing 1 mM MgCl2). The 
mixture was placed in a thermoblock and heated to 90°C for 1 minute to denature 
the nucleic acid structures. Then the entire apparatus was placed on the workbench 
for 30 minutes and denatured oligo sample was slowly cooled to allow correct 
hybridization between the two complementary strands. The hybridized product 
was always freshly prepared before each evaluation. 
2.7.10 Doxorubicin intercalation in double helix region of the hybridized 
aptamer 
A physical conjugate between hybridized aptamer carrier sample (c2C, c36C, 
c2C-d and c2C-sd) and doxorubicin was made by addition of 1:7.5 molar ratio of 
aptamer to Dox in binding buffer (PBS 1X containing 1 mM MgCl2). Dox 
fluorescence was measured (excitation: 480 nm, emission: 500-700 nm). Slits for 
both excitation and emission were set at 10 nm. The resulting complex (c2C-Dox, 
c36C-Dox, c2C-d-Dox and c2C-sd-Dox) was freshly prepared before each 
experiment. 
2.7.11 Doxorubicin release from aptamer in serum-containing media 
After physical conjugate preparation between c2C and Dox, the c2C-Dox 
complex was added to either 1% or 5% serum-containing medium, and incubated 
at 37oC for 0, 30, 60, 120 minutes, and 24h. Dox fluorescence was measured 
(excitation: 480 nm, emission: 540-700 nm. Slits for excitation and emission were 
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set at 20 and 10 nm, respectively). The amount of Dox released was determined by 
comparison with that of a Dox sample incubated in the same conditions, assuming 
the fluorescence intensity of the starting complex and of free Dox sample as 0 and 
100%, respectively. 
2.7.12 Assessment of cellular uptake by confocal microscopy 
Internalization assay in MIA PaCa-2 cells was performed using a dual-labeled 
conjugate, in which the extended c2.min was labeled with ATTO 633 and the anti-
tail was labeled with Alexa Fluor 488. MIA PaCa-2 cells were seeded 24 h before 
the experiment in WillCo dishes to reach 80-90% confluence. Standard conditions 
for incubation consisted in 15 min incubation at 37°C, 5% CO2 in DMEM 
containing 1% BSA, 0.2 mg/ml calf thymus DNA and 0.2 µM of dual-labeled 
probe in a total volume of 500 µl.  After incubation, cells were washed three times 
with PBS, fresh serum-containing medium was added and the sample was imaged 
by confocal microscopy about 20 minutes after the administration of the aptamer 
sample.  
Cellular uptake of free Dox and c2C-Dox conjugate was assessed through 
confocal imaging evaluation both on MIA PaCa-2 cells and NIH-3T3 cells. 
Briefly, the cells were seeded 24 h before experiment in WillCo dishes to reach 
80-90% confluence. Then, the cells were incubated with a 1% serum-containing 
medium with either free Dox, or c2C-Dox (1.5 µM Dox concentration) for 2 hours 
at 37°C. After incubation, cells were washed three times with PBS then fresh 1% 
serum-containing medium was added and the sample was imaged by confocal 
microscopy either immediately (i.e. after 2 hours of incubation) or after additional 
22 hours of incubation with drug-free culture medium (i.e. after 24 hours). Dox 
fluorescence in living cells was detected by confocal microscopy using 488 nm as 
excitation wavelength. All experiments were performed in triplicate.  
2.7.13 WST-8 Cell viability assay 
Cytotoxicity of free Dox and Apt-Dox complexes was evaluated by using a 
tetrazolium salt, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2Htetrazolium, monosodium salt (WST-8) assay. MIA PaCA-2 
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cells, HeLa cells and NIH-3T3 cells (1x104 cells per well) were seeded in 96-well 
plates. After culture for 24 hours, the cells were incubated with a 1% serum-
containing medium with either free Dox, or oligo-Dox conjugates for 2 hours. 
After 2h incubation, cells were washed twice with PBS then fresh 1% serum-
containing medium was added. After 24 hours from the treatment the medium was 
removed and cells were incubated with WST-8 reagent (10 µL) and 1% serum-
containing medium (90 µL) for 3 hours. Dose dependence for MIA PaCa-2, HeLa 
and NIH 3T3 was determined using increasing drug concentrations (1.5, 2.5, 3.5, 
4.5 and 5.5 µM as Dox concentration and 0.20, 0.33, 0.46, 0.6, 0.73 µM as oligo 
concentration) according with a 7.5:1 as Dox/c2C molar ratio. The unconjugated 
aptamer cytotoxicity (c2C) was evaluated treating the cells with the higher 
aptamer concentration (0.73 µM) employed in dose-response experiments. 
Absorbance (450 nm) was measured using a microplate reader (Infinite F50, 
Tecan). The percentage of cell viability was determined by comparing drug-
treated cells with the untreated cells (100% viability). Data represent the average 
of three or more independent experiments. Error bars represent the SD from three 
or more independent experiments. 
2.7.14 Statistical analysis 
Data obtained from cell viability assay were statistically analyzed using one-
way ANOVA followed by Tukey’s HSD test for multiple comparison analysis. 
Data are expressed as mean with 95% confidence intervals for all groups. P values 
< 0.05 were considered statistically significant. Statistical analyzes and graphs 
were assembled using GraphPad PRISM (version 6, GraphPad software for 
Science, San Diego, CA). 
 
2.7.15 Apoptosis assay 
Apoptosis evaluation was performed as described below, using Alexa Fluor 488 
annexin V/Dead Cell Apoptosis Kit (Life Technologies, Carlsbad, CA). Cells 
were seeded (2x105 cells per well) in Willco dishes. After culture for 24 hours, the 
cells were incubated with 1% serum-containing medium supplemented with either 
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c2C-Dox conjugate (1.5 µM Dox concentration) or free c2C (0.2 µM aptamer 
concentration) as negative control for 24 hours. The subsequent procedures were 
performed in accordance with the manufacturer’s protocol. Confocal microscopy 
was used to monitor qualitatively the cellular staining using a dual filter set for 
Alexa Fluor 488 and Propidium Iodide (PI) and a 40x 1.5 NA oil immersion 
objective. Qualitative apoptosis evaluation was determined by comparing drug-
treated cells with the untreated cells. The experiment was performed in duplicate 
with the acquisition of an elevated number of random regions of interest (ROI) for 
each experiment. 
2.7.16 pH- and nuclease-dependent drug controlled release  
Dox release in cuvette was studied as follows: the c2C-Dox conjugate (1.5 µM 
Dox concentration) was incubated into binding buffer solution (PBS containing 1 
mM MgCl2) with different pH values: 7.4, 6.5, 5.8, 5.5 or 5.0. pH values were 
adjusted by the addiction of different aliquots of HCl 1 M to each sample. The 
samples were placed in a quartz cuvette and Dox fluorescence was monitored in 
real time spectrophotometrically. The acquisition for each sample was completed 
when fluorescence intensity became stable. In order to mimic lysosomal 
environment, 2  µL of DNase II (2000 units/mL; New England Biolabs) were 
added to the c2C-Dox sample at pH 5.0, and the sample was incubated at room 
temperature. During this incubation, Dox fluorescence was recorded at regular 
time intervals (10-15 measurements per hour). Fluorescence of free Dox samples 
was measured for each pH value, and measured fluorescence changes were used to 
normalize signals detected for the c2C-Dox samples. Percentage of Dox released 
was calculated by comparing fluorescent signals of free Dox at pH 7.4 (100%) 
with the signals of the c2C-Dox samples. Data represent the average of two or 
more independent experiments. Error bars represent the SD from two or more 
independent experiments.  
2.7.17 Synthesis of the NF-κB decoy-anti-tail conjugate 
The amino residues at 3’-end of the NF-κB decoy were conjugated to the dithio-
bis(succinimidyl propionate) (DSP) using the following protocol: 10 nmoles of 
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decoy were dissolved in sodium bicarbonate buffer 0.15 M at pH 8.5 and mixed 
with 40-fold molar excess (400 nmol, in 20 mL of DMSO) of DSP, in a final 
volume of 200 µL. The reaction mixture was stirred overnight at 4°C. Analytical 
evaluation of the chemical conjugation reaction was performed at 25°C using RP-
HPLC analysis. The derivatized decoy was purified from unreacted DSP by 
dialysis using dialysis membrane (MWCO 1000) (Spectrum Laboratories), 
concentrated using centrifugal filter units (3 K MWCO) and quantified by UV-
VIS analysis. Next, a two-step reaction was performed to conjugate the carboxyl 
residue of the linker on derivatized decoy with the amino group at 5’-end of the 
anti-tail. Carboxyl group was activated with EDC (1000-fold molar excess) and 
Sulfo-NHS (10-fold molar excess) in PBS buffer for 20 minutes. Then, 5’-amino-
anti-tail (3-fold molar excess) was added, and the reaction mixture was stirred 6 
hours at room temperature in PBS buffer containing triethylamine (TEA) 1mM at 
pH 7.8. Purification of the decoy-anti-tail conjugate was performed with an IE-
HPLC on a DNA Pac PA200 4x250 mm (Dionex) at 1.0 ml/min, using Tris HCl 
20 mM pH 9.5, ACN 10% (Eluent A), and NaClO4 400 mM, Tris HCl 20 mM pH 
9.5, ACN 10% (Eluent B) as mobile phase at 25°C. Absorbance was measured 
between 200 and 650 nm. The desired product was separated by means of IE-
HPLC from the excess of the anti-tail and collected. The collected fraction was 
then dialyzed using dialysis membrane (MWCO 1000), concentrated using 
centrifugal filter units (3 K MWCO) and quantified by UV-VIS analysis. Finally, 
an aliquot was analyzed in IE-HPLC to check the purity of desired product.  
2.7.18 Detection of NF-κB by immunofluorescence staining of p65 
Immunofluorescence staining on MIA PaCA-2 cells using an antibody against 
p65 subunit of NF-κB was performed as follows: rabbit polyclonal anti-NF-κB 
p65 (phospho S536, Abcam, Cambridge, UK) was used as primary antibody and 
the Alexa Fluor 647-donkey anti-rabbit IgG (H+L) antibody (Life Technologies, 
Carlsbad, CA) as secondary antibody.  
Cells were seeded (2x105 cells per well) in Willco dishes. After culture for 24 
hours, cells were incubated with 1% serum-containing medium supplemented with 
c2C-d conjugate or with c2C alone (0.2 µM oligonucleotide concentration) as 
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negative control for 24 hours. After this incubation, cells were treated with TNF-α 
(20 ng/ml) for 1 hour. In order to assess doxorubicin effect on NF-κB nuclear 
translocation in presence and in absence of the decoy, the cells were coincubated 
with Dox (1.5 µM) either c2C-d or c2C alone as negative control for 24 hours.  
Then, the cells were first fixed with 4% paraformaldehyde and 4% sucrose in 
PBS (15 min, room temperature) and subsequently permeabilized with 0.25% 
triton X-100 (6-8 minutes, room temperature). After fixation and permeabilization 
treatment, the cells were incubated with a PBS solution containing 1% bovine 
serum albumin (BSA) as blocking agent (30 minutes, room temperature) before 
incubation with the primary antibody diluted 1:100 in 0.5% BSA/PBS (1 hour, 
room temperature). Next, the cells were washed three times with PBS and 
incubated with the secondary antibody diluted 1:150 in 0.5% BSA/PBS (45 
minutes, dark, room temperature). Finally, the cells were mounted using 
Vectashield Mounting Medium with DAPI (Vector Labs). Confocal microscopy 
was used to evaluate the cellular localization of NF-κB. The experiment was 
performed in duplicate with the acquisition of an elevated number of randomly 
regions of interest (ROI) for each experiment. 
2.7.19 Western Blot analysis 
MIA PaCa-2 cells were seeded (7x105 cells per well) in a six-well plate. After 
24 hours, cells were incubated with 1% serum-containing medium supplemented 
with either free Dox or c2C-d-Dox or with c2C alone (1.5 µM and 0.2 µM as Dox 
and oligonucleotide concentration, respectively) for PARP detection for 2 hours. 
Alternatively cells were treated with either c2C-d-Dox or c2C-Dox at the same 
conditions described above for XIAP detection. After 2h incubation, cells were 
washed twice with PBS then fresh 1% serum-containing medium was added. After 
24 hours from the treatment the medium was removed and cells were washed in 
ice-cold PBS and lysed in RIPA buffer (Sigma) supplemented with proteases and 
phosphatases inhibitors (Roche). After clarification, each post-nuclear supernatant 
was quantified for protein content by Bradford assay (Pierce), and 30 µg of each 
protein extract were resolved on 4-12% Criterion XT Bis-Tris gradient gel (Bio 
Rad). Proteins were electrotransferred to polyvinylidene difluoride membranes 
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(Bio Rad). These were washed and blocked in TBST + 5% w/v either non-fat dry 
milk (recommended for PARP) or BSA (recommended for XIAP). The 
membranes were then incubated with either rabbit monoclonal antibody to PARP 
(1:1000 diluted, 9542, Cell Signaling Technology) or rabbit monoclonal antibody 
to XIAP (1:1000 diluted, 9770, Cell Signaling Technology) in blocking solution 
for 2 hours at room temperature. Immunodetection was performed using anti-
rabbit horseradish peroxidase-linked secondary antibody (1:2000 diluted, Cell 
Signaling Technology). Filters were developed using ClarityTM Western ECL 
substrate (Biorad) and chemoluminescence signals detected by Image Quant 
LAS4000 (GE healthcare). The same membranes were also stripped and blotted 
against a rabbit monoclonal antibody to α-Tubulin (1:2000, clone B-512, Sigma) 
as loading control. Obtained images were subjected to linear contrast enhancement 
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targeted drug delivery: rational engineering 
of a DNA aptamer against transferrin 
receptor 
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Aptamers against transferrin receptor have great potential as targeting tools in 
drug delivery applications. As described in the previous chapter an RNA aptamer 
(c2.min) against human transferrin receptor was able to selectively codeliver two 
synergistic drugs into human pancreatic tumor cells, ultimately showing enhanced 
and selective cytotoxic effect. It is worth noting that this RNA motif competes 
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with the natural ligand, transferrin, for receptor binding and cell uptake, actually 
performing slightly better than Tf in competition experiments137. However, the 
high concentration of circulating transferrin (ranging from 1 to 2.4 mg/ml)57 might 
sensitively reduce the binding of c2.min to TfR when administered to animal 
models, ultimately limiting the aptamer potential as targeting ligand for in vivo 
applications.  
Therefore, aptamers that bind transferrin receptor in different sites compared to 
Tf might represent a valid alternative, thus avoiding the competition with the 
natural ligand. 
In addition, c2.min is not able to recognize and bind the murine transferrin 
receptor. This lack of cross-reactivity may strongly restrict the anti-TfR aptamer 
applications especially when mouse tumor models are used for in vivo studies. 
Indeed, although human xenograft growing in immunodeficient mice is a well-
established and useful model for studying human tumor biology, mouse allograft 
tumor systems, also known as syngeneic models, closely mimic the physiology of 
a tumor microenvironment and represent a more significant model to evaluate the 
off-target effect of targeting ligands210. Furthermore, when the aptamer activity is 
investigated using human xenograft tumor models, in vivo results may be further 
complicated by the fact that mouse transferrin binds the human transferrin 
receptor with weaker affinity137. Thus, a real competition between c2.min and the 
natural ligand will not be properly replicated in this in vivo model.  
On the basis of these observations, we turned our attention to aptamers that bind 
TfR in alternative binding sites. Recently, Chen et al. selected cell-penetrating 
DNA (GS24) and RNA (FB4) aptamers that bind selectively the extracellular 
domain of mouse TfR (mTfR), apparently with no competition with transferrin, 
and explored the suitability of GS24 aptamer as vector to deliver a lysosomal 
enzyme for enzyme-replacement therapy211.  
Although these cell-penetrating aptamers are selective for mTfR rather than 
hTfR, they expand our set of TfR ligands thanks to absence of competition with 
transferrin. Indeed, one of the main goals of this thesis is to design and in vitro 
validate targeting and delivery properties of novel drug delivery platforms, 
exploiting aptamers as targeting ligands. To this end, a modular plug and play 
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engineering in which different combinations of targeting aptamers and molecular 
payloads are used, might offer a valid approach to assess the efficacy of these 
platforms. 
Thereby, we decided to investigate the targeting property of these anti-mTfR 
aptamers, focusing on the more stable GS24 DNA aptamer. Indeed, although 
GS24 and FB4 share the same binding property towards mTfR, GS24 was 
preferentially used as nanocarrier owing to its greater nuclease resistance than 
FB4211.  
Chen and coworkers selected this anti-mTfR DNA aptamer using a combination 
of partition methods. In details, the oligonucleotide DNA library was incubated 
with the purified recombinant extracellular domain (ECD) of mTfR at room 
temperature using Nickel-agarose affinity column as partition method. Because no 
significant enrichment was observed after five rounds of selection, the authors 
decided to switch to a gel-shift assay for the subsequent round. Target-bound 
sequences were collected, cloned and sequenced. Then, each clone was assessed 
for its ability to bind TfR-ECD by gel-shift assay. At the end of this screening 
step, 10 out of 40 analyzed sequences showed significant binding, including a full 
length GS24 aptamer. Afterward, this latter was rationally truncated to a minimal 
GS24 sequence, sharing the common structural motifs of the full-length molecule 
(Fig. 1).  
 
Fig. 1 Mfold secondary structure predictions212 of full-length (on the left) and minimal 
GS24 (on the right).  
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It is worth mentioning that in a SELEX experiment, the selection pressure after 
each round gradually increases due to increasingly stringent conditions (different 
incubation temperature, buffer conditions and so on) to allow proper enrichment 
of target-bound sequences possessing the most suitable 3D shapes130. However, 
DNA or RNA molecules have the ability to assume multiple folds via reversible 
pathways213,214. Thus, when the selection pressure is not optimal to isolate the best 
ligand sequences, misfolded structures can be to some extent enriched together 
with target-bound sequences. The presence of a misfolded fraction unable to bind 
the target can significantly reduce the aptamer biological activity215. 
Therefore, investigation on the presence and activity of such different folds can 
help unveiling the actual action mechanism and provide cues for the design of 
aptamers with optimized activity. In this chapter, I shall describe a biophysical 
study aimed to elucidate the relationship between GS24 aptamer folding and its 
interaction with transferrin receptor both in vitro and in living cells. This study 
allows the identification and purification of two aptamer conformers by means of 
chromatographic techniques. Fluorescence-anisotropy measurements and 
internalization assay in living cells highlight that only one fold is able to bind 
mouse transferrin receptor. Additionally, I shall describe a rational engineering 
strategy where GS24 mutant sequences were specifically designed to enhance the 
structural stability of the active fold, thus improving the aptamer activity. After a 
description of the properties of the mutated sequences and of the protocol used in 
this engineering approach, I shall introduce a novel enhanced anti-mTfR DNA 
aptamer sequence that result as a valid tool for targeted drug delivery applications. 
This aptamer can be orthogonally used in combination with anti-hTfR aptamer as 
targeting ligand of drug delivery platform in a modular “plug and play” fashion.  
3.1 Folding conformation analysis 
The aptamer activity relies on their defined 3D structures, which allow binding 
and recognition of biomolecular targets via non-covalent interactions with high 
affinity and specificity. Thus, precise knowledge and control of aptamer 
conformation is needed to optimize aptamer activity and selectivity. In this 
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section, I shall describe a chromatographic study to explore the presence of 
different aptamer conformers. 
We first performed an HPLC weak anion-exchange analysis in native conditions 
at 25°C. This weak anion exchange (WAX) analysis is based on the interaction of 
the negatively charged ODN with tertiary amine present on the stationary phase216, 
opposed to the more commonly used strong anion exchange (SAX) 
chromatography, where the stationary phase is functionalized with quaternary 
ammonium ions217. A mobile phase with increasing percentage of ionic 
concentration is used to compete with the negatively charged ODN on the 
interaction with the positively charged stationary phase. Thus, shorter sequences 
with less negative charge elute at ionic strength of the eluting mixture.  
It is well known that ODNs with weak secondary structures are easily analyzed 
and purified by this method and show a single chromatographic peak related to 
one distinct conformation218. In contrast, DNA sequences with higher percentage 
of guanosine or RNA and modified RNA may possess strong secondary structures 
and when analyzed by anion exchange HPLC, at neutral pH and room temperature 
may result in multiple peaks218,219.  
Interestingly, our analysis on GS24 sequence showed the presence of two main 
peaks (black line in Fig. 2a) at 20:80 molar ratio, as estimated from their 
chromatographic area. To assess whether these two peaks were related with two 
distinct interconvertible/non-convertible folding conformations, three different 
chromatographic analyses were performed (Fig. 2): 
- The chromatographic pattern of GS24 was evaluated after thermal 
denaturation (unfolding) followed by a slow cooling to room temperature 
(refolding) (Fig. 2a). Indeed, if the two peaks correspond to native structures 
and these are different conformers in thermodynamic equilibrium, the same 
initial pattern must be observed after a denaturation/refolding process213,220.  
- Temperature dependence of the molar ratio between these two peaks was 
studied by monitoring changes in their chromatographic area at 25, 37, 40, 42 
and 50°C, respectively (Fig. 2b).  
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- Interconversion kinetics of each peak was analyzed after HPLC purification 
(Fig. 2c). Particularly, each sample was kept at 25°C and was analyzed at 
different times by HPLC to monitor if the initial pattern could be restored.    
The first analysis of GS24 showed a total disappearance of native elution profile 
under denaturing conditions with a single peak detected at longer retention time 
(red line in Fig 2a) in agreement with the increased number of charges exposed by 
unfolded ODNs221.  This single peak is perfectly in keeping with the presence of 
only one secondary structure (unfolded state). Most importantly, denatured 
aptamer shows a complete recovery of the native pattern after refolding at room 
temperature (blue line in Fig 2a). Therefore, this result revealed the presence of 
two distinct conformers, which we termed A-1F (first peak) and A-2F (second 
peak) with a relative free energy difference ΔG2.1 of approximately 0.88 kcal/mol, 
as estimated from their 20:80 molar ratio. 
Next, five GS24 aptamer samples were heated and eluted using WAX-HPLC at 
25, 37, 40, 42 and 50°C, to monitor the temperature dependence of the molar ratio 
between A-1F and A-2F. Interestingly, molar ratio between the conformers was 
strongly dependent on temperature (Fig. 2b). In particular, area of A-2F gradually 
decreases by increasing the temperature: at 37, 40 and 42°C the A-1F:A-2F molar 
ratios were 31:69, 52:48 and 68:32, respectively (Fig. 2b - inset). The initial 
pattern almost disappears at 50°C and chromatographic profile shows only a 
single peak (blue line in Fig 2b), suggesting an early stage of oligonucleotide 
denaturation and unfolding. It is worth noting that in the temperature range of 40-
42°C the two folds become equally populated (grey and red lines). Such 
temperature dependence is particularly relevant for biological purposes, since in 
vivo and living-cell studies are performed near 37°C.  
Finally, we examined whether the two folds were interconvertible. The two 
conformers were purified by WAX-HPLC, dissolved in a suitable buffer, and 
maintained at 25°C under stirring. We monitored equilibration of the two species 
by analysis of samples collected at different times. As shown in Fig. 2c the two 
species shows recover of initial conditions (i.e. 20:80 molar ratio) with different 
conversion rates, highlighting that A-1F and A-2F are indeed interconvertible 
folds. Then, we calculated both the interconversion kinetics and relative stability 
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of the two conformers. The kinetics of recovery of the 20:80 molar ratio was 
described by a single exponential (Fig. 2c, left panel). Interestingly, conversion of 
A-2F into A-1F occurred with τ(2→1)= 5.33 h, a sufficiently extended period to 
perform various biological studies without any appreciable conformational 
change. In contrast, A-1F showed a significantly higher conversion rate (τ(1→2) 
= 1.33 h) resulting markedly less stable than A-2F. The two different 
interconversion rates are consistent with the calculated value for ΔG2.1, i.e. τ(2→1) 
/τ(1→2)=exp(-ΔG2.1/RT) (Fig 2c, right panel). 
 
 
Fig. 2 Folding conformation analysis. (a) HPLC analysis of GS24 performed in native 
conditions (black line) revealed the presence of two main structures in 20:80 molar 
ratio. Chromatographic run performed in denaturing conditions at 80°C (red line) 
showed a single component (unfolded structure). Analysis in native conditions 
performed after a slow refolding process (blue line) showed a complete recovery of 
the initial pattern with a 20:80 molar ratio (named A-1F and A-2F on the basis of the 
different retention time). (b) Temperature dependence of the fold molar ratio. The 
aptamer sample was heated and eluted at 25, 37, 40, 42 and 50°C. (c) Temperature 
dependence of A-1F fraction in the mixture. Notably, A-1F fraction changed from the 
initial value of 0.20 at 25°C to 0.31, 0.52, and 0.68 at 37, 40, 42°C respectively (d) 
Kinetics of the equilibrium recovery of the purified A-2F (left panel) showed a 
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complete return to the initial molar ratio after 30 h from folds purification. The 
energy landscape of two confomers (right panel) shows a free energy difference ΔG2.1 
of approximately 0.88 kcal/mol. 
Interconversion between two folds with different structure can lead to 
significant changes in aptamer biological activity, thus we first evaluated the 
secondary structure predictions and then we performed a molecular dynamic 
simulation to assess the structural properties of these two conformers (such as the 
conserved motifs and the effective total charge).  
Secondary structure prediction obtained using Mfold software212 highlights the 
presence of two conformers with an estimated free energy difference (ΔGαβ = -1.53 
kcal/mol at 25°C) that was similar to our experimental value (ΔG2.1 = 0.88 
kcal/mol) (Fig. 3). Thus, we related the more stable fold α to the more populated 
A-2F on the basis of the predicted free energies. Afterwards, the secondary 
structures were converted into two 3D conformations. Molecular dynamics (MD) 
simulations were then employed to assess the structural properties of the two 
folds. For each fold, we analyzed a combined trajectory formed by ten 10-ns 
explicit-solvent molecular dynamics simulations performed using different initial 
velocities. A representative structure was obtained from each combined trajectory 
using cluster analysis (Fig. 3).  
Furthermore, we related HPLC retention times to the electrostatic properties of 
these 3D conformations to unequivocally identify more stable fold α as A-2F and 
fold β as A-1F. Indeed, HPLC retention time for ion exchange chromatography is 
based on the interaction between the ODN negative charges and the positive 
charges of the stationary phase. Thus, shorter sequences or sequence with less 
exposed surface charge elute at shorter retention times. Then, we computed an 
“effective total charge” for each conformation and we related it to HPLC retention 
times. Effective net charge was obtained by computing the electrostatic potential 
of 100 conformations within each cluster of the molecular dynamic simulation 
(see Methods for further details). The calculated “effective total charge” for 
conformer α is -13.9 ± 0.4 e and is greater than that calculated for conformer β (-
11.7 ± 1.3 e). This result confirmed our stated structural assignment: fold α (most 
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stable conformation with highest exposed surface charge) actually corresponds to 
A2F (most stable fold with longer retention time) and consequently fold β matches 
with A-1F.  
 
 
Fig. 3 Mfold secondary structure predictions of the two lowest-energy folds of GS24 
sequence and corresponding structures from MD simulations: structure of 
representative conformation (centroid) of the most populated cluster. (Figure based 
on data generated by P. Mereghetti). 
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3.2 Fluorescence anisotropy assay 
The previous analysis on the aptamer folding shed light on the presence of two 
interconvertible folds at or near physiological temperature. Thereby, it is 
extremely important investigate the binding property of these conformers to 
clarify their relationship with the aptamer activity. Indeed, the presence of two 
different 3D structures might have either a cooperative binding effect or they 
might negatively affect TfR recognition. The former effect was demonstrated by 
L. Niu group, which described a single RNA aptamer adopting two different, not 
interconvertible structures. Interestingly both conformers are essential to exploit 
aptamer biological activity, i.e. selective inhibition of one of the subunits of the 
glutamate ion channel family213. In contrast, a negative effect on the recognition of 
target receptor should represent a strong limitation to use this anti-mTfR aptamer 
as targeting ligand especially for in vivo application.  
Importantly, an analysis of the receptor-binding affinity of the original DNA 
(GS24) and RNA (FB4) aptamer against mTfR was not previously described. 
Thus, an investigation of the aptamer binding properties can clarify behavior of 
the aptamer as ligand, a feature that is quantified by the Kd value. 
To this end, we decided to use fluorescently labeled aptamer conformers to 
assess first the receptor-binding affinity of each fold, and then their internalization 
property in living cells. It is worth mentioning that in previous studies both 5’- and 
3’- ends of GS24 could be modified with different molecules without loss of 
binding affinity for the receptor211,222. Thus, we employed a 5’-aminohexyl 
modified analog of GS24 and we labeled it with a fluorescent tag (ATTO 633). 
This modification allowed us to perform reliable in vitro binding experiments and 
to accurately track the aptamer during endocytosis in living cells. Compared with 
other labeling strategies that exploit bulky fluorescent tags (such as the 
previously-used biotin-streptavidin labeling approach)211 the use of organic dyes 
has the advantage of a reduced interference on the 3D structure, and hence on the 
biological activity of the aptamer. This strategy was chosen to allow an unbiased 
evaluation of the activity of GS24 conformers.  
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As in vitro binding assay we decided to perform fluorescence anisotropy (FA) 
experiments223,224 in which we could compare the receptor-binding affinity of 
GS24, A-1F and A-2F. We performed all measurements at 25°C consistently with 
the in vitro binding assay initially performed during the SELEX process leading to 
GS24 identification211, to ease comparison of the experimental results. 
We first incubated GS24 (as mixture of the two folds with 20/80 molar ratio) 
with increasing concentration of recombinant murine TfR (mTfR) ranging from 0 
to 2500 nM. As shown in Fig. 4a,211 FA increased in the presence of mTfR owing 
to protein-aptamer complex formation. Note that the trend of the binding curve is 
compatible with a monophasic ligand-receptor binding (Fig 4a, red line/black 
sample)225. 
Afterwards, we measured the FA of the purified folds separately, at mTfR 
concentration of 600 nM (Fig. 4b). Although the measured interconversion rate is 
sufficiently slow to allow fluorescence anisotropy measurements, a partial re-
equilibration of the two fold populations took place during the course of FA 
assays. We quantitated this effect by performing HPLC analysis of purified A-1F 
and A-2F samples immediately after anisotropy measurements (Fig. 4c). We 
found that A-1F and A-2F samples contained 55:45 and 3:97 molar fractions, 
respectively in agreement with their different interconversion rates. Most 
importantly (Fig 4b), we found that the measured anisotropy for A-2F sample 
(3:97 molar ratio) exceeded that found for GS24 (20:80 molar ratio), which in turn 
was higher than that relative to the A-1F sample (55:45 molar ratio). A scrambled 
sequence (GS24mt) which is unable to recognize mouse transferrin receptor222  
was also incubated with 600 nM of mTfR, and revealed a remarkably lower 
anisotropy change when compared with GS24 (Fig. 5a).  
The measured anisotropy values for A-2F, GS24 and A-1F correspond to a 
fraction of bound aptamer (fB) of 0.85, 0.69, and 0.46, respectively. These fB 
values are proportional to the measured population of A-2F in the three samples 
(i.e. 97%, 80% and 45%). Therefore, these results did unveil an essential 
functional property of GS24, i.e. that A-2F is the only fold able to bind mTfR. 
This conclusion is also in agreement with the monophasic ligand-receptor binding 
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curve measured for GS24. Indeed, binding of A-1F with a different Kd would 
have resulted in a biphasic curve of the anisotropy225.  
 
Fig. 4 Fluorescence anisotropy assay. (a) Titration of GS24-ATTO 633 (50 nM) with 
mTfR (0-2500 nM) at 25°C. A-2F binding was examined at 600 and 1300 nM, the 
latter considered as concentration close to the saturation. The curve of the mixture 
(black squares) was obtained by fitting the anisotropy values as a function of mTfR 
concentration. The fit afforded both Kd and AB (anisotropy in saturating condition). 
The curve of A-2F (red squares) was obtained as above, using the value of AB 
obtained from the fitting of GS24 anisotropy curve. (b) Binding efficiency of the two 
folds and GS24 was measured at [mTfR]=600 nM. In this case the anisotropy change 
is defined as the difference between aptamer anisotropy in the presence and in 
absence of protein. (c) HPLC analysis after FA measurements. Immediately after FA 
assay, the samples were analysed by IE-HPLC. A-1F and A-2F samples contained 
55:45 and 3:97 molar fractions, respectively. This clearly indicates that an 
interconversion between two folds occurred during anisotropy measurement.  
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Then we measured anisotropy of A-2F sample in saturating conditions 
([mTfR]=1300nM) and we found a value comparable with the measured 
anisotropy of GS24. This behavior is extremely important and implies that the 
unbound fraction eventually equilibrates between the two folds during the course 
of FA measurements. Within this assumption, the Kd of the mixture and that of 
the purified A-2F should be related by Kdmix=(1+L)KdA-2F, L being the molar ratio 
between A-1F and A-2F (L=0.25 from the HPLC assay).  
Fitting the FA data yields a dissociation constant for the mixture Kdmix = 0.25 ± 
0.04 µM, and a theoretical estimate for KdA-2F ≈ 0.2 µM. The FA results obtained 
from the A-2F sample yield an estimate of a lower KdA-2F = 0.13 ± 0.03 µM. This 
discrepancy probably stems from an incompletely equilibrated molar fraction 
during the titration of the GS24 mixture. Thus, A-2F displays higher affinity for 
mouse TfR than GS24 since the latter is actually a mixture of the two folds.  
After our investigation on GS24 affinity we turned our attention to the 
selectivity property of GS24. We incubated GS24 aptamer with saturating 
amounts of bovine serum albumin (BSA) and transferrin (Tf) and then the 
measured FA values were compared with the anisotropy change recorded in 
presence of 600 nM of mTfR (Fig. 5a). Interestingly, only negligible anisotropy 
change was observed after incubation with either BSA or Tf. A similar result was 
found even when the unconjugated fluorophore was incubated with 600 nM of 
mTfR. Overall, these results suggest that the significant anisotropy enhancement 
observed during FA is mainly dependent on aptamer structure, and is due to the 
interaction between mTfR and the A-2F conformation, rather than to nonspecific 
adsorption. 
Interestingly, we also detected a substantial anisotropy change when GS24 was 
incubated with the human recombinant TfR (600 nM) (Fig 5a), suggesting that 
GS24 might effectively recognize the human receptor, possibly via its active form 
A-2F. Therefore, we compared the FA of GS24, A-2F and A-1F when incubated 
with hTfR at concentration of 600 nM. As shown in Fig. 5b these three species 
exhibit a similar anisotropy trend even towards hTfR (A-2F > GS24 > A-1F). 
Furthermore, addition of hTfR to the scrambled sequence GS24mt under identical 
conditions caused only a minor anisotropy change (Fig. 5a). Overall, these results 
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indicate that GS24 via A-2F is actually able to bind hTfR albeit with lower 
efficiency compared with that detected for mTfR (fluorescence anisotropy is 7.6 ± 
0.5 and 13.3 ± 0.7 for hTfR and mTfR, respectively). 
 
 
Fig. 5 Fluorescence anisotropy assay. (a) Aptamer selectivity control experiments. 
Anisotropy change was measured for GS24 mutant (GS24mt) and unconjugated 
ATTO 633 (50 nM) in presence of 600 nM mTfR respectively. Next, GS24 aptamer 
selectivity was tested incubating the sample (50 nM labeled GS24) with saturating 
amounts of BSA, Tf and hTfR. The anisotropy change of each sample was compared 
with the anisotropy measured in the presence of 600 nM mTfR. GS24mt was also 
tested in presence of 600 nM of hTfR (b) Binding efficiency of the two folds, and GS24 
was measured at [hTfR]=600 nM. In this case the anisotropy change is defined as the 
difference between aptamer anisotropy in presence and in absence of the human 
receptor. (c) Fraction bound of aptamer (fB) for mouse (black squares) and human 
(red squares) TfR was calculated from the corresponding anisotropy titration curves. 
The mixture of two folds (GS24) showed a different affinity for each protein.  
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Therefore, we investigated the affinity of GS24 towards the human receptor. To 
this end, we performed a second titration experiment using increasing 
concentrations of hTfR against GS24-ATTO 633 conjugate. By applying the same 
model described above the calculated Kd for human receptor was 1.0 ± 0.25 µM 
(Fig. 5c).  
It is worth noting that KdGS24 towards hTfR is about four-fold higher than the 
measured KdGS24 for mTfR. Although the sequence homology between hTfR and 
mTfR is about 77%, the capability of GS24 to bind both receptor species might 
indicate that the aptamer binding site is located nearby a conserved –yet not 
identical- portion of the receptor. 
These results unveiled the receptor-binding property of each conformer, 
identifying the only active fold (A-2F) of the aptamer. Interestingly, we also 
revealed intriguing aptamer cross-reactivity towards both the murine receptor (the 
biomolecular target used during the selection process) and its human counterpart. 
3.3 Internalization assay in living cells 
Receptor-binding property is not the only feature required for targeting ligands. 
Indeed, a targeting aptamer should be able to interact with a cell-surface marker 
and internalize into target cells upon binding with it. Thereby, we evaluated 
whether the different binding activities of the two folds observed in vitro lead to 
different cell-internalization properties. To this end, we first performed 
internalization assays on mouse fibroblasts (NIH 3T3) using the purified folds and 
the scrambled aptamer sequence. Each sample (A-1F, A-2F and GS24mt) was 
incubated in cultured cells for 25 minutes at a concentration of 1 µM. Short 
incubation times (e.g. 10-30 minutes) and relatively low oligonucleotide 
concentrations (< 5 µM) are critical to minimize nonspecific aptamer uptake that 
could occur through fluid-phase endocytosis, such as pinocytosis226. Indeed, the 
receptor-mediated endocytosis, in particular TfR-mediated internalization, is 
kinetically more efficient than pinocytosis226. Furthermore, BSA and calf thymus 
DNA were added as competitors for nonspecific binding sites227,228. Minimization 
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of nonspecific endocytosis is an essential step to avoid misleading results due to 
internalization of oligonucleotide sequences through a TfR-independent uptake. 
After the incubation, we monitored by confocal microscopy the fluorescently 
labeled aptamer during its endocytosis process. Fig 6 qualitatively shows the three 
endocytic patterns for GS24mt (panel a), A-1F (panel b), and A-2F (panel c).  
 
 
Fig. 6 Internalization assay of the labelled aptamer folds in mouse fibroblasts (NIH 
3T3). Each sample was incubated in cultured cells at a concentration of 1 µM and 
endocytosis was monitored by confocal fluorescence microscopy. (a) GS24mt-ATTO 
633 probe was not able to recognize and bind mTfR, consequently only weak 
vesicular signal was detected into the cells. (b) Vesicular signal of A-1F-ATTO 633 
was weakly detected into the cell cytoplasm, indicating a negligible activity, likely due 
to partial conversion in the active fold A-2F during incubation. (c) A-2F-ATTO 633 
showed strong perinuclear vesicular signals. Scale bars: 10 µm. 
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Notably, only A-2F sample displays cell-internalization properties with an 
intense vesicular fluorescence signal located in the perinuclear region. It is worth 
noting that this endocytic pattern is in keeping with the punctate pattern typical of 
a receptor-mediated endocytosis process. On the other hand, A-1F shows 
negligible uptake, which is not significantly different from that of the scrambled 
sequence GS24mt. It is tempting to hypothesize that the weak vesicular signal 
displayed upon treatment with A-1F stems from the small fraction of A-1F 
converting to A-2F during the short 25-minutes incubation. Thereby, besides 
showing different in vitro binding affinities towards transferrin receptor, A-1F and 
A-2F also display remarkably different cell-internalization efficiency in living 
mouse fibroblast cells.  
Next, we investigated in more details the mechanism of the A-2F internalization 
in living cells. First, in order to verify that the observed internalization is an 
active, receptor-mediated process, we performed time-lapse imaging at low 
temperature (4°C)229 after treatment with this aptamer conformer. Indeed, the low 
temperature should inhibit significantly any active energy-dependent transport 
process across the membrane, including TfR-mediated endocytosis230,231 
Interestingly, when cells were kept at 4°C only a cell membrane staining was 
detected and consequently no internalization occurred. In contrast, A-2F-ATTO 
633 was rapidly internalized upon warming to 37°C as expected from an active 
energy-dependent process230  (Fig. 7). This result together with the negligible 
internalization signal detected upon treatment with the scrambled sequence, 
confirm that the cell uptake of the active conformer, i.e. A-2F, is effectively due to 
TfR-mediated endocytosis. 
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Fig. 7 A-2F-ATTO 633 internalization pattern after incubation at 4°C and after 
warming to 37°C. Scale bars: 10 µm. 
After that, we performed a colocalization assay between A-2F-ATTO 633 and 
lysosomal marker, lysosensor green, to monitor the intracellular fate of A-2F at 
longer time. As shown in Fig. 8a, we found partial colocalization of A-2F with 
lysosomes after 120 minutes. This result is in agreement with previous GS24 
findings by Chen et al. on the internalization process of GS24211. It is worth 
mentioning that internalized, not-recycled molecules are actually located mainly in 
the lysosomal compartment during the final stages of receptor-mediated 
endocytosis232.  
Interestingly, the fluorescence signal arising from A-2F-ATTO 633 is still 
detectable in the cells with a vescicular pattern even at longer times (180 minutes) 
(Fig. 8b). Most importantly (Fig. 8c), A-2F was also internalized in living cells 
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after a short 25-minutes incubation at lower concentration (200 nM), 
demonstrating high affinity towards mTfR even in a cellular physiological 
context.  
 
Fig. 8 (a) Aptamer intracellular fate in mouse fibroblasts (NIH 3T3). Partial 
colocalization between A-2F-ATTO 633 (red) and lysosomes (Lysotracker green) was 
observed 120 minutes after administration. Colocalized vesicles were mainly found 
close to the perinuclear region. (b) Aptamer signal 3 hours after administration to 
mouse fibroblasts (NIH 3T3). A-2F-ATTO 633 showed remarkable fluorescence in 
cell cytoplasm even 180 minutes after administration. (c) A-2F tested in mouse 
fibroblasts (NIH 3T3). A-2F-ATTO 633 is internalized via a receptor-mediated 
endocytosis, even at lower concentration (200 nM) with respect to usual amount used 
in all other evaluations.  Scale bars: 10 µm. 
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Overall, these results confirm what observed during the in vitro fluorescence 
anisotropy measurements: A-2F is the only effective conformer of GS24 able to 
bind mTfR with high affinity and to internalize in mouse fibroblasts via a 
receptor-mediated endocytosis. 
In addition, the in vitro binding assay clearly demonstrates that GS24 is able to 
bind the recombinant form of the human transferrin receptor –albeit with lower 
affinity- inducing a significant anisotropy change. Therefore, we performed an 
internalization assay to assess whether the aptamer maintains this capability even 
in a cellular physiological context. It is worth noting that in previous works 
administration of GS24 (as mixture of conformers) to human cell lines did not 
result in a significant cellular uptake.  On the basis of these results and given the 
lower in vitro aptamer affinity towards hTfR, we decided to (i) use the purified 
active fold, i.e. A-2F, (ii) increase the aptamer concentration (3 µM vs 1 µM, i.e 
the standard concentration used on mouse cell investigations) though still using 
short incubation time, and (iii) test it into a cell line overexpressing hTfR, e.g. the 
human pancreatic tumor cells (MIA PaCa-2) we used in the previous chapter for 
testing the aptacoy-Dox activity.  
As shown in Fig. 9a, A-2F was able to bind the cell-surface receptor on the 
plasma membrane upon short incubation, showing a cell membrane staining. 
Notably, at longer times (60 minutes), we could detect vesicular fluorescence 
signal arising from the cell cytoplasm, but yet a certain amount of aptamer was 
present on the cell surface (Fig. 9b). Interestingly, at a later stage (140 minutes) no 
fluorescence signal was detected from the plasma membrane, while the endocytic 
pattern displayed vesicular signals in the perinuclear region (Fig. 9c).  
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Fig. 9 Endocytosis of the A-2F in human pancreatic tumor cells (MIA PaCa-2). 3 µM 
A-2F-ATTO 633 was incubated in cultured cells. (a) After incubation, fluorescence 
signal was mainly present on plasma membrane. (b) Significant vesicular signals 
could be observed into cell cytoplasm after 60 minutes since incubation, but A-2F 
fluorescence was still present on the cell surface. (c) At longer times (140 minutes) all 
A-2F was internalized into the cells and perinuclear signals were observed. Scale 
bars: 10 µm. 
In contrast, when the scrambled aptamer sequence (GS24mt) was tested, only a 
negligible intracellular fluorescence was observed (Fig. 10a), in keeping with the 
endocytic pattern observed in mouse cells. Although we employed a higher 
aptamer concentration during the incubation, we observed almost null absence of 
fluorescence signals after treatment with the scrambled sequence. This result 
strongly suggests that internalization of A-2F is not due to nonspecific fluid phase 
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uptake. This result strongly suggests that actually A-2F conformer may bind hTfR 
on the cell-surface, being taken up in human cells by constitutively present 
internalization mechanisms. 
To assess whether the cell-internalization property exhibited by A-2F was due to 
a TfR-mediated endocytosis, we performed a colocalization experiment between 
A-2F and the monoclonal antibody anti-hTfR (mAb anti-CD71). In details, cells 
were incubated with both A-2F and mAb anti-CD71; after 60 minutes, we 
observed extensive, although not complete, colocalization between the aptamer 
and the antibody in many vesicular compartments, as assessed by a Pearson’s 
correlation coefficient of 0.63 (Fig. 10b). 
 
 
Fig. 10 (a) Endocytosis of GS24mt into human cells (MIA PaCa-2). Only weak 
vesicular signal was detected into the human pancreatic cancer cells when the 
GS24mt-ATTO 633 (3 µM) was used. (b) Colocalization assay between A-2F-ATTO 
633 and mAb anti-CD71-FITC probes in human cells. Confocal images of MIA PaCa-
2 cells treated with A-2F-ATTO 633 (3 µM) and monoclonal antibody anti-CD71-
FITC (1:250 dilution, Invitrogen) show extensive vesicular colocalization into the cell 
cytoplasm. Scale bar: 10 µm. 
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Overall, these results suggest that the active conformer of GS24 aptamer can 
recognize and bind even human transferrin receptor both in vitro and in living 
human cells, allowing cell-internalization via a receptor-mediated endocytosis. 
The slower kinetics of internalization observed in this case suggests that the Kd in 
a live cell context might be higher than the affinity measured in vitro by FA assay. 
Indeed, the high A-2F concentration incubated in the MIA PaCa-2 cells is not 
sufficient to balance the lower affinity towards hTfR, allowing a fast 
internalization also in human cells.  
3.4 Rational engineering of GS24 aptamer 
Next, we turned our attention to the identification of conserved motifs within 
GS24 structure responsible for its receptor-binding property with the aim to 
generate an enhanced aptamer sequence endowed with higher binding affinity. 
Consequently we started our investigation with a closer inspection of the two 
GS24 conformers, A-1F and A-2F. As shown in Fig. 3, secondary-structures 
predictions and our molecular dynamics simulations revealed a significant 
difference in the region including nucleotides 16-50. Particularly, A-2F displays a 
folded domain comprising residues 26 to 50, which is completely absent in the A-
1F conformation.  
It is worth mentioning that the anti-mTfR DNA aptamer (GS24) and RNA 
aptamer (FB4) generated by Chen et al. were selected using the same recombinant 
extracellular domain of mouse transferrin receptor (mTfR-ECD) and displayed 
similar functional properties, in terms of binding selectivity and no competition 
with Tf211. Indeed, the authors used these sequences as interchangeable ligands in 
their biological applications. This suggests that GS24 and FB4 sequences might 
share conserved structural domains needed for mTfR recognition. Therefore, we 
examined and compared the secondary structures prediction of both full-length 
and truncated DNA and RNA aptamers. Importantly, as shown in Fig. 11, all 
sequences share a highly-conserved stem-loop domain, approximately located in a 
central region, which contains a conserved nonamer (CGTTSTYTG; where S = G 
or C, Y = T or C. Note that in the RNA structure U replaces T). This conserved 
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sequence is also included in the folded region within the 26-50 sequence of A-2F 
conformation.  
 
Fig. 11 Secondary structure prediction of DNA aptamer GS24 and RNA aptamer FB4  
(full-length and truncated versions) originally selected by Chen et al., highlights that 
all sequences share a highly conserved stem loop domain (dashed boxes), 
approximately located in a central region. This domain is constituted by a conserved 
nonamer (CGTTSTYTG; where S = G or C, Y = T or C. Note that in the RNA 
structure U replaces T). 
On the basis of these observations, we decided to further minimize the GS24 
sequence. In details, we designed a truncated sequence that still retains the folded 
region of GS24 (A-2F conformation) but lacks the 5’-end domain, i.e. the less 
conserved motif of GS24 and FB4 secondary structures. Moreover, the 5’-end 
domain of GS24 is the only common region included in the A-1F and A-2F 
conformers, suggesting that this domain might play a minor role during the 
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binding of TfR. Thus, we designed a truncated version of GS24 comprised of 35 
nucleotides, hereafter referred to as minimal GS24 (GS24min). As shown in Fig. 
12 secondary structure predictions of GS24 (A-2F) and GS24min showed a 
remarkable structural homology and GS24min secondary structure still displayed 
the conserved stem-loop regions. 
 
 
Fig. 12 Mfold secondary structure predictions of DNA aptamer GS24 (A-2F) and 
GS24min. Notably, GS24min still shows the conserved stem-loop domain (dashed 
boxes).  
The minimization process aimed at unveiling the minimal, essential aptamer 
motif required to bind the target receptor. To this end, we investigated two 
important features of GS24min, such as (i) the presence of different conformers by 
native HPLC analysis, and (ii) the in vitro binding affinity towards mTfR by FA 
measurements. 
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In details, HPLC investigation displayed one major peak for our truncated 
sequence with only two minor shoulders present on the descending phase of the 
peak (Fig. 13a). This result suggests that our truncation led to a significant 
reduction of competing folding pathways. Although GS24min showed a reduced 
amount of misfolded material, the FA assay performed to calculate the Kd towards 
the recombinant mouse receptor displays a reduced affinity. Indeed, as shown in 
Fig. 13b the measured Kd was nearly five times higher than the dissociation 




Fig. 13 (a) HPLC analysis of GS24min performed in native conditions revealed the 
presence of two main structures in 80:20 molar ratio (top panel). (b) Fluorescence 
anisotropy assay (bottom panel). FA of GS24min-ATTO 633 (50 nM) was measured 
with increased amount of mTfR (0-2500 nM) at 25°C. The aptamer titration curve 
was obtained by fitting the anisotropy values as a function of mTfR concentration. 
The fit afforded both Kd and AB (anisotropy in saturating condition). 
It is worth mentioning that reduction of aptamer affinity towards its 
biomolecular target is a quite common issue occurring during aptamer 
minimization. For example, the anti-hTfR c2.min, deeply investigated in the 
previous chapter, exhibits a dissociation constant that is five times higher than the 
full-length c2 sequence (102 nM vs 17 nM, respectively)137, the same reduction 
that we found for GS24min compared with GS24.  
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Next we assessed whether GS24min is as effective as the parent sequence in 
binding to mTfR even in a physiological cell context. A critical feature in 
monitoring the endocytosis of relatively small aptamers (e.g. 25-35 mer in length) 
binding cell-surface markers is represented by the possibility to be internalized 
through nonspecific receptors. Indeed, over the last two decades, it has been 
reported that at very low concentration (< 0.5 µM) small oligonucleotides (< 30 
mer in length) may internalize in cells in a saturable, size-dependent manner 
compatible with receptor-mediated endocytosis233. Particularly, smaller 
oligonucleotides (e.g. 5-15 mer in length) displayed higher efficiency of 
internalization than longer sequences205. In contrast, at high concentration 
(micromolar), the receptor-mediated endocytosis is rapidly saturated and small 
oligonucleotides are generally internalized via a slower nonspecific pinocytotic 
process. The identity of the receptor involved in the uptake of free 
oligonucleotides is still unknown. However, several attempts were performed to 
identify it, but much of this literature is controversial234. The main evidence seems 
that there is no a universal cell-surface receptor but rather a cell-dependent 
mechanism, which exploits various unidentified proteins depending on the cell 
type235.  
Thus we evaluated the cell-internalization property of GS24min in living cells, 
performing endocytosis assays both on mouse fibroblasts (NIH 3T3) and on 
human pancreatic tumor cells (MIA PaCa-2). As stated above, short incubation 
time (25 minutes) was employed to minimize the uptake due to pinocytosis. In 
addition BSA and calf thymus DNA were added as competitors for nonspecific 
binding sites. Interestingly, while the labeled GS24min was internalized in mouse 
cells, very weak vesicular signal was detected in human cells even at high 
concentration (i.e. 3 µM) (Fig 14a). As shown in Fig. 14, the endocytic pattern of 
GS24min is similar to that of A-2F. Spotty vesicular signals were found in the 
perinuclear region of NIH 3T3 cells that partially colocalize, as in the case of 
parent sequence A-2F, with the lysosomal compartment (Fig. 14b). Overall, these 
results together with the FA measurement (Fig. 13b) indicate that GS24min is still 
able to bind the mTfR in its native physiological form and to internalize upon 
binding with it via TfR-mediated endocytosis. It is worth noting that the existence 
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of a single fold within GS24min suggests that our rational minimization stabilized 
the most stable and active structure removing the trend of GS24 (A-2F) to 
equilibrate with other inactive conformations. 
However, the negligible uptake in the human cells strongly suggests that 
truncated sequence GS24min either does not recognize the human receptor, or that 
its affinity towards hTfR is remarkable decreased.  
 
 
Fig. 14 Endocytosis of GS24min in mouse fibroblasts (NIH 3T3, upper panels) and in 
human pancreatic tumor cells (MIA PaCa-2, lower panels). Aptamer concentration 
during incubation with NIH 3T3 and MIA PaCa-2 cells was 1 and 3 µM respectively. 
(a) Significant vesicular signals could be observed into cell cytoplasm after incubation 
in mouse cells with labeled GS24min. In contrast weak spotty cytoplasmic signals 
were detected into human cells after incubation of GS24min. Scale bars: 10 µm. (b) 
Intracellular fate of the truncated aptamer sequence (GS24min) in mouse fibroblasts 
(NIH 3T3). Partial colocalization between GS24min-ATTO 633 (red) and lysosomes 
(Lysotracker green) was observed 120 minutes after administration. Colocalized 
vesicles were mainly found close to the perinuclear region. Scale bar: 5 µm. 
DNA aptamer activity modulated by two conformers  115 
 
Thereby, to increase A-2F stability and minimize the presence of misfolded 
structures, we moved to a more conservative approach based on point mutations 
performed on the basis of secondary structure predictions and molecular modeling 
approaches (Fig. 15). In details, we turned our attention to the folded domain 
comprising bases 26-50 in order to enhance its stability and shift the 
thermodynamic equilibrium towards the most stable and active fold (A-2F). 
Molecular dynamic simulation depicted in Fig. 15a led to the identification of two 
critical base pairs: T29-T47 (which, in our simulations, showed a non-canonical 
base-pairing), and A30-T46. These two base pairs (highlighted in Fig. 15) were 
selected as sites critically involved in the stabilization of the folded domain 




Fig, 15 Mfold predictions of the two A-1F (fold β) and A-2F (fold α) conformers and 
corresponding structures from MD simulations. From left to right, secondary-
structure diagrams, structure of representative conformation (centroid of the most 
populated cluster), magnification of the domains. A dashed line in the complete 3D 
structure separates the two domains. (Figure based on data generated by P. 
Mereghetti). 
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Most importantly, mutations at these sites did not change the conserved 
nonamer sequence in the stem-loop region. Thus, we designed four mutants: 
T29A; T29G T47C; A30G T46C; T29G A30G T46C T47C; hereafter called 
DW1, DW2, DW3 and DW4, respectively. These mutants were chosen as 
candidates capable of stabilizing the active fold by either transforming a non-
canonical pairing into a more stable Watson-Crick coupling, or strengthening an 
A-T base pair by mutation into a stronger G-C.  
To identify the best mutant sequence several parameters were took in 
consideration: 
- Calculation of the predicted ΔΔG between the two lowest-energy structures. 
- HPLC analysis in native conditions to quantify the percentage of the inactive 
fold. 
- In vitro binding affinity towards the mouse recombinant TfR. 
- Cell-internalization properties in living mouse cells. 
Table 1 summarizes all parameters for each mutant sequence. Notably, all 
mutants displayed an increased difference in the ΔΔG of the two conformers as 
calculated by MFold.  The percentage of the inactive fold for each structure was 
investigated by HPLC analysis both at 25ºC and at physiological temperature, 
37ºC. Interestingly, percentage of the active fold is higher in all mutants, 
compared with the parent structure GS24. In two cases (DW2 and 4), the 
percentage of the inactive fold was nearly identical to that attained for A-2F after 
the HPLC purification of GS24 (3%). It is worth noting that both DW2 and DW4 
showed limited amount of the secondary conformer even at 37°C (≤ 10%).  
As expected, percentage of inactive fold was unaffected by insertion of a 
fluorophore (ATTO 633) at 5’ end of the sequences, confirming that this small 
fluorescent tag did not alter the aptamer conformation and the ratio between the 
two folds. 
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GS24 -1.53 19.8% 31.3% 13.3 
DW1 (T29A) -2.01 9.9% 14.6% 13.9 
DW2 (T29G T47C) -3.21 4.6% 10.2% 14.5 
DW3 (A30G T46C) -3.64 9.9% 17.6% 14.3 
DW4 (T29G A30G 
T46C T47C ) -3.64 5.3% 8.5% 15.9 
GS24min - - - 8.4 
A-1Fc - 55% - 8.5 
A-2Fc - 3% - 16.4 
a ∆∆G were calculated from the folding ∆G of α and β conformers as ∆∆G=∆Gα-∆Gβ: bAll 
values were obtained as the average of two or more independent measurements, with errors 
(SD) in the range 0.5-0.9; cFreshly purified; partial equilibration occurred within 1-2 hours  
Then, we assessed the in vitro binding affinity of all mutants towards mTfR by 
FA measurements. As rapid screening of the aptamer binding property, we 
evaluated the anisotropy change at a single protein concentration (600nM) by 
using the same protocol adopted in the case of the purified folds. As shown in 
table 1, all mutations showed increased binding efficiency compared with GS24. 
This result is consistent with the increased percentage of the active fold exhibited 
by each mutant. Moreover, all fluorescently labeled aptamer mutants were also 
able to internalize in living mouse fibroblasts (NIH 3T3), demonstrating that our 
mutations did not affect the capability to bind mouse receptor in its native form. 
Interestingly, for each mutant we observed a slightly enhanced intracellular 
fluorescence signal when compared with the parent aptamer sequence (GS24) but 
no significant difference in internalization kinetics or efficiency, compared with 
the active fold (A-2F).  
At the end of this screening, DW4 was identified as the most promising 
sequence in terms of thermodynamic stability and in vitro binding capability. 
Thus, a further investigation of its properties was performed, firstly building an 
118 DNA Aptamer activity modulated by two conformers 
 
anisotropy titration curve to calculate the in vitro dissociation constant towards 
mTfR (Fig. 16a). In details, our results yielded Kd = 0.19 ± 0.01 µM, 25% lower 
than the value found with GS24 (0.25 ± 0.4 µM), in keeping with the lower 
amount of inactive fold in DW4 sample. Notably, although this value is somewhat 
higher than the calculated value for pure A-2F (0.13 ± 0.03 µM), one must 
consider that the present mutant outperforms the purified fold in terms of thermal 
stability, ease of manipulation, and overall potential for in vitro and in vivo use. 
Finally, we investigated whether DW4 retains cell-internalization property also 
in human pancreatic tumor cells. Importantly, not only this mutant sequence was 
internalized also in MIA PaCa-2 cells in the same experimental conditions used 
for A-2F, but it showed a faster uptake rate compared with A-2F. Indeed, intense 
vesicular signal was already present immediately after 25-minutes incubation 
while only weak plasma membrane staining was detected (Fig. 16b). Note that, 
Fig. 16b highlights similar endocytic pattern for DW4 in both mouse and human 
cell lines.  
To investigate the nature of this enhanced uptake in human cells, we evaluated 
the in vitro binding property of DW4 towards hTfR at a single protein 
concentration (600nM). A comparison of the measured fluorescence anisotropy 
enhancements detected for GS24, A-1F, A-2F and DW4 is shown in Fig. 16c. 
Interestingly, we found that DW4 has a higher anisotropy change compared with 
A-2F (11.8 ± 0.6 and 9.2 ± 0.4 respectively). This result is consistent with the 
faster endocytosis kinetics exhibited by DW4 towards human cells.  
It is worth noting that a differential rate of TfR internalization in living cells has 
been recently observed upon treatment with anti-TfR antibodies having different 
affinity. In particular, high-affinity anti-TfR (Kd= 20 nM) induced a higher 
uptake, over the first 20 min after antibody addition, compared with low-affinity 
antibodies (Kd= 600 nM)236. This interesting analogy between the differential 
antibody endocytosis and our findings on DW4 and A-2F, lays the foundations for 
further experiments needed to clarify the different aptamer behavior in human 
cells.  
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Fig. 16 (a) Fluorescence anisotropy assay. FA of DW4-ATTO 633 (50 nM) was 
measured with increased amount of mTfR (0-1200 nM) at 25°C. The aptamer 
titration curve was obtained by fitting the anisotropy values as a function of mTfR 
concentration. The fit afforded both Kd and AB (anisotropy in saturating condition). 
(b) Endocytosis of GS24min and DW4 in mouse fibroblasts (NIH 3T3, upper panels) 
and in human pancreatic tumor cells (MIA PaCa-2, lower panels). DW4 shows 
efficient internalization both in mouse and human cells.  Scale bars: 10 µm. (c) 
Binding efficiency of the two folds, GS24 and the mutant DW4 was measured at 
[hTfR]=600 nM. In this case the anisotropy change is defined as the difference 
between aptamer anisotropy in presence and in absence of the human receptor. 
It is worth noting that the rational mutations present on DW4 increase 
significantly the capability of this sequence to bind the hTfR. Indeed DW4 shows 
improved binding properties compared with A-2F towards the human receptor. On 
the other hand, DW4 and A-2F can bind mTfR with similar binding affinities. 
This outcome is really interesting and might be exploited to set up a second 
SELEX experiment exploiting a doped-library to obtain a novel sequence able to 
bind both mouse and human receptor with similar high affinity. Indeed, starting 
from DW4 sequence, the positions involved in the folding stability might be 
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randomized and a doped-SELEX130 experiment could be performed for few 
rounds using the human recombinant TfR as biomolecular target. This approach 
might lead to novel aptamer sequences able to bind efficiently both mouse and 
human TfR. 
3.5 Concluding remarks 
In this chapter, I described a rational engineering strategy to generate a novel 
aptamer sequence with enhanced binding property towards mouse transferrin 
receptor. In details, starting from the observation that an anti-mTfR aptamer 
(GS24) is actually a mixture of two interconvertible folds (A-1F and A-2F), we 
investigated how their presence affects the biological activity of GS24. The 
presence of two folds might be rationalized by considering the SELEX strategy 
that led to GS24 selection, which did include only in vitro binding assays at 25°C 
to evaluate aptamer affinity for the receptor. This strategy does not provide 
significant selection pressure to identify the best ligands, but only provides 
information regarding the average activity of a given mixture of conformers, but is 
intrinsically unable to report on the presence -and hence the activity- of different 
conformers sharing the same primary structure. 
Thanks to fluorescence anisotropy measurements and cell internalization assays, 
we found that only one of these folds (A-2F) recognizes its target and internalizes 
in living cells. This observation suggests that the main conformational difference 
between the two folds occurs in a region critically involved in binding to mTfR. 
The results obtained with the engineering of GS24, and in particular those related 
to the minimization process and the point mutations strategy, confirm this 
hypothesis.  
Our engineering of GS24 led to a novel sequence (DW4), which shows 
enhanced activity compared to the parent molecule. Thermal dependence of molar 
ratio showed that with this sequence the inactive fold is less than 10% both at 
25°C and 37°C. Furthermore, this sequence is also able to bind the hTfR, although 
with a lower affinity when compared with the natural target, i.e. mTfR.  
This novel sequence, DW4 can be used in combination with anti-hTfR aptamer, 
c2.min to target both mouse and human TfR in targeted drug delivery applications 
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using different models (such as allograft and xenograft tumor models).  Indeed, it 
is extremely important possess targeting aptamers with cross-reactivity to test 
them in different physiopathological contexts in order to evaluate the effective 
potential of a drug delivery platform for targeted therapy. 
Based on this observation, in the next chapter, I shall describe an application of 
this modular plug-and-play engineering using both DW4 and c2.min as targeting 
ligands embedded in a more complex oligonucleotide nanostructure.  
 
 
Fig. 17. DNA aptamer GS24 activity modulated by two conformers with different 
binding properties. 
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3.6 MATERIALS AND METHODS 
3.6.1 Materials  
All chemicals were purchased from Sigma Aldrich unless otherwise specified, 
and were used as received. Human pancreatic carcinoma cells (MIA PaCA-2), 
human cervical cancer cells (HeLa) and mouse embryonic fibroblast cells (NIH-
3T3) were purchased from the American Type Culture Collection (ATCC). All 
cell lines were growth using the same protocol reported in the experimental 
section of Chapter 2. Recombinant mouse and human transferrin receptor 
(TFRC/CD71) were purchased from Sino Biological Inc. (Beijing, China). 
Proteins were dissolved in 20 mM HEPES with 1mM EDTA (pH 7.4). 
Transferrin-Alexa Fluor 488 conjugate, monoclonal antibody anti-human CD71-
FITC conjugate (clone T56/14), Lysotracker green and Hoechst dye were 
purchased from Invitrogen. All oligonucleotides were purchased from Integrated 
DNA Technologies (IDT, Coralville, IA, USA) and HPLC purified. Synthetic 
aptamer samples were dissolved in DNase free water and stored at -20°C. The 
concentration of oligonucleotides was measured by UV spectrophotometry at 
25°C using a JASCO V550 spectrophotometer (JASCO Europe, Cremello, Italy). 
All sequences contained a 5’amino group attached by a C-6 alkyl chain.  
The sequence of full-length DNA aptamer (GS24) was the following:  
5’-G C G T G T G C A C A C G G T C A C T T A G T A T C G C T A C G T T C T T T G G T T C C G T T C 
G G-3’ 
The minimal sequence of GS24 aptamer (GS24min) was the following:  
5’-CACTTAGTATCGCTACGTTCTTTGGTTCCGTTCGG-3’ 
The mutant sequences of GS24 were the following. 
DW1 (T29A): 
5’-G C G T G T G C A C A C G G T C A C T T A G T A T C G C A A C G T T C T T T G G T T C C G T T C 
G G-3’ 
DW2 (T29G T47C):  
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5’-G C G T G T G C A C A C G G T C A C T T A G T A T C G C G A C G T T C T T T G G T T C C G T C C 
G G-3’ 
DW3 (A30G T46C):  
5’-G C G T G T G C A C A C G G T C A C T T A G T A T C G C T G C G T T C T T T G G T T C C G C T C 
G G-3’ 
DW4 (T29G A30G T46C T47C):  
5’-G C G T G T G C A C A C G G T C A C T T A G T A T C G C G G C G T T C T T T G G T T C C G C C C 
G G-3’ 
The scrambled sequence of DNA aptamer (GS24mt) was the following: 
5’-G C C A T T G C C A T T G C C A T T G C C A T T G C C A T T G C C A T T G C C A T T G C C A T T 
G C C A T T G-3’ 
3.6.2 Chromatographic analyses, and purification of labeled folds 
All HPLC analyses were performed using the HPLC equipment described in the 
experimental section of Chapter 2. Analytical analysis of oligonucleotide samples 
and purification of labeled GS24 aptamer folds (labeled A-1F and A-2F) GS24min 
and DW1, DW2, DW3, DW4 aptamer mutants were performed with an IE-HPLC 
on a Clarity® 10 µm Oligo-WAX, LC Column 100 x 4.6 mm (Phenomenex) at 
2.2 ml/min, using Tris HCl 20mM pH 8.0, ACN 10% (Eluent A), and NaCl 1.2 M, 
Tris HCl 20 mM pH 8.0, ACN 10% (Eluent B) as mobile phase. Chloride gradient 
was 0.36-1.2 M NaCl during 15 minutes. Native conditions analysis was 
performed at 25°C. Analyses in denaturing condition were performed at 80°C. In 
this experiment aptamer samples were heated in a thermoblock at 95°C for 5 
minutes, and then analyzed by IE-HPLC. Absorbance was measured between 200 
and 650 nm.  
The amino residue at 5’-end of oligonucleotide sequences (GS24, GS24mt, 
truncated and mutants GS24) was conjugated to the ATTO 633 NHS fluorophore 
by means of standard NHS coupling procedures between the primary amine of 
aptamer and NHS-derivative of the fluorophore as described in Chapter 2.  
Purification of the labeled folds was performed as follows: the folds were 
separated by means of IE-HPLC, and collected. Each fold was then rapidly 
desalted on illustra™ NAP-25 Columns containing Sephadex G-25 DNA grade 
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(GE/Healthcare) equilibrated with DNase free water. The collected fractions were 
freeze-dried, resuspended in appropriate volume of DNase free water and stored at 
-20°C. The whole process, from separation to freeze-drying, usually lasted less 
than 30 minutes. Finally, an aliquot of each sample was quantified by UV-VIS 
analysis and analyzed in IE-HPLC to check the purity of each fold.  
Dye-to-aptamer fold ratio was evaluated from absorbance measured at 260 and 
633 nm and was 1 within experimental error. 
3.6.3 Fluorescence anisotropy assay 
Fluorescence intensity and anisotropy measurements were carried out with a 
Cary Eclipse fluorometer (Varian, Palo Alto, CA). Excitation was set at 630 nm 
and emission at 650 nm. Slits for both excitation and emission were set at 10 nm. 
A 100 µl quartz cuvette (Hellma, Milan, Italy) was used in all experiments. The G 
factor, i.e. the ratio of IHV to IHH, where IHV and IHH are the observed intensities at 
horizontal or vertical orientations of the polarizers, was determined before the first 
experiment and this value was used throughout the experiments in which 
instrumental factors (emission wavelength and spectral bandpass) were kept 
constant.  
During fluorescence-anisotropy measurements, a highly concentrated (~15 µM) 
solution of mouse and human TfR was used for each titration to minimize dilution 
effects (final volume after titration was 1.15 times the initial volume).  
Equilibrium binding isotherms were constructed by titrating 50 nM of aptamer-
ATTO 633 probe (labeled GS24, GS24min and DW4) with increasing 
concentration of TfR in PBSM buffer (PBS containing 1 mM MgCl2) at 25°C. The 
anisotropy value was automatically calculated by the instrument. The integration 
time was set to 1.0 s for each anisotropy measurement, while the acquisition time 
for each protein concentration was 30 minutes for mouse TfR and 60 minutes for 
human protein. The average anisotropy-value used for data processing was 
calculated on at least 40 data points for each protein concentration. Equilibrium 
binding isotherms were evaluated also for the labeled GS24, A-1F, DW1, DW2, 
DW3, DW4 at [mTfR]=600 nM and for A-2F at 600 nM and 1300 nM.  
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Data represent the average of two or more independent experiments. Error bars 
represent the SD from two or more independent experiments.  
3.6.4 Fluorescence Anisotropy Data Analysis 
The aptamer fraction bound (fB) is related to the measured anisotropy by: 
 
, (1) 
where A, AF, and AB  are the anisotropies of the sample, free aptamer, and 
aptamer saturated with protein, respectively. The factor q takes into account 
fluorescence quantum yield changes upon binding237 and is given by: 
 
,  (2) 
where IVV and IHV are the observed intensities at different orientations of the 
polarizers as described earlier. The value of q was 0.89 for GS24 and 0.82 both for 
minimal GS24 and DW4. Binding was assumed to be described by a 1:1 binding 
model: L + P → LP where L, P, and LP are free aptamer, TfR, and aptamer/TfR 
complex, respectively. The aptamer fraction bound (fB) is given by: 
 
 (3) 
where LT and PT are the total aptamer and TfR concentrations, respectively.  
Frequently, the aptamer anisotropy in saturating condition (AB) cannot be 
measured directly.  In order to avoid the self-consistent evaluation of AB we 
preferred to fit directly the anisotropy A as a function of TfR concentration. This 
fit directly gave both Kd and AB, and was performed using the following 
expression: 
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, (4) 
where fB is taken from Eq. 3. This procedure yielded both a better estimate of AB 
and its error. Using the experimentally determined values of A, AF, and q, the 
anisotropy data were fitted by nonlinear least squares regression to Eq. 4 with both 
Kd and AB as parameters using Origin Pro 8S0 (One Roundhouse Plaza 
Northampton MA 01060 USA). 
3.6.5 Secondary and tertiary structure generation 
Secondary structure prediction was obtained using the webserver Mfold212 with 
the default settings. Using these parameters the two lowest free-energy structures 
were retained. The Mfold generated secondary structures were used to obtain two 
coarse three-dimensional structures using the software RNA2D3D238.  
3.6.6 Simulated annealing 
We performed a simulated annealing scheme imposing Watson and Crick 
hydrogen bond constraints to refine the two folds obtained with RNA2D3D.  
Simulated annealing were performed using AMBER software version 12239. The 
AMBER forcefield ff12SB was used. Each fold was solvated in a dodecahedral 
box of minimum 0.8 nm distance from the aptamer using TIP3P water model. 
Sodium and Chloride ions were added to reach an ionic strength of 150 mM 
reproducing the experimental environment. The solvent was minimized using 
1000 steepest-descent steps keeping the nucleic acid structure restrained. Then, the 
full system was minimized by 500 conjugate-gradient steps. The minimized 
structure was subjected to a simulated annealing procedure in the NVT ensemble. 
The temperature was first raised to 600 K and slowly decreased to 300 K in 50 ns. 
Temperature was kept constant using Langevin dynamics with the collision 
frequency parameter set to 2 ps-1, The SHAKE algorithm was used to constraint 
bonds length, allowing to use a 2 fs integration time step.  Van der Waals and 
Coulomb interactions were truncated at 0.8 nm. Long range electrostatic 
interactions where calculated using the Particle-mesh Ewald (PME) summations 
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scheme. Distance restraints were applied on the Watson and Crick hydrogen bonds 
(using AMBER parameters nmropt = 1 and ipnlty = 1). 
3.6.7 Molecular dynamics simulations 
We assessed the stability of two folds given as output from simulated annealing 
procedure by performing NPT molecular dynamics (MD) simulations without 
hydrogen bond distance restraints. The same parameters described for the 
simulated annealing were used here with the addition of the pressure coupling. 
Pressure was kept constant at 1.013 bar using a relaxation time of 1.0 ps. To 
improve conformational sampling, ten 10 ns simulations were carried out starting 
from different initial velocities. The ten trajectories were then combined into a 
single trajectory, which was used for all subsequent analysis. 
Hierarchical cluster analysis was performed using the average linkage 
criteria240. The root mean squared deviation between the backbone atoms was used 
as distance metric. 
3.6.8 Electrostatic properties 
Effective net charge was obtained by computing the electrostatic potential of 
100 conformations within each cluster solving the non-linear Poisson-Boltzmann 
equation using the UHBD software241. Each electrostatic potential was radially 
averaged and then averaged over the ensemble of 100 conformations. The Debye-
Hückel potential was fitted on the average monodimensional electrostatic potential 
leaving the total charge (z) as free parameter. 
According to the Debye-Hückel theory of dilute electrolyte solutions, all ions in 
the solvent are treated as point charges while each macromolecule is treated as a 
sphere with diameter a (the radius of gyration was used) and net charge z. The 
electrostatic potential is given by: 
 
, (5) 
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where e is the elementary charge, r is the distance form the center, ε0 is the 
vacuum permittivity, εr is the relative permittivity of the solvent and κ is the 
inverse of the Debye length and is proportional to the ionic strength. 
3.6.9 Endocytosis assays in living cells 
In a typical endocytosis assay in mouse fibroblasts, NIH-3T3 cells were seeded 
24 h before the experiment in WillCo dishes to reach 80-90% confluence. 
Standard conditions for incubation consisted in 25-min incubation at 37°C, 5% 
CO2 in DMEM containing 1% BSA, 0.2 mg/ml calf thymus DNA, 5 µg/ml of 
Hoechst dye and 1 µM of aptamer-ATTO 633 probe (labeled A-1F, A-2F, GS24 
mt, GS24min, DW1, DW2, DW3 and DW4) in a total volume of 500 µl.  After 
incubation, cells were washed three times with PBS, fresh serum-containing 
medium was added and the sample was imaged by confocal microscopy. All 
experiments were performed in triplicate. Cells were imaged using the same 
microscopy setup described in Chapter 2. 
Colocalization experiments in mouse fibroblasts were performed as follows: 
NIH-3T3 cells were coincubated for 25 min at 37°C with aptamer-ATTO 633 
probe (either A-2F or GS24min) and Lysotracker green to a final concentration of 
1 µM and 70 nM, respectively. After incubation, the sample was washed three 
times with PBS, fresh serum-containing medium was added and the sample was 
imaged by confocal microscopy. 
To verify that aptamer endocytosis was an active, receptor-mediated process, 
NIH-3T3 cells were left 12 h before the experiment in DMEM with 2% serum. 
Cells were then kept on ice for 15 min, and incubated for 25 min on ice with 1 µM 
of A-2F-ATTO 633. After incubation, cells were washed with cold PBS and fresh 
serum-containing medium (10% serum) pre-heated at 37°C was added. Real-time 
monitoring of endocytosis was performed by confocal microscopy. 
In internalization assays in human pancreatic carcinoma cells, MIA-PaCa-2 
cells were seeded 24 h before experiment in WillCo dishes to reach 80-90% 
confluence. Six hours before each experiment the complete growth medium was 
replaced with a 2% serum-containing medium. At time of assay, cells were 
incubated for 25 min with a medium composed of DMEM containing 1% BSA, 
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0.2 mg/ml calf thymus DNA, 5 µg/ml of Hoechst dye and 3 µM of aptamer-ATTO 
633 probe (A-2F, GS24mt, GS24min and DW4) in a total volume of 500 µl. After 
incubation, cells were washed three times with PBS then fresh 10% serum-
containing medium was added and the sample was imaged by confocal 
microscopy.  
Colocalization experiments in human tumor cells were performed as follows:  
MIA PaCa-2 cells, growth in WillCo dishes, were coincubated for 30 min at 
37°C with A-2F-ATTO 633 (3 µM) and monoclonal antibody anti-CD71-FITC 
conjugate following manufacturer's protocol with minor modification (1:250 
diluition, Invitrogen). At the end of incubation, the cells were washed with PBS 
and fresh 10% serum-containing medium was added. Cells were incubated at 37°C 
for further 30 min and then fixed with 4% paraformaldehyde and 4% sucrose in 
PBS for 20 min. Fixed cells were washed with PBS and the sample was imaged by 
confocal microscopy. All experiments were performed in triplicate. Pearson’s 
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Aptamer-mediated delivery of large 
functional RNA 
The work in this chapter was carried out in collaboration with Dr. Donald H. Burke and 
Khalid K. Alam at the University of Missouri - Columbia. It is anticipated that it will be 
submitted for peer-reviewed publication in modified form. DH Burke designed the study. 
D. Porciani and DH Burke designed the aptamer-aptamer complex and analyzed the data. 
D. Porciani and K. K. Alam performed the electrophoretic mobility shift assay and 
synthesized all RNA sequences. Unless otherwise specified, experiments and data shown in 
each figure were performed and analyzed by D Porciani. 
 
As stated in the first chapter, cell-type-specific aptamers have been used to 
deliver a variety of molecular payloads, such as small drugs and small interfering 
RNAs. Therapeutic aptamers, larger RNAs, such as long non-coding RNA 
(lncRNA), messenger RNA (mRNA) and engineered RNA nanostructures, offer 
tremendous potential as therapeutic and regulatory agents. Unfortunately, their 
aptamer-mediated delivery into cells has not yet been demonstrated. A critical 
point of this strategy is to design assemblies in which the structured 
oligonucleotide modules retain their proper folding with no unwanted inter- and 
intra-molecular interactions. First, the aptamer motif should retain its folded 
structure to interact with its biomolecular target and perform an aptamer-mediated 
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targeted delivery. Additionally, the released payload should assume its correct 3D 
structure to exhibit the therapeutic effect (e.g. binding and inhibition of cancer-
associated protein). Thus, testing the potential of several designs and monitoring 
both folding properties and the effective cargo delivery into targeted cells might 
be a very time-consuming process. 
To address these limitations, we took inspiration from the design used to 
generate aptamer-siRNA conjugates as starting point for further rational 
engineering. In addition, the use of fluorescent RNA aptamers as payloads may 
greatly accelerate the testing of various designs. The benefit is twofold: their 
successful delivery into targeted cells is readily detected by fluorescence 
microscopy, and this fluorescence readout is sensitive to structural variations, 
highlighting potential perturbations of the aptamer folding. 
Fluorescent RNA aptamers are RNA mimics of the green fluorescent protein, in 
that they are able to bind small molecules structurally similar to the GFP 
chromophore242. These molecules are poorly fluorescent in solution but become 
highly fluorescent within the folded protein or upon formation of a complex with 
the aptamer. This property is also perfectly suited to the SELEX approach, which 
indeed has been used to identify nucleic acid sequences able to activate their 
fluorescence. Among the selected aptamers, one can cite the brightest sequence, 
termed “Spinach”, which binds an analogous of GFP chromophore, (Z)-4-(3,5- 
difluoro-4-hydroxybenzylidene)-1,2-dimethyl-1H-imidazol- 5(4H)-one (DFHBI), 
affording a green-emitting complex242,243. Free DFHBI exhibits low background 
fluorescence in cells, thus fluorescence signals are readily attributable to 
Spinach−DFHBI complexes (Fig. 1). Although Spinach aptamer has been used as 
a fluorescent reporter of native RNA trafficking (Fig. 1)242,244, it can be used also 
as payload to track its fluorescence signal during endocytosis, and to evaluate 
folding alterations within the oligonucleotide platform.  
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Fig. 1 Detection of RNA localization and dynamics by fluorescent RNA aptamers. The 
sequence encoding the cellular RNA of interest is fused to the Spinach aptamer and 
transcribed by its natural promoter or an artificial promoter. The aptamer binds the 
cell-permeable fluorophore DFHBI. Binding leads to green fluorescence, allowing the 
RNA of interest to be visualized and its movement tracked in live cells. Adapted from 
Mattick and Clark.245 Reprinted by permission from Macmillan Publishers Ltd: Nature 
Biotechnology (Ref. 240), Copyright © 2011 
Starting from the Spinach-DFHBI system, novel enhanced RNA mimics GFP 
such as Spinach2 and Broccoli, together with and an improved GFP-like 
fluorophore (DFHBI-1T) were recently generated246–248. These new generations of 
fluorescent RNA aptamers were selected to overcome some intrinsic limitations 
linked to the poor intracellular folding shown by Spinach. Jaffrey and coworkers 
used a systematic mutagenesis to generate an enhanced RNA aptamer, named 
Spinach2, which shows higher thermal stability and greater fraction of properly 
folded aptamer than the parent sequence246. In addition, Spinach2 was fused to the 
tRNA sequence, which acts as folding scaffold249, further increasing the 
percentage of properly structured Spinach2246.  
In 2014, two parallel studies revealed that the crucial part of Spinach involved 
into binding of DFHBI folds in a G-quadruplex structure243,250. In particular, the 
Spinach G-quadruplex motif and its adjacent nucleotides stabilize the planar 
conformation of the DFHBI fluorophore and restrict its rotational motion, 
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inhibiting non-radiative decay and enhancing fluorescence quantum yield. The 
interactions between DFHBI and the nucleotide residues of the G-quadruplex are 
mainly based on π-π aromatic stacking and hydrogen bonds. Starting from these 
findings, the authors generated a minimal aptamer sequence, termed Baby 
Spinach, which retains the same properties of its parent sequence243.  
The structures of the two GFP-like fluorophores recognized by the Spinach 
aptamer’s family are shown In Fig. 2a, and the secondary structures of Spinach 
and its sequence variants based on crystallographic and NMR analyses are shown 
in Fig. 2b.  
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Fig. 2 (a) GFP-like fluorophore structures (DFHBI and DFHBI-1T) designed on the 
basis of the GFP chromophore (HBI). (b) Secondary structure of Spinach and its 
sequence variant, Spinach2, based on the crystal structure of the Spinach-DFHBI 
complex. Abbreviations: DFHBI, (Z)-4-(3,5-difluoro-4-hydroxybenzylidene)-1,2-
dimethyl-1H-imidazol-5(4H)-one. DFHBI-1T is the 1,1,1-trifluoroethyl derivative of 
DFHBI. DFHBI-1T [(Z)-4-(3,5-difluoro-4-hydroxybenzylidene)-2-methyl-1-(2,2,2-
trifluoroethyl)-1H-imidazol-5(4H)-one)]. Reprinted by permission from Macmillan 
Publishers Ltd: Nat. Struct. Mol. Biol (Ref. 238), Copyright © 2014 
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Notably, a further improved RNA aptamer, named Broccoli, was generated at 
the end of 2014 by using a SELEX–FACS approach248. Broccoli aptamer has the 
same high folding efficiency in vitro as Spinach2, but exhibits markedly lower 
dependence on magnesium for folding and increased thermal stability, leading to 
enhanced brightness in living cells. 
In this chapter, I shall report on the design and synthesis of a modular plug-and-
play platform for the aptamer-mediated cellular delivery of increasingly large 
RNA payloads (~50-60 kDa). In details, anti-transferrin receptor aptamers 
described in the first chapters (c2 and DW4) were used as cell-penetrating 
aptamers (“delivery modules”) and were annealed via a short oligonucleotide 
bridge to fluorescent RNA aptamers (“payload modules”). In addition to c2 and 
DW4, we also used a novel cell penetrating RNA aptamer, termed Waz, which 
binds the human transferrin receptor in a different binding site than the natural 
ligand. This sequence was kindly provided by Levy group and it is currently under 
a restrictive patent (N° WO 2013163303 A2).  
The modular design of this assembly should allow swapping in virtually any 
targeting aptamer and any regulatory cargo, making this experimental platform 
quite powerful and flexible for a broad range of applications. 
4.1 Design and synthesis of a plug-and-play platform for 
targeted delivery 
To generate a self-assembling aptamer-aptamer complex, we took inspiration 
from the aptacoy design already described in chapter 2. In this design, the delivery 
aptamer bears an extended sequence (tail) at the 3’-end that forms a duplex region 
upon hybridization with its complementary sequence (anti-tail). In turn, this anti-
tail part is directly conjugated with the molecular payload, i.e. decoy ODN. 
Starting from this design, we decided to exploit the same tail (CGA)7 at the 3’-end 
of the delivery aptamers and to design a novel extended sequence (GAT)7 for the 
payload module. As shown schematically in Fig. 3, the final platform is generated 
through self-assembly by means of a synthetic oligodeoxynucleotide bridge (ODN 
bridge) that contains regions complementary to both tails. Delivery aptamer 
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carries a tail GC-rich, and payload aptamer bears a tail AT-rich. These 
oligonucleotide tails do not interact with each other, thereby limiting undesired 
intermolecular interactions and impaired self-assembly. 
 
Fig. 3 Self-assembly of the aptamer-aptamer platform. Proposed design for our plug-
and-play platform, which exploits the nucleic acid annealing between the bridge and 
the two aptamer modules. 
Secondary structure predictions were performed using NUPACK tool175 to 
assess the potential for correct hybridization of each module, to identify some 
potential misfolding structures and consequently to monitor whether each aptamer 
still retain its proper folding within the platform. As shown in Fig. 4, 
computational results suggest that after hybridization with Spinach2 both DW4 
and c2 do not affect Spinach folding, but retain their predicted minimum free 
energy secondary structure. Note that in all our evaluation Spinach2 was fused to 
the tRNA sequence to increase its folding property246. Hereafter, I refer to the 
Spinach2-tRNA as Spinach2, unless the tRNA form is specifically indicated.  
It is worth mentioning that, the Spinach2 region is not accurately reproduced in 
the secondary structure prediction of the whole complex (Fig. 4), as expected 
owing to the presence of G-quadruplex motif and several non-canonical base 
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parings, which make the structure very difficult to predict by basic computational 
approaches such as NUPACK. Indeed, as mentioned before, the correct structure 
of Spinach2 was resolved only after crystallographic and NMR studies, and is 
reported in Fig. 2. However, the secondary structure of the tRNA domain is 
correctly predicted (Fig. 4) pointing to a reliable conformation also for the 
annealing region.  
 
Fig. 4 Secondary structure predictions of DW4-Spinach2 and c2-Spinach2 complexes. 
On the left secondary structures predictions after hybridization simulation of 
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DW4/c2, Spinach2 and oligo bridge by NUPACK calculation. On the right depiction 
of the helicity of the hybridized oligo complexes. Color legend. Green: Spinach2.  
Dark red: delivery aptamers (DW4 and c2). Light red: bridge 
It is worth noting that secondary structure predictions offer a good starting point 
to elucidate some potential misfolding limitations. However, only experimental 
analyses may provide a deep understanding of the folding properties related to 
structured nucleic acids as well as any other folded biomolecule.  
 
4.1.1 Assembly of aptamer-aptamer complexes: annealing reaction with 
equimolar concentration of aptamer modules and excess of bridge 
Formation of self-assembled ternary oligonucleotide complexes (i.e. payload 
aptamer-bridge-delivery aptamer) was assessed by electrophoretic mobility shift 
assay (EMSA). Maximum efficacy in terms of hybridization yields critically 
depends on several important parameters during the hybridization phase.  
Particularly, the molar ratio of the oligonucleotides in the mixture plays an 
important role to avoid the presence of residual unreacted oligonucleotides. 
Indeed, the presence of free payload aptamer could affect the fluorescence 
microscopy analysis in living cells. Thereby, we aimed at reducing the fraction of 
free Spinach2 resulting by the hybridization reaction. First, we evaluated the 
performance of the annealing process using a slight molar excess of the bridge i.e. 
1.2 fold excess with respect to “delivery” and “payload” aptamer. Thus, in this 
mixture the aptamer modules represent the “limiting reagent” and ideally should 
completely interact with the bridge sequence.  
Additionally, a gradual cooling/annealing step is essential when dealing with 
sequences with such significant secondary structure. Therefore, the oligo mixture 
was first heated at high temperature and then slowly cooled to room temperature 
over 45–60 minutes to allow correct hybridization among the complementary 
strands.  
Next, we assessed the formation of the assembly by monitoring the band shift 
into a native polyacrylamide gel electrophoresis (native PAGE). To better 
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understand the efficiency of the annealing process, we estimated the band intensity 
of three species for each sample: unconjugated Spinach2, Spinach2-bridge 
complex, and ternary oligonucleotide complex (Spinach2-c2 and Spinach2-DW4). 
Starting from the band intensity values, we calculated an approximate value of 
hybridization yields for all samples. It is worth noting that Spinach2 does not 
show complete hybridization with the ODN bridge sequence. An estimation of the 
band intensity of both free Spinach2 and Spinach2-bridge complex in the lane 2 
indicates that only ∼50% of total amount of Spinach2 is actually annealed with the 
ODN bridge (Fig. 5). Furthermore, we found that the annealing process is tightly 
dependent by the delivery aptamer employed in the annealing step. Indeed, 
different hybridization yields were observed with c2 and DW4. Particularly, a 
very low amount (∼20%) of the whole conjugate was generated with c2 aptamer 
(lane 3). In contrast, the annealing process with DW4 led to the formation of a 
higher amount of the final conjugate (∼50%). Consequently, a negligible band was 
detected for the Spinach2-bridge (∼10%) in this sample (lane 4). Note that an 
almost constant amount of free Spinach2 was present in all annealing samples, in 
percentage ranging from 40 to 50% (Fig. 5). The existence of a fraction of 
unconjugated Spinach2 might be linked to the presence of misfolded structures. 
Indeed, as mentioned above, it has been recently demonstrated that the fraction of 
properly folded Spinach2-tRNA is ∼80% at 25 °C and ∼60% at 37°C246. Our 
findings are consistent with the latter value since we estimated that the 
free/misfolded fraction is about 40% of Spinach2. Thereby, taking into account 
only the hypothetical aptamer folded fraction represented here by the amount of 
Spinach2 effectively annealed with the bridge (∼60% in lane 3 and 4), the 
calculated hybridization yields exceed the previously found values. Indeed, we 
estimated that ∼30% of the Spinach2-bridge (calculated from band intensities 
according to the following formula: ternary complex/(ternary complex + 
Spinach2-bridge)*100) is actually able to generate the ternary oligonucleotide 
complex through self-assembly with c2 (lane 3). On the other hand, the annealing 
efficiency rises to ∼85% when the Spinach2-bridge is annealed with DW4 (lane 
4). 
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Fig. 5 Electrophoretic Mobility Shift Assay (EMSA) to assess the formation of the 
ternary complex among the payload aptamer (Spinach2), oligo bridge and the 
delivery aptamer (c2 or DW4). The molar equivalents were 1:1:1.2 for Spinach2, 
c2/DW4, and bridge, respectively. Lane 1: free Spinach2. Lane 2: Spinach2+bridge. 
Lane 3: Spinach2+bridge+c2. Lane 4: Spinach2+bridge+DW4. Lane 5: low range 
DNA ladder. 
4.1.2 Assembly of aptamer-aptamer complexes: annealing reaction with 
an excess of delivery aptamers and bridge 
In view of these considerations on the Spinach2 folding, we explored different 
conditions to improve the hybridization yields and reduce the fraction of 
unconjugated Spinach2. To this end, a different molar ratio and a different 
annealing protocol were employed. In details, we used a slight molar excess of 
both ODN bridge and delivery aptamer (1.4 and 1.6) compared to the molar 
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concentration of Spinach2 (molar ratio for Spinach2, ODN bridge and delivery 
aptamer: 1:1.4:1.6). Moreover, we prepared different annealing mixtures 
containing the ODN bridge with either the payload or delivery aptamer to increase 
the folding performance of both aptamer modules during the cooling step. The 
mixture was denatured at high temperature and slowly cooled at room 
temperature. Meanwhile, the payload or delivery aptamer was denatured and 
added to the corresponding sample during the cooling phase when the temperature 
was at ∼45°C. For this evaluation, beyond c2 and DW4 we employed a third anti-
TfR aptamer, a 2’-fluoro-modified RNA, termed Waz.  
As shown in Fig. 6 the assembly of the final ternary complex was still 
dependent on the delivery aptamer present in the annealing mixture and on the 
nature of the aptamer added later during the cooling step. Particularly, we 
observed preferential annealing and improved yields when the RNA aptamers, c2 
and Waz, were added at 45°C (lane 3 and 7). In contrast, addition of Spinach2 
during the cooling step led to the formation of a remarkably lower amount of the 
same ternary complex (lane 4 and 8). It is worth noting that when the delivery 
RNA aptamers were added at a later stage in the process, we barely observed the 
presence of unreacted Spinach2-bridge (∼5%). Thus, taking into account only the 
Spinach2 fraction effectively hybridized with the ODN bridge, the yield for the 
ternary complex formation is about 90% for both c2 and Waz.  
On the other hand, when the DNA aptamer DW4 was used as delivery module 
(lane 5 and 6), we estimated similar annealing efficiency both when DW4 was 
added at 45°C during the cooling phase and when it was directly incubated with 
the ODN bridge. Interestingly, both approaches afforded lower hybridization 
yields compared with our first annealing protocol (see Fig. 5, lane 4).  
Note that, even in this second EMSA evaluation, each sample containing all the 
oligo sequences showed a quite constant amount (∼50-55%) of free Spinach2, 
which might be actually related to misfolded aptamer structures.  
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Fig. 6 Electrophoretic Mobility Shift Assay (EMSA) to assess the formation of the 
ternary complex among the payload aptamer (Spinach2), oligo bridge and the 
delivery aptamer (c2, DW4, or Waz). The molar ratio were 1:1.4:1.6 for Spinach2, 
bridge and c2/DW4/Waz, respectively Lane 1: Spinach2. Lane 2: Spinach2+bridge. 
Lane 3: Spinach2+bridge+c2 (secondary addition of c2). Lane 4: Spinach2+bridge+c2 
(secondary addition of Spinach2). Lane 5: Spinach2+bridge+DW4 (secondary 
addition of DW4). Lane 6: Spinach2+bridge+DW4 (secondary addition of Spinach2).  
Lane 4: Spinach2+bridge+DW4. Lane 7: Spinach2+bridge+Waz (secondary addition 
of Waz). Lane 8: Spinach2+bridge+Waz (secondary addition of Spinach2). Lane 9: 
Low range DNA ladder. 
Overall, these results highlight some limitations in the assembly of the ternary 
oligonucleotide complex. Particularly, the folding property of Spinach2 and its 
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relatively limited thermal stability (melting temperature for Spinach2 in absence 
of tRNA is Tm~ 38°C) affect its capability to fully interact with the 
complementary strand. This behavior led to lower than expected hybridization 
yields, with a fraction of unconjugated Spinach2 still present in the annealing 
mixture. Furthermore, it is worth noting that delivery aptamers interfere at 
different degrees with Spinach2, leading to different hybridization yields in 
dependence on their structural nature (DNA or RNA). 
In the next section, I shall describe results of the investigation on functional 
properties of both payload and delivery aptamers within the ternary complex. To 
this end, the aptamer-aptamer conjugations were performed using tailored protocol 
for each delivery module employed based on the results described above. 
Particularly, to maximize the hybridization yield, c2 and Waz were added during 
the annealing/cooling step using 1.6 molar ratio delivery aptamer (c2 or 
Waz)/Spinach2. In contrast DW4 was directly incubated and denatured in 
presence of Spinach2 and bridge using equimolar concentration of the two 
aptamers. 
4.2 Aptamer functional assays 
4.2.1 Spinach2 fluorescence assay 
The assembled complex was subjected to functional assays to clarify whether 
both aptamers (delivery and payload) still retain their functions even when 
embedded in the aptamer-aptamer platform. To this end, we firstly monitored 
emission of Spinach2 module within the oligonucleotide complexes in cuvette. 
The fluorescence emission of Spinach2-DFHBI complex is directly dependent on 
aptamer folding, thus fluorescence variations are tightly related with its structural 
changes. We measured fluorescence emission of each assembly (Spinach2-bridge, 
Spinach2-DW4, Spinach2-c2 and Spinach2-Waz) and we compared them with 
what found for Spinach2 alone; this step was necessary to understand to what 
extent conjugation with the different modules affects the ability of Spinach2 to 
bind DFHBI. In all our annealing experiments, we employed a binding/annealing 
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buffer containing cytosolic ion concentrations and increased magnesium 
concentration (5 mM)246.   
As shown in Fig. 7, fluorescence emission spectra from all samples retain the 
same shape. Therefore, we directly compared the fluorescence emission of each 
assembly with the value recorded for Spinach2 alone. Note that conjugation of 
Spinach2 with the delivery RNA aptamers (c2 and Waz) causes a modest 
reduction of Spinach2-DFHBI fluorescence. Indeed, brightness of Spinach2-c2 
and Spinach2-Waz samples was ∼85% of what shown by unconjugated Spinach2. 
On the other hand, annealing with the bridge (i.e. Spinach2-brigde) and DW4 (i.e. 
Spinach2-DW4) does not affect significantly fluorescence emission  (Fig. 7b). As 
expected, when the same concentration of DFHBI (10 µM) was incubated in 
presence of binding buffer, we detected minimal fluorescence emission247,248.  
It is worth noting that hybridization with the bridge sequence might stabilize 
Spinach2 folding, as shown by the slightly increased fluorescence intensity 
compared with Spinach2 alone. This behavior is likely due to the presence of a 
flexible free tail at the 3’-end of Spinach2 that may, to some extent, affect RNA 
folding. Upon hybridization of the tail with its complementary sequence on the 
bridge, a stable double helix is generated at the 3’-end of Spinach2, leading to 
enhanced stability. 
 
Fig. 7 Fluorescence emission of free Spinach2, Spinach2-bridge, Spinach2-DW4, 
Spinach2-c2, and Spinach2-Waz. (a) Fluorescence emission spectra from 0.1 µM of 
indicated RNAs and 10 µM DFHBI, measured at 25°C. Fluorescence was excited with 
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450 nm light and emission was recorded from 470 nm to 600 nm. All curves are 
represented as average of three independent experiments. (b) Fluorescence intensity 
measured for all samples as fluorescence spectrum area measured from 480 and 560 
nm, and then normalized for the intensity recorded for Spinach2.   
After this evaluation, we could affirm that the Spinach2 module still retains its 
ability to activate the fluorescence of DFHBI when inserted into the aptamer-
aptamer complex.  
Next, we turned our attention to the development of a nuclease resistant 
Spinach2 variant. Indeed, the presence of serum nucleases can hamper both in 
vitro but especially in vivo applications of this fluorescent RNA aptamer. To this 
end, we replaced the natural pyrimidine nucleotides (uridine and cytidine) with 
different combinations of 2’-modified pyrimidines (2’-fluoro, 2’-deoxy, and 2’-O-
methyl pyrimidines). We generated through in vitro transcription several RNA 
Spinach2 transcripts and then we tested their ability to bind DFHBI on the basis of 
fluorescence readout. Interestingly, only cytidine derivatives, 2’-fluoro cytidine 
(Fig. 8) and 2’-deoxy cytidine (data not shown), retained the fluorescence 
properties of the RNA Spinach2 transcripts although with a reduced brightness 
(∼50%) with respect to wild type Spinach2 (Fig. 8). In contrast, all our attempts to 
replace the uridine nucleotide led to significant reduction of the Spinach2 
fluorescence property with almost complete loss of activity. Indeed, RNA 
transcripts with either 2’-fluoro or 2’-deoxy uridine were ∼15-20% as bright as 
Spinach2, and the brightest molecule (∼30%) was obtained after insertion of 2’-O-
methyl-uridine.  
It is worth mentioning that while our measurements were ongoing, Jaffrey and 
coworkers determined the 3D structure of Spinach2 and Spinach2-DHBI complex, 
unveiling the essential role of two uridine residues (U32 and U61) for binding of 
DFHBI243. Particularly, the 2’-hydroxyl group of U61 is implicated in a hydrogen 
bond to stabilize the interaction with the dye. Thereby, our findings related to the 
loss fluorescence emission of 2’-modified uridine RNAs are fully consistent with 
the proposed 3D conformation of Spinach2-DFHBI complex. Indeed, all our 
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modified Spinach2 transcripts did not include in their structure the 2’-hydroxyl 
group of the U61.  
 
 
Fig. 8 Fluorescence properties of 2’-modified Spinach2 transcripts. Fluorescence 
signal from 0.4 µM of indicated RNAs and 2 µM DFHBI, measured at 25°C and 
normalized to the fluorescence intensity recorded for wild type Spinach2. 
Abbreviations: Spinach2 2’F-U (included 2’-flurouridine); Spinach2 2’F-C (included 
2’-flurocytidine); Spinach2 2’F-Py (included both 2’-flurouridine and 2’-
flurocytidine); Spinach2 dt (included 2’-deoxythymidine); Spinach2 dT-dC (included 
both 2’-deoxythymidine and 2’-deoxycytidine); Spinach2 dt-2’F-C (included both 2’-
deoxythymidine and 2’-flurocytidine); Spinach2 2’-OMe-U (included 2’-O-
methyluridine); DFHBI (DMSO), fluorescence measured in DMSO; DFHBI (aq), 
fluorescence measured in aqueous solution. Each measure represents average values 
for three independent experiments.  
Finally, we also recorded the fluorescence emission spectrum of free DFHBI in 
organic solvent (DMSO), and we compared it with that found in aqueous solution. 
The shape of the spectrum did not change; however, DFHBI itself (2 µM) in an 
organic environment was ∼75% as bright as Spinach2-DFHBI complex in aqueous 
solution. Conversely, as previously observed, the unbound dye did not show 
appreciable fluorescence in an aqueous milieu (∼10%). This phenomenon, which 
is frequently observed with many other solvatochromic dyes251, is likely due to the 
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lack of deactivation pathways induced by polar protic solvents such as water, and 
might lead to unwanted background fluorescence due to interaction of the dye 
with hydrophobic intracellular compartments, such as viscous membrane bilayers.  
4.2.2 Endocytosis assay  
Once verified that the Spinach2 module is still functional within the aptamer-
aptamer assembly, we turned our attention to cell internalization of the delivery 
aptamers. Particularly, we assessed whether their ability to internalize into specific 
cell lines was retained even in presence of a large RNA molecule (Spinach2) as 
payload. Therefore, we performed an internalization assay using two different cell 
lines: mouse fibroblast cells (NIH 3T3) and human cervical cancer cells (HeLa) as 
target cells for DW4 and c2, respectively. The aptamer-aptamer complexes 
(Spinach2-DW4 and Spinach2-c2) were generated in presence of 20-fold molar 
excess of DFHBI (10 µM). In addition, the previously described scrambled 
aptamer sequences for DW4 and c2 (GS24mt, hereafter renamed scrDW4, and 
c36) were used as negative control.  
It is worth mentioning that the Spinach-DFHBI complex displays relatively fast 
fluorescence decrease under continuous light irradiation due to cis-trans 
photoisomerization of the fluorophore252. However, in contrast with the 
irreversible photobleaching mechanism of GFP, the fluorescence of Spinach-
DFHBI can be easily restored. Indeed, cis-trans photoisomerization induces fast 
unbinding of DFHBI from Spinach; consequently, a new ground-state (i.e. cis) 
DFHBI molecule can interact with Spinach, thus apparently restoring fluorescence 
of the complex in a [DFHBI]-dependent manner.  
Therefore, before treatment with the oligonucleotide complexes, cultured cells 
were pre-treated with free DFHBI to ensure the presence of a large molar excess 
of dye in the intracellular compartments, and to interact with the internalized 
Spinach2, ultimately increasing the fluorescence recovery rate of the Spinach2-
DFHBI complex. Moreover, since proper fold of Spinach2 only occurs in the 
presence of high levels of magnesium, we supplied exogenous magnesium to the 
culture media to increase its intracellular concentration.  
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The internalization of the oligonucleotide complexes was monitored by confocal 
microscopy. As stated in the previous chapter, we shortly incubated (30 minutes) 
the samples at very low oligonucleotide concentration (~0.5 µM) to minimize the 
nonspecific internalization of the aptamer-aptamer via pinocytosis. Additionally, 
BSA and tRNA were added as competitors for nonspecific binding sites. 
However, as shown in Fig. 9, for both cell lines (NIH 3T3 and HeLa), we detected 
similar fluorescence signal in the aptamer-aptamer complex-treated cells and after 
treatment with either DFHBI alone or the scrambled aptamer-Spinach2 
complexes. The very low signal-to-noise ratio did not allow a clear distinction of 
the internalization property of each assembly. Interestingly, Jaffrey group has 
already described the presence of a low-level background fluorescence in DFHBI-
treated cells, in absence of Spinach, with punctate fluorescence signals that reflect 
interactions of DFHBI with intracellular debris-like structures247. This is not 
uncommon between lipophilic dyes, which accumulate nonspecifically in many 
subcellular organelles251 and the very dim fluorescence emission lead to low 
signal-to-noise ratio, which hampered a clear understanding of the internalization 
property of each assembly.  
The significant background fluorescence exhibited by free DFHBI is consistent 
with our measurements related to the activation of DFHBI fluorescence in 
presence of an aprotic relatively non-polar solvent, such as DMSO. Indeed, this 
nonspecific signal is likely due to the interaction of this dye with hydrophobic 
intracellular compartments. 
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Fig. 9 Internalization assay of the aptamer-aptamer complexes in mouse fibroblasts 
(NIH 3T3) and human cervical cancer cells (HeLa). Confocal imaging microscopy 
shows the intracellular fluorescence of DFHBI alone, Spinach2-DW4 and Spinach2-
scrDW4 in mouse fibroblasts and DFHBI alone, Spinach-c2 and Spinach2-c36 in 
human cervical cancer cells. Scale bars: 10 µm 
Note that, besides showing considerable background fluorescence, DFHBI 
suffers also from another limitation for live cell imaging: Spinach-DFHBI 
complex exhibits spectral properties (e.g. fluorescence excitation maximum at 447 
nm) that do not fully match with the filters commonly used for GFP in 
fluorescence microscopes. Then, we decided to replace DFHBI in our analysis 
with its improved version, DFHBI-1T, which exhibits reduced background 
fluorescence, higher extinction coefficient (22000 M-1cm-1 and 31000 M-1cm-1 
respectively for Spinach2-DFHBI and Spinach2-DFHBI-1T) and better quantum 
yield (0.72 and 0.94 respectively for Spinach2-DFHBI and Spinach2-DFHBI-1T). 
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In addition, the resulting Spinach2-DFHBI-1T complex has spectral properties 
that are more compatible with the existing microscopy filter sets (e.g. fluorescence 
excitation maximum at 482 nm)247  The enhanced optical properties of DFHBI-1T 
are particularly relevant when dealing with processes occurring during 
endocytosis. In fact, the intravesicular pH drops along the endocytic pathway from 
the neutrality into the clathrin pits to pH 6.0–6.5 in early endosomes and finally to 
pH 4.5–5.5 in late endosomes and lysosomes. These pH changes shift the 
equilibrium from the deprotonated form (which is the most represented at 
physiological pH) to the protonated, nonfluorescent, one. In the pioneristic work 
that led to the first fluorogenic RNAs, Spinach-DFHBI complex exhibited a 
reduction up to 50% of its brightness at pH 6242. This translated in an overall loss 
of sensitivity during the endocytosis process, which can be circumvented to a 
certain extent by using a dye with  higher brightness, such as DFHBI-1T. 
Analogously to what already done for DFHBI, we generated aptamer-aptamer-
DFHBI-1T conjugates, and measured fluorescence of the Spinach2-DFHBI-1T 
complex within each assembly. As expected, Spinach2 was able to bind also 
DFHBI-1T after annealing with the delivery aptamers, exhibiting similar relative 
fluorescence properties, and confirming the results shown in Fig. 7.  
We next evaluated the DW4-mediated uptake of Spinach2 in mouse fibroblasts. 
Cells were treated with either the whole complex or Spinach2-scrDW4 assembly, 
and fluorescence arising from the two cell samples was compared with that of 
DFHBI-1T-treated cells (Fig. 10). Upon incubation, vesicular signals were 
detected inside the cells after treatment with Spinach2-DW4. Conversely, in the 
case of Spinach2-scrDW4 only a weak signal was detected into the cells appearing 
as cytosolic dots, possibly due to negligible nonspecific internalization of this 
complex. Most importantly, DFHBI-1T-treated cells showed almost null 
fluorescence, highlighting the reduced background fluorescence arising from this 
dye compared with its parent version, DFHBI. Notably, only some punctate 
signals could be detected in this sample, likely due to the interaction of DFHBI-1T 
with intracellular debris-like structures247. Thanks to the enhanced properties of 
DFHBI-1T, we could observe different internalization properties exhibited by 
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each complex, demonstrating that the large RNA Spinach2 was effectively 
internalized into the mouse cells via the DW4 aptamer (Fig. 10). 
 
 
Fig. 10 Internalization assay of the aptamer-aptamer complexes in mouse fibroblasts 
(NIH 3T3). Confocal imaging microscopy shows the intracellular fluorescence (green) 
of DFHBI-1T alone, Spinach2-DW4, Spinach2-scrDW4, and Hoechst nuclear marker 
(blue) in mouse fibroblasts. Scale bars: 10 µm 
Importantly, analogous results were obtained when Spinach2-c2 and Spinach2-
Waz complexes were incubated in the presence of human cervical cancer cells 
(HeLa) (Fig. 11). It is worth noting that endocytic signals showed by this 
scrambled sequence (i.e. c36) exceeded that found for the DW4 scrambled 
aptamer (scrDW4) used as negative control towards mouse cells. This result might 
be linked to the use of serum-free medium during our incubation, an experimental 
condition that could lead to increased nonspecific binding with cell membrane, 
ultimately resulting in nonselective uptake. Unfortunately, as scrambled sequence, 
c36 has been identified by Levy group and its activity and nonspecific 
internalization have been always tested in presence of serum-containing 
medium137. In contrast scrDW4 has been identified as non-internalizing sequence  
in absence of serum222. The poor nuclease resistance of the RNA Spinach2 
module, however, did hamper the use of serum during our endocytosis assay, and 
each sample was incubated in a serum-free medium (see methods for further 
details).  
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Fig. 11 Internalization assay of the aptamer-aptamer complexes in human cervical 
cancer cells (HeLa). Confocal imaging microscopy shows the intracellular 
fluorescence (green) of DFHBI-1T alone, Spinach-c2, Spianch2-Waz, Spinach2-c36, 
and Hoechst nuclear marker (blue) in human cervical cancer cells. Scale bars: 10 µm 
To test whether the aptamer-aptamer complexes still retain their cell specificity, 
we incubated Spinach2-c2 and Spinach2-DW4 with their non-target cells, mouse 
and human cells, respectively (Fig. 12). As expected, the two assemblies showed 
weak intracellular signals, suggesting that DW4 and c2 were not able to deliver 
Spinach2 in cells lacking target receptor. Very low fluorescence was detected in 
mouse fibroblasts after treatment with Spinach2-c2 owing to the specificity 
exhibited by c2 towards the human transferrin receptor. On the other hand, 
Spinach2-DW4 showed a slightly higher fluorescent signal in HeLa cells, which is 
likely due to the ability of DW4 to recognize even hTfR although with lower 
affinity (see Chapter 3). Indeed, the aptamer-aptamer complexes were incubated at 
very low concentration (~0.5 µM), possibly below the effective Kd range of DW4 
towards hTfR. 
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Fig. 12 Endocytosis of Spinach2-DW4 and Spinach2-c2 in mouse fibroblasts (NIH 
3T3) and human cervical cancer cells (HeLa). Confocal imaging microscopy shows 
the intracellular fluorescence of, Spinach2-DW4 and Spinach2-c2 in NIH 3T3 and 
HeLa cells. Scale bars: 10 µm 
Overall, these results are the first evidence of an aptamer-mediated aptamer 
delivery. Most importantly, each delivery aptamer is able to promote cell-specific 
aptamer-mediated endocytosis of Spinach2. These findings demonstrate the 
modularity of our platform design with the possibility to swap the delivery module 
without losing its selective uptake property. 
4.3 An improved fluorescent aptamer sequence: rational 
multimerization of Baby Spinach  
Besides exploiting different cell-penetrating aptamers as delivery module, we 
aimed to assess the possibility to swap even the payload portion of our platform in 
a “plug-and-play” fashion. Thus, we performed a rational multimerization of the 
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Spinach system to replace the Spinach2 aptamer with a novel fluorescent aptamer 
having enhanced brightness and folding stability.  
As previously mentioned in this chapter, Jaffrey and coworkers recently 
generated a truncated version of the Spinach aptamer, termed Baby Spinach, with 
fluorescence comparable to that of the parental RNA243. The reduced size of this 
aptamer sequence (51 nt of Baby Spinach versus 97 nt of Spinach2 without the 
tRNA scaffold) provides a flexible tool to study multimerization engineering. 
Taking into account the Baby Spinach folding, we designed a linear multimeric 
sequence containing up to 5 copies of Baby Spinach. As shown in Fig. 13 the stem 
region, or paired region (P2), at the 5’- and 3’- ends of Baby Spinach was 
extended to improve the folding stability of each aptamer module within the 
multimeric structure by increasing the number of base pairings. Thus, we decided 
to call this extended Baby Spinach sequence “s-Baby Spinach”, where “s” stands 
for both stemmed and stabilized. Note that the choice of these “extended stem 
sequences” was quite critical. We performed secondary structure predictions to 
verify and test each designed sequence, excluding those that induced alteration of 
the aptamer folding, especially in the stem region (P2). In addition, the flanking 
sequences between each s-Baby Spinach module were designed with a unique 
nucleotide composition, thus we could generate the single monomer, dimer, 
trimer, tetramer and pentamer using the appropriate couple of PCR primers. Then, 
the proper PCR amplicon was transcribed in vitro to generate the corresponding 
RNA transcript.  
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Fig. 13 Multimerization of Baby Spinach. Secondary structure predictions of Baby 
Spinach are based on previously findings on the crystal structure of both unbound 
Spinach and Spinach-DFHBI complex. The extended stem sequences and the flanking 
sequences between each module are depicted in grey. Each module of the linear 
multimeric sequence is composed by s-Baby Spinach unit (s=stemmed). 
To determine whether the multimerization of Baby Spinach affects the ability of 
each aptamer module to activate DFHBI fluorescence, we performed fluorescence 
measurements using identical RNA concentration (0.1 µM) and an excess of 
DFHBI (10 µM), normalizing each value to the monomer fluorescence at 25°C. 
Importantly, both dimeric and trimeric s-Baby Spinach showed increased 
fluorescence emission, respectively, of 1.7 and 1.8 times compared with the 
monomer (Table 1). However, fluorescence enhancement induced by the presence 
of multiple copies of s-Baby Spinach did not show a linear trend. In particular, the 
efficiency detected for each aptamer unit, or module, within the multimeric 
structures significantly decreases with increasing of the number of copies. This 
trend might suggest the presence of undesired intramolecular interactions that 
affect folding of each aptamer, ultimately lowering their ability to bind DFHBI 
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and activate its fluorescence. In particular, the unit of Baby Spinach could 
potentially hybridize each other. Indeed, the strands from one aptamer might 
interact with the complementary strand in another aptamer, leading to an 
interaptamer hybridization that could prevent the binding with DFHBI. Another 
possible explanation is related to the presence of several fluorophores confined 
within the same biomolecular architecture, which might contribute to the loss of 
fluorescence signal due to self-quenching. Note that a reduction of fluorescence 
has been reported for multiple-fluorophore labeled antibodies and proteins (e.g. 
four to six dyes per molecule)253. Indeed, the increase in the number of 
fluorophores conjugated to the same antibody/protein leads to a self-quenching 
effect, thereby reducing the overall fluorescence. 
 








s-Baby Spinach monomer 1.0 90  1 
s-Baby Spinach dimer 1.7  159 0.8 
s-Baby Spinach trimer 1.8 228 0.6 
s-Baby Spinach tetramer 1.0 297 0.2 
s-Baby Spinach pentamer 1.7 366 0.3 
Spinach2-tRNA 1.2 189 1 
1 All values were obtained as the average of two or more independent measurements, with errors 
(SD) in the range 0.05-0.1; 2The oligonucleotide length includes both the extended stem 
sequence and the annealing sequence to hybridize with the ODN bridge 
Despite the known stability of Spinach2-tRNA, which compares favorably both 
with its parent Spinach sequence and with Baby Spinach, our measurements 
display that Spinach2-tRNA is only 1.2 times brighter than our monomer (s-Baby 
Spinach) at 25°C. This is likely due to the presence of the extended stem sequence 
in our s-Baby Spinach design that leads to enhanced folding stability. The 
generation of a shorter RNA aptamer sequence with fluorescence properties 
comparable with Spinach2-tRNA offers significant advantages. In particular, it is 
known that tRNAs precursors are recognized by specific RNases, resulting in the 
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cleavage near the base of the tRNA254. Additionally, it has been recently 
demonstrated that tRNA scaffold is rapidly targeted by endonucleases, leading to 
RNA cleavage, degradation and instability both in bacterial and mammalian 
cells255. Thus, the presence of these highly susceptible tRNA motifs might 
represent a strong limitation when used as scaffold for live cell applications. In 
this context, our tRNA-free multimeric versions of Baby Spinach offer valid 
alternatives to the Spinach2-tRNA. On the basis of the improved brightness (~1.7 
and ~1.5 times higher than s-Baby Spinach and Spinach2, respectively) and unit 
efficiency (~80% of each module is still functional), dimeric s-Baby Spinach was 
the most promising sequence (Table 1). Therefore, we termed this molecule as 
Twins and we sought to investigate its fluorescence property both in vitro and in 
living cells, aiming to perform a live cells imaging of our aptamer-aptamer 
platform.  
In conclusion, the proposed multimerization strategy results a valid method to 
generate enhanced multimeric sequences containing up to two to three copies of 
fluorescent RNA aptamer per molecule. However, it suffers for some limitations 
related to the synthesis of RNA sequences with a high number of fluorescent units. 
It is worth mentioning that insertion of point mutations might potentially reduce 
the probability of interaptamer hybridization. Furthermore, insertion of additional 
stabilizing elements, such as longer stem sequences or three-way junction (3WJ) 
motifs originated from the bacteriophage phi29176, might lead to enhanced folding 
stability even for the multimeric sequences with a high number of copies. 
Before testing the enhanced fluorescence property of Twins in living cells, we 
performed an EMSA to assess the annealing property of this new sequence with 
delivery aptamers (Fig.14).  
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Fig. 14 Electrophoretic Mobility Shift Assay (EMSA) to assess the formation of the 
ternary complex among the payload aptamer (Twins), oligo bridge and the delivery 
aptamer (DW4, Waz and c2). The molar equivalents were 1:1.4:1.6 for Spinach2, 
bridge and c2/DW4/Waz, respectively Lane 1: free Twins. Lane 2: Twins+bridge. 
Lane 3: Twins+bridge+Waz (secondary addition of Waz) Lane 4: 
Twins+bridge+DW4 Lane 5: Twins+bridge+c2 (secondary addition of c2) Lane 6: 
Low range DNA ladder. 
We observed, for the first time, complete hybridization of the payload aptamer 
with the bridge sequence, as shown by complete disappearance of the band related 
to free Twins (Fig. 14, lane 2). This behavior was observed even when Twins and 
bridge were incubated with delivery aptamers to generate the aptamer-aptamer 
complex (Fig. 14, lane 3-5). This suggests that Twins exhibits a higher aptamer 
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folded fraction than Spinach2, thus allowing complete annealing with the bridge. 
These findings are consistent with the similar fluorescence properties exhibited by 
Spinach2 and s-Baby Spinach in our previous measurements (table 1). Indeed, 
although is known that Baby Spinach shows a significantly reduced fluorescence 
than Spinach2, the insertion of an extended stem sequence leads to enhanced 
folding stability, and consequently s-Baby Spinach displays improved 
fluorescence properties and its dimeric version (Twins) exhibits full hybridization 
with the bridge.   
Despite the excellent annealing efficiency between Twins and bridge, overall 
hybridization yields are still strictly dependent on the nature of the delivery 
aptamer included in the annealing mixture, confirming our previous findings (see 
Fig. 5 and 6). Particularly, DW4 shows best annealing properties compared with 
Waz and c2 (lane 3-5). The poor hybridization yield (~30%) obtained with c2 led 
us to exclude this delivery aptamer for the assessment of the aptamer-mediated 
Twins delivery in living cells. Therefore, only Twins-DW4 and Twins-Waz, 
showing respectively ~95% and ~50% yields, were incubated with their target 
cells. The scrambled aptamer c36 (i.e Twins-c36), which showed a hybridization 
yield comparable with that found for Waz, was used as negative control.  
Before performing the endocytosis assay, we measured the fluorescence of 
Twins-DFHBI-1T complex within each assembly. As shown in Fig. 15, annealing 
with delivery aptamers did not affect the ability of Twins to bind and activate the 
fluorescence of DFHBI-1T.  
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Fig. 15 Fluorescence properties of free Twins, Twins-bridge, Twins-DW4, Twins-c2, 
and Twins-Waz. (a) Fluorescence emission spectra from 0.1 µM of indicated RNAs 
and 10 µM DFHBI-1T, measured at 25°C. Fluorescence was excited with 480 nm light 
and emission was recorded from 500 nm to 600 nm. All curves are represented as 
average of three independent experiments. (b) Fluorescence intensity measured for all 
samples as fluorescence spectrum area measured from 500 and 560 nm, and then 
normalized for the intensity recorded for Twins.  
This result confirms that besides Spinach2, even another payload aptamer still 
retain its original folding and functionality when embedded in a more complex 
structure.  
Finally, we evaluated the aptamer-mediated uptake of Twins both in mouse 
fibroblasts and human cervical cancer cells. Upon incubation, punctate 
cytoplasmic signals were detected after treatment with both Twins-DW4 and 
Twins-Waz in NIH 3T3 and HeLa cells, respectively (Fig. 16). In contrast, 
DFHBI-1T-treated cells showed almost null intracellular signal. Notably, the 
intracellular fluorescence related to the Twins-Waz complex exceeded that found 
for Twins-c36, confirming our previous observations. 
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Fig. 16 Internalization assay of the aptamer-aptamer complexes in mouse fibroblasts 
(NIH 3T3) and human cervical cancer cells (HeLa). Confocal imaging microscopy 
shows the intracellular fluorescence (green) of DFHBI-1T alone, Twins-DW4 in 
mouse fibroblast and DFHBI-1T alone, Twins-Waz and Twins-c36 in human cervical 
cancer cells, and Hoechst nuclear marker (blue) in both cell lines. The image 
processing was performed using ImageJ and the HiLo LUT plugin for the subtraction 
of the measured background fluorescence. Scale bars: 10 µm  
As shown in Fig. 17, all the complexes containing Twins as payload aptamer 
show somewhat increased cellular fluorescence signal compared with the 
Spinach2-aptamer assemblies.  
It is worth noting that, besides showing an enhanced fluorescence than Spinach2 
(1.5 times higher), Twins does not exploit tRNA as aptamer scaffold, which is 
targeted in the intracellular environment by endonucleases, leading to RNA 
cleavage and hence to a reduction of the cellular fluorescent signal. This important 
feature yields Twins a novel fluorogenic RNA tool with enhanced potential than 
Spinach2.  
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Fig. 17 Comparison of the intracellular fluorescence signal related to the Spinach2-
aptamer (Spinach2-DW4 and Spinach2-Waz) and Twins-aptamer (Twins-DW4 and 
Twins-Waz) complexes in mouse fibroblasts (NIH 3T3) and human cervical cancer 
cells (HeLa). The image processing was performed using ImageJ and the HiLo LUT 
plugin for the subtraction of the measured background fluorescence.  
Overall, these results demonstrate that our Twins aptamer could represent an 
improved tool for RNA imaging in living cells. However, although Twins shows 
improved fluorescence properties, the reported fluorescence enhancement is still 
limited, and is only ~1.5 higher than Spinach2 and ~1.7 than the parental RNA 
(i.e. s-Baby Spinach). Thus, Twins may represent a useful starting point for further 
optimization of the Spinach system, and our strategy may pave the way to further 
multimerization strategies aiming to increase the sensitivity of RNA imaging. In 
addition, the limitations of our approach related to the development of multimeric 
sequences with a high number of fluorescent aptamer units, might offer useful 
hints on which aptamer domains and sequences should be engineered to reduce the 
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intraptamer interactions, increasing folding stability and ultimately the 
fluorescence properties. 
4.4 Concluding remarks 
In this chapter, an approach to design and generate a modular plug-and-play 
drug-delivery platform to perform an aptamer-mediated aptamer delivery was 
presented. This platform exploits (i) targeting and delivery abilities exhibited by 
anti-transferrin receptor aptamers and (ii) fluorescence properties of RNA mimics 
of GFP. We demonstrated that both the delivery and payload modules of our 
platform could be swapped using different combinations of aptamers, highlighting 
the modularity of our design. Most importantly, both anti-mouse TfR aptamer 
(DW4) and anti-human TfR aptamer (c2) were able to deliver Spinach2 into their 
specific target cells with limited nonspecific cell uptake. In addition, the ability to 
track the internalized fluorescent RNA aptamers (Spinach2 and Twins) during the 
endocytic pathway, suggested that these RNAs still retain their folding and 
functionality during early stages of the endocytosis process. This proof-of-
principle is the first demonstration of aptamer-mediated delivery of large 
functional RNA and may represent a useful starting point for further targeted 
delivery applications in living cells, simply swapping the fluorescent RNA 
aptamers with therapeutic and regulatory RNAs, such as, therapeutic aptamers, 
long non-coding RNA (lncRNA), messanger RNA (mRNA), and engineered 
structure containing multiple copies of miRNAs or siRNAs.  
However, although our oligonucleotide platform exhibits remarkable features as 
delivery system, further molecular engineering strategies may increase and 
overcome some intrinsic limitations related to the hybridization step, reducing 
unwanted intra- and inter- molecular interactions and increasing the folding 
stability. To this end, middle-term goals include insertion of aptamer scaffolds, or 
stabilizing sequences (such as 3WJ motifs) within the platform, to increase the 
conformational stability of each module, ultimately increasing the annealing 
properties. In addition, novel designs of the oligo bridge sequence will be 
evaluated, including the presence of cleavable linkers, such as disulfide bond, to 
facilitate intracellular release of the payload RNAs at the early- or late- endosomal 
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stage of the endocytosis process. Although endosomal escape is an essential step 
in many therapeutically relevant applications, such as RNAi-mediated gene 
silencing, other strategies aim at targeting only endosomes. Indeed, the endosomal 
system is not a simple transient environment for the degradation or recycling of 
cell-surface receptors and uptake of nutrients, it is also an essential site of signal 
transduction mediated by different classes of receptors, such as receptor tyrosine 
kinases (RTKs), G protein-coupled receptors (GPCRs) and Toll-like receptors 
(TLRs)256. Particularly, in several form of cancers, mutations affecting either some 
of these receptors (e.g. mutations in RTKs that maintain them in hyperactivated 
states of dimerization and/or phosphorylation) or adaptor proteins involved in the 
signal transduction lead to tumorigenesis257. In the endosomes these mutated 
receptors trigger different signals from those at the plasma membrane both 
mechanistically and temporally, resulting in distinct physiological responses, such 
as uncontrolled cell proliferation, and enhanced cell survival256,257.  
Our flexible aptamer platform could be exploited, for instance, to perform 
endosomal delivery of therapeutic aptamers able to inhibit either specific domains 
that are inaccessible at the plasma membrane level or signaling components 
exclusively localized to endosomes, thus affecting only the endosomal signaling.  
In the context of targeted therapy a strategy that targets endosomal signaling 
relevant to disease offers a more selective tool with potentially minor side effects 
than targeting primary steps of receptor signal transduction. 
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4.5 MATERIALS AND METHODS 
4.5.1 Reagents, oligonucleotides, and transcription templates  
All chemicals were purchased from Sigma-Aldrich unless otherwise noted, all 
restriction enzymes were obtained from New England BioLabs (NEB) and all cell 
culture products were purchased from Gibco BRL/Life Technologies. DFHBI 
((Z)-4-(3,5-difluoro-4-hydroxybenzylidene)-1,2-dimethyl-1H-imidazol-5(4H)-
one) and DFHBI-1T ((Z)-4-(3,5-difluoro-4-hydroxybenzylidene)-2-methyl-1-
(2,2,2-trifluoroethyl)-1H-imidazol-5(4H)-one) were purchased from Lucerna 
Technologies. 
DNA aptamer DW4, scrambled DW4 (scrDW4), DNA oligo-bridge, DNA 
templates and primers for PCR were purchased from Integrated DNA 
Technologies (IDT, Coralville, IA, USA). They were stored in lyophilized form 
and suspended before use in the appropriate volume of TE buffer (10 mM Tris-
HCl at pH 7.5, 0.1 mM EDTA at pH 8.0) to reach a concentration of 100 µM. The 
concentration of all DNA and RNA suspensions was measured by UV 
spectrophotometry using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific). All enzymatic amplification reactions were performed using high-
fidelity PhusionDNApolymerase (NewEngland Biolabs) or TaqDNA polymerase 
(NEB) according to the manufacturer’s protocols. The pET28-Spinach2 plasmid 
was a kind gift of Samie Jaffrey (Cornell University) and contains the Spinach2 
aptamer inside a tRNA scaffold. 
4.5.2 Aptamer sequences 
The sequence of the anti-human TfR RNA aptamer (c2.min) with a short tail 
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The sequence of the anti-human TfR RNA aptamer (Waz) with a short tail 
(CGA)7 was the following (tail sequence is underlined):  
5’-GGGUUCUACGAUAAACGGUUAAUGAUCAGCUUAUGGCUGGCAG 
UUCCCCGACGACGACGACGACGACGA-3’ 
 The sequence of the scrambled aptamer (c36) with a short tail (CGA)7 was the 
following (extended sequence of aptamer is underlined):  
5’-GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCCCGACGAC 
GACGACGACGACGA-3’ 
All pyrimidines of the RNA aptamer motif were 2’-fluoro-modified. 
The sequence of the anti-mouse TfR DNA aptamer DW4 with a short tail 
(CGA)7 was the following (tail sequence is underlined):  
5’-GCGTGTGCACACGGTCACTTAGTATCGCGGCGTTCTTTGGTTCCGC 
CCGGCGACGACGACGACGACGACGA-3’ 
The scrambled sequence of DNA aptamer scrDW4 with a short tail (CGA)7 was 
the following (tail sequence is underlined):  
5’-GCCATTGCCATTGCCATTGCCATTGCCATTGCCATTGCCATTGCCA 
TTGCCATTGCGACGACGACGACGACGACGA-3’. 
The sequence of DNA oligo-bridge was the following:  
5’- ATCATCATCATCATCATCATCTCGTCGTCGTCGTCGTCGTCG -3’ 
The sequence of RNA aptamer Spinach2-tRNA with a short tail (GAU)7 was the 
following (tail sequence is underlined while tRNA-derived sequences are 






The sequence of the RNA aptamer s-Baby Spinach monomer was the following 
(extended stem sequences are underlined):  
5’-AAAAAGCAGGGUGAAGGACGGGUCCAGUAGUUCGCUACUGUUG 
AGUAGAGUGUGAGCUCCCUGCAAAAC-3’ 
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The sequence of the RNA aptamer s-Baby Spinach dimer was the following 





The sequence of the RNA aptamer s-Baby Spinach trimer was the following 






The sequence of the RNA aptamer s-Baby Spinach tetramer was the following 








The sequence of the RNA aptamer s-Baby Spinach pentamer was the following 
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The sequence of the RNA aptamer s-Baby Spinach dimer (Twins) with a short 





4.5.3 Secondary structure and hybridization predictions  
All DNA and RNA secondary structure predictions and intra- and 
intermolecular interactions were analyzed using the NUPACK server 
(http://www.nupack.org/)175 as described in Chapter2. 
4.5.4 In vitro RNA transcription  
All RNA aptamers (both delivery and fluorogenic RNAs) were PCR amplified 
with primers that appended a T7 promoter and PCR amplified DNA duplexes 
were resolved by agarose gel electrophoresis and visualized by ethidium bromide 
staining to check the yield of PCR reactions and confirm the proper size of the 
PCR amplicons. Spinach2 transcription templates were amplified using primers 
specific to the flanking plasmid sequence (pET28-Spinach2 plasmid). 
For in vitro run off transcription reactions was performed by incubating the PCR 
product in buffer containing 120 mmol/l HEPES–KOH, pH 7.5, 30 mmol/l MgCl2, 
40 mmol/l DTT, 4% wt/vol PEG 8000, 4 mmol/l NTPs and mutant Y639F T7 
RNA polymerase for 3 hours at 37°C. 2’-fluoro modified CTP and UTP (TriLink 
Biotechnologies) or 2’-O-Methyl CTP and UTP were used to generate 2’-modified 
RNAs. Mutant Y639F/H784A T7 RNA polymerase was used to yield 2’-O-
Methyl-modifed RNAs. At the completion of the reaction 1–2 µL aliquots were 
analyzed by denaturing PAGE. 
4.5.5 Denaturing PAGE and RNA purification 
The 6-8% polyacrylamide gels containing 7M urea were prepared using 40% 
acrylamide and bis-acrylamide solution, 19:1 (Bio-Rad) in 1X TBE buffer (89 
mM Tris Base, 89 mM Boric acid, 2 mM EDTA at pH 8.0) containing 0.04% 
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ammonium persulphate and 0.1% TEMED. An equal volume of 2X denaturing 
dye (7 M urea, 1X TBE, 50% glycerol, 50 mm EDTA, 0.1% bromophenol blue 
and 0.1% Xylene Cyanol) was added to the RNA samples, incubated at 65°C for 3 
min, and then stored on ice until loading. GeneRuler Low Range DNA Ladder 
(Thermo Scientific) was used as size marker. The run was performed at 400 V at 
room temperature for about 1 hour, thus glass plates could reach ~50°C. The gel 
was wrapped in a transparent film and placed on a silica gel plate containing 
Fluorosyl, and the bands were visualized by UV shadowing at 354 nm, which 
shows a detection limit around 300 pmoles of nucleic acid. Alternatively, gels 
were stained for 10 min with ethidium bromide (Life Technologies) prior to 
visualization on the Typhoon LFA 7000 (GE Healthcare). For RNA purification, 
desired bands were excised from the gel and the RNA was eluted using the “crush 
and soak” method using ammonium acetate 0.3 M, pH 5.5 as elution buffer. The 
suspension was shaked overnight or at least 16 hours at 4°C. The supernatant 
containing the RNAs was recovered and oligonucleotides were ethanol 
precipitated, then RNA pellets were washed once in 70% ethanol, and finally 
resuspended in the desired volume of nuclease-free water or TE buffer. 
4.5.6 Preparation of self-assembled aptamer-aptamer complexes 
Two distinct protocols were used to generate ternary oligonucleotide complexes 
with DNA aptamer (DW4) and RNA aptamers (c2 and Waz) as cell penetrating 
aptamers. To generate the ternary complex with DW4, this delivery aptamer, 
fluorogenic RNA aptamer (either Spinach2 or Twins) and bridge were mixed with 
1:1:1.2 molar ratio (final strand concentration, 1 µM of fluorescent RNA aptamer) 
in a binding buffer solution, (40 mM HEPES pH 7.4, 125 mM KCl, 5 mM 
MgSO4). The mixture was placed in a thermoblock and heated to 90°C for 1 
minute to denature the nucleic acid structures. Then the entire apparatus was 
placed on the workbench for 30 minutes and denatured oligo sample was slowly 
cooled to allow correct hybridization of complementary strands.  
To generate the ternary complex with c2 and Waz, fluorogenic RNA aptamer 
(either Spinach2 or Twins) and bridge were firstly mixed with 1:1.4 molar ratio 
(final strand concentration, 1 µM of fluorescent RNA aptamer) in a binding buffer 
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solution, (20 mM HEPES pH 7.4, 125 mM KCl, 5 mM MgSO4). After 
denaturation at high temperature, 1.6 fold-molar excess of delivery RNA aptamer 
(either c2 or Waz) was added at 45°C during the slow cooling step. 
Electrophoretic mobility shift assay was performed to monitor the efficiency of 
annealing. 
4.5.7 Electrophoretic Mobility Shift Assay  
Native 6% polyacrylamide gels were prepared to check the “band-shift” relative 
to the formation of ternary complexes. Gels were prepared using 40% acrylamide 
and bis-acrylamide solution, 19:1 (Bio-Rad) in 1X TBE buffer (89 mM Tris Base, 
89 mM Boric acid, 2 mM EDTA at pH 8.0) containing 0.04% ammonium 
persulphate and 0.1% TEMED. An equal volume of 2X native loading dye (1X 
TBE, 50% glycerol, 50 mm EDTA, 0.1% bromophenol blue and 0.1% Xylene 
Cyanol) was added to the oligo samples. GeneRuler Low Range DNA Ladder 
(Thermo Scientific) was used as size marker. The run was performed at 230 V at 
4°C for about 1 hour to avoid increase of temperature of gel plates and 
consequently separation of annealed strands. Gels were stained for 10 min with 
ethidium bromide (Life Technologies) prior to visualization on the Typhoon LFA 
7000 (GE Healthcare). In case the efficiency of annealing was rather high, no 
purification of the bands was performed.  
For ODN complex purification, desired bands were excised from the gel and the 
ODN was eluted using the “crush and soak” method using water as elution buffer. 
The suspension was shaked overnight or at least 16 hours at 4°C. The temperature 
of this step is essential to avoid melting of duplex region within the nucleic acid 
structure. The supernatant containing the ODNs was recovered and nucleic acid 
samples were concentrated using centrifugal filter units (3 K MWCO) and 
quantified by UV-VIS analysis. Hybridized complexes were incubated with 100-
fold molar excess of DFHBI (or DFHBI-1T) for 30 minutes at room temperature, 
and then fluorescence and internalization properties were evaluated. 
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4.5.8 Measurement of Spinach Fluorescence  
Free Spinach2, s-Baby Spinach (monomer, dimer, trimer, tetramer and 
pentamer), Spinach2-aptamer complexes, and Twins-aptamer complexes were 
incubated with 100-fold molar excess of DFHBI (or DFHBI-1T) for 30 minutes in 
20 mM HEPES pH 7.4, 100 mM KCl, 5 mM NaCl, 100 µM MgCl2, at 25°C. 
Fluorescence was measured in cuvette for each RNA and ODN assembly under 
the following conditions: 0.1 µM RNA (or ODN complex) and 10 µM of DFHBI 
(or DFHBI-1T). Fluorescence was normalized to that of 0.1 µM Spinach in 20 
mM HEPES pH 7.4, 100 mM KCl, 5 mM NaCl, 100 µM MgCl2, and 10 µM 
DFHBI (or DFHBI-1T). Final concentrations for Spinach2 and Spinach2 mutants 
(2’-modified RNAs) were 0.4 µM RNA and 2 µM DFHBI. In this case 
fluorescence was normalized to that of 0.4 µM Spinach incubated with 2 µM 
DFHBI. Fluorescence measurements were performed, at least in triplicate, using a 
96-well EnSpire Multilabel plate reader (PerkinElmer Life Sciences) using the 
following instrument parameters: DFHBI excitation: 450 nm, emission 480-600 
nm; DFHBI-1T excitation 480 nm, emission 500-600 nm.  
4.5.9 Endocytosis in living cells and cell imaging 
In a typical endocytosis assay, 2 × 105 HeLa cells and NIH-3T3 cells were 
seeded 24 h before the experiment in 8-well chamber slide (Nunc™ Lab-Tek™ 
chamber slide, Thermo Scientific) to reach 80-90% confluence. Thirty minutes 
prior to experiment, DMEM supplemented with 10% fetal bovine serum (FBS) 
was replaced with pre-treatment medium: DMEM (or PBS) supplemented with 
5% FBS, 1% BSA, 20 µΜ tRNA, 5 µg/ml of Hoechst 33342, and 20 µM of 
DFHBI-1T (or DFHBI). BSA and tRNA were used as competitors for nonspecific 
binding sites. This step allows internalization and intracellular accumulation of the 
cell-permeable DFHBI-1T. After that, cells were washed twice with PBS and 
incubated in a free-serum medium (to avoid nuclease-mediated degradation of the 
RNA aptamer, i.e. either Spinach2 or Twins): DMEM containing 0.5 µM ODN 
assembly, 5 mM MgSO4, 125 mM KCl, and 20 µM DFHBI-1T. After 30-minute 
incubation at 37°C, cells were washed twice with PBS and fresh DMEM 
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supplemented with FBS (10%), 20 µM DFHBI-1T, 5 mM MgSO4, 125 mM KCl 
was added. About 35 minutes after the administration of the aptamer complex, the 
sample was imaged by confocal microscopy. Cells were imaged using a Leica 
TCS SP8 SMD inverted confocal microscope (Leica Microsystems AG) interfaced 
with a diode laser (Picoquant) for excitation at 405 nm, and with an Ar laser for 
excitation at 488 and. Glass bottom chamber slides containing cells were mounted 
in a thermostated chamber at 37°C (Leica Microsystems) and viewed with a 63x 
1.2 NA water immersion objective (Leica Microsystems). The pinhole aperture 
was set to 1.0 Airy. All data collected were analyzed by ImageJ software version 
1.44o. HiLo LUT plugin was used during image processing for the subtraction of 







Concluding remarks and research 
perspectives 
The main purpose of this work was the development of novel aptamer-based 
nanoscale platforms for targeted cancer therapy having versatile designs, ease of 
scale-up and straightforward aptamer-payload preparation.  
To discriminate between tumor and healthy cells, the delivery system should 
possess a targeting moiety able to recognize proteins that are expressed 
differentially -or exclusively- on the surface of cancer cells. Thus, I identified in 
the research of the proper cell-surface marker to perform targeted cancer therapy 
the starting point for my investigation. Transferrin receptor (TfR) is one of the 
most investigated tumor-associated receptors owing to its upregulation on a 
variety of cancer cell types over the last decade (Chapter 1) and its endogenous 
ligand, transferrin (Tf), has been widely investigated as targeting nanocarrier. 
However, exogenous Tf derivatives compete with saturating concentration of 
endogenous Tf, thus limiting adequate delivery of payloads to target tissues. 
Aptamers recognizing TfR have been recently introduced using the SELEX 
technology and they offer a valid alternative to Tf since they can bind different 
sites on TfR, avoiding the competition with the endogenous Tf or even show 
higher affinity towards TfR compared to the natural ligand. Importantly, besides 
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having potential targeting properties, these aptamers are able to internalize upon 
binding to TfR via receptor-mediated endocytosis.  
In Chapter 2, I presented a molecular-engineering strategy to generate a drug-
delivery platform able to co-deliver a chemotherapeutic agent (doxorubicin) and 
an inhibitor of a cell-survival factor, the NF-κB decoy oligonucleotide to human 
pancreatic cancer cells via an anti-human TfR RNA aptamer (c2). First, I 
rationally designed an extended c2 sequence bearing a double stranded DNA 
region to exploit the natural tendency of doxorubicin to intercalate into DNA 
duplex and generate an aptamer-doxorubicin conjugate. Secondary structure 
prediction analysis and internalization assay using dual-labeled assembly 
confirmed that the cell-penetrating aptamer still retain its activity after the rational 
modification. I assessed the stability of this complex and its potential use in an in 
vitro tumor model. Aptamer-doxorubicin complex did not release the anticancer 
drug after 1h incubation in serum-containing medium at 37°C, and only minor 
leakage was observed (<10%) after 2h incubation. The assembly resulted quite 
stable even at longer incubation (24h) when the leakage from the double helix was 
about 25%. Next, I demonstrated that aptamer-doxorubicin assembly was selective 
internalized into pancreatic tumor cells; intracellular release of doxorubicin was 
triggered by pH changes that occur at the endolysosomal compartment; negligible 
cytotoxic effect was detected after treatment of non-tumoral cells; doxorubicin-
mediated apoptosis were specifically observed towards two different cancer cell 
lines (pancreatic and cervical cancer cells) though with different cytotoxicity. 
Particularly, cervical cancer cells displayed higher sensitivity to doxorubicin 
compared with the pancreatic tumor model. To sensitize resistant pancreatic 
cancer cells to Dox-induced apoptosis, I performed a codelivery strategy aimed at 
inhibiting a cell-survival factor, NF-κB, which is activated to suppress the 
apoptotic potential of doxorubicin, leading to chemoresistance. I designed and 
generated a self-assembling structure to conjugate the targeting RNA aptamer with 
a well-known NF-κB inhibitor, the NF-κB decoy oligonucleotide. The self-
assembly process is straightforward and exploits two complementary single-
stranded DNA sequences: one located within c2, which is also essential for 
doxorubicin intercalation, and one covalently linked to NF-κB decoy with a 
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disulfide bridge. I called aptacoy, the chimera generated by one aptamer and one 
decoy. Upon doxorubicin loading, I demonstrated that the resulting aptacoy-
doxorubicin assembly was able to perform a targeted codelivery of doxorubicin 
and NF-κB decoy towards resistant pancreatic tumor cells, sensitizing them to 
doxorubicin-mediated apoptosis owing to selective inhibition of constitutive NF-
κB activity.  
To expand our set of TfR ligands and demonstrate the flexibility of the platform 
design presented in the Chapter 2, I turned my attention on a DNA aptamer 
(GS24) recognizing mouse TfR with no competition with the natural ligand. 
Particularly, this aptamer can be orthogonally used in combination with anti-
human TfR aptamer as targeting ligand of drug delivery platform in a modular 
“plug-and-play” fashion. Chemical and biophysical studies revealed the presence 
of competing folding pathways, which sensibly decreased the activity of GS24 
(Chapter 3). In details, chromatographic analysis shed light on the identification of 
two interconvertible aptamer conformers (A-1F and A-2F). Fluorescence-
anisotropy measurements and internalization assay in living cells highlighted that 
only one fold (A-2F) was effectively able to bind mouse transferrin receptor and 
internalize into mouse cells. The purified active fold could also bind human TfR, 
albeit with a lower affinity, and it was internalized in a human pancreatic cancer 
cell line, which is known to overexpress human TfR. Most importantly, the two 
folds become nearly equimolar in the 40–42 °C interval. These data imply that the 
actual active form present when GS24 is administered in living cells or in vivo is 
markedly lower than expected from the nominal aptamer concentration. Thus, 
before to investigate the flexibility of our delivery system using GS24 as targeting 
tool, I fine-tuned a molecular engineering strategy aimed to stabilize the active 
aptamer conformation and generate a sequence with enhanced biological activity. 
Particularly, I exploited the synergy between molecular dynamic simulations and 
point mutations of GS24 to unveil the essential part involved in the folding 
stability of A-2F. Based on this approach, I generated four aptamer mutants and I 
evaluated for each sequence the percentage of the inactive fold by 
chromatographic analysis, the in vitro binding affinity towards mouse TfR, and 
cell-internalization properties in living mouse cells. The screening of these 
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aptamer features allowed us to identify an enhanced sequence, termed DW4, 
which exhibits increased binding efficiency and improved folding stability than 
the parental sequence (the inactive fold is less than 10% at 37 °C). Furthermore, 
this sequence was also able to bind the hTfR, more effectively than the purified 
active fold (A-2F) but still with a lower affinity when compared with its natural 
target, i.e. mTfR. Besides introducing an enhanced ligand for targeted delivery 
applications, this biophysical study might pave the way to a second SELEX 
experiment, using a doped-library. Indeed, starting from DW4 sequence, the 
positions involved in the folding stability might be randomized and a novel brief-
selection could be performed using the human recombinant TfR as biomolecular 
target. This approach might lead to novel aptamer sequences able to bind 
efficiently both mouse and human TfR. 
In Chapter 4, I reported the design and the synthesis of a modular system 
tailored for delivery large functional RNAs (~50-60 kDa). Starting from the 
platform design described in Chapter 2, I studied a strategy to generate a self-
assembling oligonucleotide structure composed of two distinct modules: (i) a cell 
penetrating aptamer that promotes selective internalization in tumor cells and (ii) a 
large fluorescent RNA aptamer used as payload to track its fluorescence during 
endocytosis, and to evaluate folding alterations within the oligonucleotide 
platform. The anti-transferrin receptor aptamers (c2 and DW4) described in 
Chapter 2 and 3 were used as cell-penetrating aptamers (“delivery modules”) and 
were annealed via a short oligonucleotide bridge to Spinach2, a fluorescent RNA 
aptamer, (“payload module”). I investigated different conditions of annealing 
monitoring the efficiency of hybridization among the two aptamers and the bridge. 
Then, aptamer-aptamer assemblies were subjected to functional assays to clarify 
whether both aptamers (delivery and payload) still retained their functions even 
when embedded in the complex. On one side, I demonstrated that Spinach2 was 
still able to induce the fluorescence of GFP-like chromophores after hybridization 
with the delivery aptamers without significant changes in its fluorescence 
emission. On the other, internalization assay in living cells highlighted that both 
anti-mouse TfR aptamer (DW4) and anti-human TfR aptamer (c2) were able to 
deliver Spinach2 into their specific target cells with limited off target effect. To 
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demonstrate the flexibility of our platform, another anti-human TfR aptamer 
(Waz) and an engineered dimeric version of Baby Spinach (Twins) I generated 
were successfully employed respectively, as delivery aptamer and fluorescent 
RNA payload. This work is the first demonstration of an aptamer-mediated 
aptamer delivery. Based on these findings, one might swap the fluorescent RNA 
aptamer on the platform with other therapeutic and regulatory large RNAs, such 
as, therapeutic aptamers, long non-coding RNA (lncRNA), and engineered 
structure containing multiple copies of miRNAs or siRNAs for different targeted 
delivery applications in living cells.  
In this thesis the potential of anti-transferrin receptor RNA and DNA aptamers 
as targeting and delivery tools was explored. Aptamer-based nanoscale platforms 
were designed and generated through straightforward self-assembly, exploiting the 
ability of nucleic acids to yield stable complexes after annealing. Different 
molecular payloads ranging from an anticancer drug and a small therapeutic 
oligonucleotide to large fluorescent RNAs were selectively delivered in target 
cells via cell penetrating aptamers where they could exhibit respectively, their 
therapeutic activity or fluorescence. I believe that thanks to these findings further 
aptamer-based targeted nanocarriers will be generated taking inspirations from the 
designs and the strategies described in this thesis. Thanks to their flexibility, our 
platforms represent useful starting points for further engineering with the 
intriguing possibility to use appropriate combinations of aptamer ligands, 
therapeutic oligonucleotides and anticancer drugs that could pave the way to the 
development of highly functional targeted therapy representing a “magic bullet” 
for clinical treatments. 
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